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Abstract of thesis entitled: 
Molecular Investigations of Ornithine Transcarbamylase Mutants 
Submitted by LAWTak Yin 
for the degree of Master of Philosophy 
at The Chinese University of Hong Kong in July 2004 
Ornithine transcarbamylase (E.C. 2.1.3.3) is the second enzyme in urea cycle, 
responsible for catalyzing the condensation of ornithine and carbamyl phosphate to 
citrulline. OTC deficiency will result in hyperammonaemia. Up to date, more than 
278 mutations of the OTC gene have been identified, including missense mutations, 
small and large gene insertions and deletions. In this study, we performed mutation 
analysis of the OTC gene in 8 unrelated Chinese patients diagnosed with OTC 
deficiency. Seven different mutations, namely Arg26Gln, Glul22Gly, Argl29His, 
Lysl44Term, Thrl78Met, Asnl98Ile, and IVS5+1G^T were identified. Asnl98Ile 
and IVS5+1 G—>T are novel mutations and the others are known mutations. In one 
of the patients, no mutation was detected in all the exons and the flanking introns of 
the gene. Instead, a previously reported polymorphism l l lPro, was found. This 
polymorphism was only reported once in the literature in an OTCD patient. The 
rediscovery of this polymorphism in another OTCD patient suggested that 111 Pro 
might be a disease-causing mutation rather than a polymorphism. 
To investigate the effects of the mutations to subcellular localization of OTC, 
) 
the pre-OTC mutants fused with GFP were transfected into Hep3B and HepG2 cells 
for transient expression and observed under fluorescence microscopy. All the 
missense mutants, except Argl29His, showed a punctate pattern, which is consistent 
with mitochondria distribution. Intriguingly, the signal peptide mutation Arg26Gln 
ii 
Abstract ^ B 
does not abolish the mutant pre-OTC from entering into the mitochondria. 
To establish the genotype-phenotype relationship of these mutations, the 
pre-OTC mutants were further expressed in a cell-free system. SDS-PAGE and 
His-tag in-gel stain revealed the mutants were expressed. However, the enzyme 
activity assay showed that the expressed wild-type pre-OTC was not active, even with 
the presence of GroE to assist folding. This may be due to the presence of a 
5'-terminal peptide fused with the pOTC interfering the assembly of OTC monomers 
into active trimers. The underlying cause still awaits confirmation by cleaving the 
5'-terminal peptide with enterokinase to release the native protein for activity assay. 
> 
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Pre face_^ | 
H n w i t h f t n i n s 
The story of ornithine transcarbamylase (OTC) or ornithine 
carbamoyltransferase (OCT) began with the discovery of the ornithine cycle (now 
known as the urea cycle) by Sir Hans Krebs and a medical student associate, Kurt 
Henseleit in 1932. The urea cycle is the first discovered cyclic metabolic pathway. 
Since then, extensive researches have been carried out on the urea cycle enzymes, 
and of course including OTC, which is the enzyme in the second step of the cycle, 
catalyzing the conversion of ornithine and carbamyl phosphate to citrulline. The 
purification of OTC, the diagnosis of patients with defects in OTC, and the mapping 
and cloning of the gene have all lead scientists to a better understanding of OTC and 
the consequences of its deficiency. 
In this thesis, attempts were made to study the cause of OTCD by DNA basis 
involving mutation detection and protein basis involving mutant expression. The 
thesis begins with a brief introduction to the science of OTC, from some basic 
information of the gene, the processing, the protein, to the symptoms, diagnosis and 
treatment of OTC deficiency. It is then divided into 2 parts, with part I about 
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1.1.1 Mapping 
The human OTC gene was K ^ U ^ K a M U l i i i ^ ^ ^ ^ l ^ ^ ^ ^ ^ H l 
[llchthyosis, X-Unlwd mapped to the short arm of the X _ \nacmtd steroid sulfatasearfldencyl 
Kallmann syndroma 
^ ^ L Qtondrodysplasla puncuta, X-llnked recessive 
Chromosome at Xp21.1 by in situ i i B f J & ' ^ i r . ' ' ' 
22.1 ^ H ~ I ^ o m a g n m m i a , X-Unked b^ tlnoBchisis 
hybridization with a cDNA probe p ^ f c l ^ ^ ^ K S S c i a v c y 
11.4 jDuchetm« muscular dystrooly (DMD)| 
(Lindgren et al.’ 1984). Fig 1.1 
shows the location of OTC in the i U HSSi^S^to^-z 
13 ^ H Alport-like hereditary nephritis 
X-chromosome. 二 • 
q wM 
iil 
1.1.2 Isolation 26 • 
After the first isolation of OTC 23 • 口 
cDNA clone in rat (Horwich et al.’ Adapted from ChUdrenS Research Institute. 2002 
1983)，isolation and expression of 
human OTC cDNA was accomplished by using part of the rat cDNA as a probe to 
screen the liver cDNA library (Horwich et al” 1984; Davies et al,, 1985; Hata et al” 
1988). 
1.1.3 Structure 
The OTC gene spans a region of 73 kilobase pairs (kb). It contains 10 exons 
interrupted by 9 introns. The introns are in highly variable sizes, with the smallest 
of 80 base pairs (bp) and the largest 21.7 kb (Hata et al.’ 1988). Fig 1.2 shows the 
genomic organization of OTC. 
The investigation of regulatory elements in OTC were mostly performed in rat. 
At about 200 bp upstream from the transcription initiation site, the promoter 
elements "CAAT box"- and "TATA box"-like sequences were located (Takiguchi et 
2 
All Ah。"fr orr 
JJATA CAAT 細 
EnWe. r ^ [ — 
5, I ] 让 一 切 \\\ 
碰 」 
Ezonl Ezon2 77 bp 139bp 
* n i ^ — — ： f•烹 14.7 kb Protein iBwiar 拟 b 9equBn:e(32aA}  Exon3 Exon4 82 bp 88 bp 5' m my IiitiiDn2 — — - ~ I n t r a n S 23 kb \ Ser-Thr-Aig^ Thr-Are 125 kb \ jputofthecaibui^  p^hoiplMtB b iiding lit^ ExonS 154 bp 5' T—r mmy Izitzcn4 217U> Ezon6 Exan7 EzonS 123 bp 54 bp ISO bp 
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Adapted from Children 's Research Institute. 2002 
al.，1987). There are also one negative and two positive regulatory elements within 
this region (Murakami et al., 1990). At 11 kb upstream from the transcription 
initiation site, an enhancer was located (Murakami et al” 1990). Within the 
enhancer, there are 4 protein-binding sites for liver-selective transcription factors 
which are responsible for the high expression of OTC in liver (Nishiyori et al” 1994). 
Two of these sites are specific for binding of hepatocyte nuclear factor-4 (HNF-4) or 
chicken ovalbumin upstream promoter transcription factor (COUP-TF). HNF-4 
activated expression from the OTC promoter while COUP-TF repressed expression 
from the OTC promoter (Kimura et al.，1993). The other 2 sites are specific for 
binding of CCAAT/enhancer binding protein (C/EBP). Within 383 bp downstream 
of the transcription termination site, a polyadenylation signal sequence was 
identified. 
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In human OTC gene，several other regulatory elements were located by pattern 
recognition in the 5'-flanking region (Snodgrass PJ, 2004.). A cyclic AMP-
responsive transcriptional factor, consensus AP2, with sequence CCCCAGGC, was 
found. And a urea cycle element (UCE) was also located. UCE was also found in 
other urea cycle enzymes (Ohtake et al., 1988), which may account for coordinate 
inductivity of the urea cycle (Engelhardt et al., 1991). 
The binding sites of the two substrates, carbamyl phosphate (CP) 
(S58-T59-R60-T61-R62) and ornithine (H270-C271-L272-P273) were located in 
exon 3 and exon 9 respectively. 
1.1.4 OTC in different species 
OTC gene was isolated and sequenced in various species, including mammals, 
birds, plants, and bacteria. Table 1.1 summaries the species from which OTC gene 
was isolated or sequenced. 
» 
4 
A N Ahn,»fr n x r m 
b r h r to Protein 
1.2.1 Synthesis ofpOTC 
The OTC gene is transcribed into an mRNA precursor in the nucleus. The 
mRNA precursor is then spliced at specific splice sites, so that the introns are spliced 
out and the ten exons joined together. The splice sites of OTC can be found in 
Appendix A.3. Mature OTC mRNA contains 1572 bases, including 150 bases of 
5'-untranslated region, 30 bases of 3'-untranslated region, and 1062 bases of coding 
sequence with 96 bases coded for a leading peptide and the remaining 966 bases 
coded for the mature protein. 
OTC mRNA is then translated by free ribosomes in the cytosol (Morita et al., 
1981) to synthesize pOTC, which is the preprotein of OTC. pOTC is a 38 
kilodalton (kDa) protein with a leading peptide of 32 amino acids (aa) at the N 
terminus followed by 322 aa. 
As pOTC is released from ribosomes, it binds to several different molecular 
chaperones to prevent aggregation or irreversible folding. One of these chaperones 
includes 70-kDa heat shock cognate protein (hsc70) (Terada et al., 1995), which is a 
member of the 70-kDa heat shock protein (HSP70) family. The Hsp70 family binds 
non-native proteins targeted to several subcellular compartments (Schatz, 1996). 
Other molecular chaperones include mitochondrial import stimulating factor (MSF), 
which specifically binds mitochondria matrix targeting signals for mitochondrial 
protein import (Hachiya et al., 1993); HSDJ, which is a human homolog of bacterial 
heat shock protein DnaJ (Kanazawa et al., 1997); and ^resequence binding factor 
(PBF), which is a protein factor (Murakami et la., 1992). This pOTC-chaperone 
complex moves to the mitochondria, possibly along microtubules. 
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1.2.2 Transport of pOTC into the mitochondria matrix 
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pOTC is recognized by a specific import receptor on the mitochondrial surface, 
made up of four integral membrane proteins called Transport across the outer 
membrane (Tom) subunits Tom70, Tom37, Tom22, and Tom20. pOTC-MSF binds 
to the Tom70-Tom37 complex. The adenosine triphosphatase (ATPase) of MSF is 
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quenched, and MSF is recycled to the cytosol. While pOTC is transferred to the 
Tom22-Tom20 complex (Komiya et al, 1996). Polyamines may also play a role in 
the binding of pOTC to the outer mitochondrial membrane (Gonzalez-Bosch et al., 
1991). 
The receptor-bound pOTC is then delivered to a protein import channel in the 
outer mitochondrial membrane, made up of five Tom subunits, Tom40, Tom38, Tom7, 
Tom6, and Tom5 (Hachiya et al.’ 1995). Tom34 may also be involved in this 
process too (Chewawiwat et al., 1999). 
In the presence of a translocating chain, the outer and inner mitochondrial 
membranes come into apposition at the translocation contact sites (Schleyer et al,, 
1985). 
After pOTC moves across the outer membrane, its positively charged leader 
peptide is electrophoretically pulled across the inner membrane by the 
electrochemical potential across that membrane (Martin et al., 1991). pOTC then 
moves through a transmembrane channel in the inner mitochondrial membrane, made 
up of six Transport across the inner membrane (Tim) subunits, Tim33, Tim23, Tim 17, 
Tim 14, and Timll , and Tim44 (Berthold et al., 1995). Tim44, which binds to the 
chaperones mitochondrial hsp70 (mhsp70) (Schneider et al., 1994) and mGrpE 
(Kronidou et al, 1994) pulls pOTC across the inner membrane through the Tim 
channel into the mitochondrial matrix in the presence of ATP (Kolansky et al, 1982). 
The transport and processing of pOTC require potassium ion and magnesium ions, 
probably as co-factors for the ATPase (Miura et al., 1983). 
1.2.3 Processing of pOTC into mature OTC 
Once in the matrix, pOTC is kept in an unfolded state by mhsp60 (Cheng et al, 
1989) and hsplO (Hartman et al., 1992). It then first encounters a protease, 
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mitochondrial processing peptidase (MPP) that removes the first twenty four 
N-terminal amino acids by cleaving the bond between asn24 and phe25 (Kalousek et 
a l , 1988). This results in iOTC, which is the intermediate form of OTC with 37 
kDa. 
iOTC then encounters a second protease, mitochondrial intermediate peptidase 
(MIP) which removes the next eight N-terminal amino acids by cleaving the bond 
between gin 32 and asparagine at the N-terminus of the mature subunit (Isaya et al., 
1992). The mature form of OTC is 36 kDa. 
1.2.4 Assembly of OTC monomer into trimer 
The OTC monomer is then assembled into the active trimer in the mitochondrial 
matrix assisted by mhsp60 and cpnlO, homologs of the bacterial chaperones GroEL 
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1.3.1 Structure 
Human OTC [EC 2.1.3.3] was 
purified (Pierson et al., 1977) and ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
shown to contain 354 aa, having a " 
molecular weigh of 38 kDa (Kalousek r ^ ^ T j ^ l ^ I f f ' 
et al., 1978). Three-dimensional - •！ 
structures of enzyme crystals by X-ray '纖 
diffraction were reported for human 一^ 
(Shi et al” 1998)， catabolic ' 
Adapted from Children 's Research Institute. 2002 
Pseudomonas aeruginosa (Villeret et  
a/., 1995) and E.coli OTCs (Jin et al” 
1997; Ha et al.’ 1997). These ^ S ^ ^ f f i l ^ I B I I M ^ H I 
structures revealed that OTC has 14 a J ^ V 
-helices and 10 ^ -strands per ^ ^ q^ J S K T ^ ^ Q m I w ^ 
monomer. It assembles into a 
homotrimerwhen functional X J j j j f r W fll ^ S i ^ S 
The CP binding site and ornithine 
binding site of human OTC are 
recognized as S58-T59-R60-T61-R62 
and H270-C271-L272-P273 Adapted from Children ！s Research Institute, 2002 I 
respectively. A comparison of the CP 
binding site and ornithine binding site was performed among 23 species, with OTCs 
from 4 mammalian livers, 1 chicken kidney, 1 plant, 6 yeasts/fungi and 11 bacteria 
(Snodgrass PJ, 2004). The ornithine binding site reveals absolute conservation 
while the CP binding site is highly conserved with variation in only 2 species. The 
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two exceptions are found in the plant Arabidopsis thaliana with sequence SMRTR; 
and the bacterium Pseudomonas syringae pv. phaseolicola with sequence SGRTS. 
1.3.2 Distribution and location 
• j L » r U � I I J i l U l j l i l l l l l i l l l l i l l T T ^ ^ M ^ ^ 1 ^ ^ ^ 
咖 Key: 
g BMR - Bone marrow 
§ SPL-Spleen 
^ • TMS - Thymus 
：! 100- H BRN - Brain 
1 • SPC - Spindal cord 
呈 . HRT - Heart 
I • • 鬥 ^ I B MSL - Skeletal muscle 丨 • • 門 • • • _ • LVR - Uver 
^ T T ' I ' I I I I I ' 'f' T T T T T ' PNC-pancreas 
BMR SPL TMS BRN SPC HRT MSL LVR PNC PST KDN LNG PST - Prostate 
KDN - Kidney 
Immune Nervous Muscle Secretory Other LNG - Lung 
White rectangles above bars show min-max range for duplicates 
Adapted from GeneCards. 2001. 
OTC is mainly expressed in liver and intestinal mucosa, which can be explained 
by gene regulation mentioned in Chapter 1.1.3. The protein is located exclusively 
in the mitochondrial matrix. 
1.3.3 OTC in different species and its role 
OTC was isolated and purified from various species, including mammals, 
amphibians, birds, plants, yeasts, fungi, and bacteria. Table 1.1 summaries the 
species from which OTC protein was isolated, purified or sequenced. Interestingly, 
OTC is found to have different functional roles in some of these species. 
Ureotelic organisms including human and most terrestrial animals excrete waste 
nitrogen in the form of urea. OTC participates in the urea cycle for detoxification 
of ammonia to urea. 
Bacteria and free-living protozoans simply release waste nitrogen directly in the 
form of ammonia to the aqueous environment. OTC is involved in both synthesis 
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and degradation of arginine (Legrain et al., 1972). This also occurs in yeasts and 
fungi (Eisenstein et al., 1984). 
Uricotelic organisms such as birds and reptiles excrete waste nitrogen in the 
form of uric acid. This adaptation is necessary because excretion of urea into urine 
requires simultaneous excretion of a large volume of water. In birds, the weight of 
this required water would impede flight. In reptiles, as they live in dry 
environments, conservation of water is important. Uric acid is a relatively insoluble 
compound that can be stored without the need of water as a solvent. However, 
OTC is still found in uricotelic animals, such as chicken for unknown function (Tsuji, 
1983). 
Ammonotelic organisms including most aquatic species, excrete waste nitrogen 
directly in the form of ammonia from the blood to the large volume of water passing 
through their gills. However, ammonotelic organisms still need OTC to synthesize 
urea for other purposes. Chimaera and Elasmobranches such as sharks, rays, skates 
use urea for osmoregulation (Mommsen and Walsh, 1989). Toadfish uses urea for 
nitrogen cycling between the liver and the gut (Mommsen and Walsh, 1989). 
Plants, which recycle virtually all amino groups have no need for nitrogen 
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Citrus limonum leaves 
Crucifer leaves, Arabidopsis thaliana 
Kidney bean leaves, Phaseolus vulgaris 
Legume leaves, Canavalia lineata 
Pea seedling, Pisum sativum 
Phaseolus vulgaris 
Yeasts, fungi 
Neurospora crass a 
Saccharomyces cerevisiae 
DNA 
Koger and Jones, 
1997 
Protein 
Marshall and Cohen, 
1972 
DeGregorio et al., 
1993 
Pierson et al., 1977 
Kalousek et al. , 1978 
Koger et al., 1994 
lusty et al., 1979 
Joseph et al., 1964 
Shimogiri et al., 1998 Tsuiji , 1983 
Joseph et al., 1964 
OeGregorio et al. , 
1993 
Xiong and Anderson , 
1989 
Bellocco et al., 1993 
Quesada et al., 1999 Slocum et al. , 1997 
Lee et al., 1998 
Lee et al. , 1997 
Williamson et al., 
1996 
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Slocum and Richar, 
1991 
Lee et al., 1998 
Bates et al., 1985 
Eisenstein et al., 
1984 
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Sources ^ Protein 
Actinomycetes 
De La Fuente et al., 
Nocardia lactamdurans 
1996 
Marshall and Cohen, 
Streptococcus faecalis 
1972 
Streptococcus lactis Ravel et al., 1959 




Halobacterium halobium(salinarium) Ruepp et al., 1995 Ruepp et al., 1995 
Pyrococcus furiosus Roovers et al., 1997 Legrain et al., 1997 
Eubacteria 
Aeromonas formicans Tricot et al., 1989 
Bacillus licheniformis Legrain et a I., 1977 
Mountain et al., 1990 Neway and Switzer, 
Bacillus subtilis 
1983 
Escherichia coli K-12 Kuo et al., 1985 
Legrain and Stalon, 
Escherichia coli W 
1976 
Mycobacterium bovis Timm et al., 1992 Timm et al., 1992 
Mycobacterium smegmatis Ahmad et al., 1986 
Mycoplasma hominis Schimke et al., 1966 
Baur et a I., 1987 已 aur et a I., 1987 
Pseudomonas aeruginosa 
Itoh etal., 1988 
Pseudomonas fluorescens Stalon et al.., 1972 
Pseudomonasputida Legrain etal., 1977 
Salmonella typhimurium Abdelal et al., 1977 
Thermus thermophilus Sanchez et al., 1997 Sanchez et al., 1997 
) 
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Rnifi nf nin In the Urea Cycle 
1.4.1 The urea cycle 
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In our food intake, approximately 16% of protein consists of nitrogen. 
Nitrogen is converted to ammonia in metabolism but the accumulation of ammonia is 
toxic. Thus, 90% of nitrogen not used by the body is metabolized by the urea cycle 
to form urea, which is a less toxic substance for excretion. 
The urea cycle begins inside the mitochondria and continues into the cytosol. 
Ammonia (NH4+) and HCO3" produced by mitochondria respiration, are combined 
into carbamyl phosphate by carbamyl phosphate synthetase I in the mitochondrial 
matrix, with N-acetylglutamate as the positive modulator. 
Carbamyl phosphate donates its carbamyl group to ornithine to form citrulline 
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and release Pi, catalyzed by OTC. Citmlline is released from the mitochondrial into 
the cytosol. 
The carbonyl group of citmlline condenses with the amino group of aspartate to 
form argininosuccinate, catalyzed by arginosuccinate synthetase. This introduces 
the second amino group into the urea cycle. 
Argininosuccinate is then reversibly cleaved to form arginine and fumarate by 
argininosuccinate lyase. 
Arginine is cleaved to yield ornithine and urea by arginase. Ornithine is thus 
regenerated and can be transported into the mitochondrial to initiate another round of 
urea cycle. The urea synthesized in the liver is then transported to the kidneys, 
which excretes it in urine. 
The overall reaction of the urea cycle is shown as follows: 
2NH4+ + HCO3- + 3 ATP4- +H2O + Urea + 2ADP^- + + A M P � .+ 5H+ 
1.4.2 Catalytic mechanism of OTC 
+ H H3N. I COO" C 
( C ‘ ) 2 R 
H + ^ ^ H a \ 0 OTC 1 H 
H + O - P - 0 - ^ „ / | ！ / N + O 
� 0 - — J f c / V / < o O 
� 藝 
Ornithine + Carbamyl Phosphate Tetrahedral intermediate Citmlline + Pi 
Adapted from Snodgrass PJ, 2004 
The catalytic mechanism of OTC (Snodgrass, 2004) was developed from that of 
aspartate carbamyltransferase (ATC), which is closely related to OTC in sequence, 
structure, and functions. ATC [E.G. 2.1.3.2] catalyzes the conversion of aspartate 
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and CP to form carbamoylaspartate, which is the second step in the de novo 
biosynthesis of pyrimidine nucleotides. With OTC, ornithine and CP forms a 
tetrahedral intermediate in a chair conformation. This intermediate allows the 
phosphate group of CP to receive a proton from the d -amino group of ornithine and 
become a better leaving group, leading to the collapse of the intermediate and the 
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1.5.1 Urea cycle disorders 
Urea cycle disorders involve inborn errors in the enzymes of the urea cycle. 
The urea cycle consists of five enzymes: carbamyl phosphate synthetase (CPS), OTC, 
arginocuccinate synthetase (AS), argininosuccinate lyase (AL), and arginase. In 
addition, five cofactors are necessary for optimal urea cycle enzyme activity. The 
most clinically important one is N-acetylglutamate (NAG), which activates CPS. A 
deficiency of any one of these enzymes or cofactors results in abnormal 
accumulation of ammonia in blood. 
The six urea cycle disorders are named as follows: CPS deficiency (CPSD); 
OTC deficiency (OTCD); argininosuccinate acid synthetase deficiency 
(citrullinemia); argininosuccinase acid lyase deficiency (argininosuccinic aciduria); 
arginase deficiency (argininemia); and N-acetylglutamate synthetase deficiency. 
1.5.2 OTCD 
OTCD (OMIM #311250) was first documented in 1962 in two female first 
cousins (Russell et al., 1962). It was the first reported urea cycle disorders. The 
main consequence of OTCD is hyperammonemia, which further leads to a series of 
disorders in the body. 
1.5.3 Prevalence of OTCD 
Among the first five urea cycle disorders, OTCD is the most common. In 
Japan, the estimated frequency of urea cycle disorders collectively is 1 per 30,000 
while that of OTCD is 1 per 80,000 (Nagata et al., 1991). 
Urea cycle disorders were thought to be rare disease but this may not be the case 
based on another estimation of their frequency (Brusilow and Horwich, 1995). Of 
17 
All Ahn»»fr n r r ^ J j 
the cases referred to The John Hopkins Hospitals from 1974 to 1994, 
argininosuccinase deficiency contributes 57 out of a total 545 cases of urea cycle 
disorders. Another screening performed at 4 weeks of age showed that 
argininosuccinase deficiency occurs at an incidence of 1 per 70,000 live births. By 
combining these two data, the incidence of urea cycle disorders can be calculated to 
be 1 per 8,000. As OTCD constitutes 61% of urea cycle disorders, its frequency 
becomes 1 per 14,000. The above calculations show that the occurrence of urea 
cycle disorders, as well as OTCD, is similar to many commonly recognized diseases, 
for example, childhood leukemia with an incidence of 1 per 25,000 and end-stage 
renal disease with an incidence of 1 per 100,000. 
Because OTCD and other urea cycle defects can often go unrecognized, it is 




All Ahn"fr n x r m 
f^ ymptnmsofOTCD 
1.6.1 Symptoms 
The clinical phenotype of OTCD in hemizygous males and in heterozygous 
females shows a spectrum of severity ranging from neonatal hyperammonaemic 
coma to asymptomatic adults. This phenotypic variability may be caused by 
different mutations in the gene. As OTCD is an X-linked dominant disorder, 
hemizygous males are more severely affected, while heterozygous females tend to 
have milder symptoms or remain asymptomatic. 
OTCD patients are arbitrarily classified by the onset of disease into a neonatal 
group and a late-onset group. The neonatal group represents patients presenting 
symptoms from the second day after birth to 28 days; while the late-onset group 
presents symptoms beyond 29 days after birth (Snodgrass, 2004). Neonatal 
hyperammonemia usually presents with feeding difficulties, lethargy, respiratory 
alkalosis, vomiting, impairment of consciousness, convulsions, and coma. Patients 
with late-onset hyperammonaemia present with headache, loss of appetite, protein 
avoidance, cyclical vomiting, lethargy, hyperventilation and episodes of abnormal 
behavior, such as hyperactivity, night restlessness, biting, self-injury, delusions, 
hallucinations, and psychosis. Sometimes, patients also manifest disorientation, 
confusion, ataxia and hyptonia. Asymptomatic individuals often have a specific 
anorexia for high protein foods (Legras et al., 2002), sometimes leading to the 
voluntary adoption of a vegetarian diet. 
Table 1.2 lists some common symptoms developed in OTCD, and the 
corresponding case numbers in neonatal onset males, late-onset males, and females. 
Focal neurological signs, such as hemiplegia are observed in some patients 
(Nicolaides et al., 2002). This may be due to alterations in vascular endothelial 
wall integrity or alterations in cerebral perfusion and metabolism with an 
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accumulation of toxic metabolites (Schwab et al., 1999). Acrodermatitis 
enteropathica-like rashes have also been reported (Lee et al., 2002). This may be 
linked to a deficiency of the essential amino acid arginine, which is a major 
constituent in human epidermal keratin. Secondary carnitine deficiency develops in 
some patients, especially during a hyperammonemic attack. Persistent carnitine 
deficiency may be present even when plasma ammonia is normal (Mayatepek et al., 
1991). Acute pancreatitis has also been reported as a complication (Anadiotis et al., 
2001). 
Symptoms Neonatal-onset Late-onset Females  
males males  
Vomiting 16 68 71 
Lethargy, coma 91 87 81 
Seizures 33 28 28 
Abnormal behavior 16 30 42 
Protein intolerance 6 7 31 
Delayed growth 2 6 21 
Delayed development 13 9 34 
Incoordination 5 7 25 
Positive family history 78 6 44 
Persistent CNS deficit 0 4 10 
Total cases 67 82 118 
Remarks: Figures are shown as percentage of total cases. 
(Adapted from Snodgrass, 2002) 
1.6.2 OTCD in males 
In neonatal onset males, the average liver OTC activity is only 1.1 士 3.1o/o of 
normal. With such a low activity, the affected fetus can still survive because 
placental circulation dialyzes the toxic wastes from the fetal circulation. Minimal 
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protein ingestion in the perinatal period may delay the development of symptoms to 
several days after birth. With a high protein load after birth, hemizygous males 
with little or no OTC activity develop a hyperammonemic crisis and proceed rapidly 
to coma and death in the first few days after birth. 
In contrast to neonatal onset males, the disease in the late-onset group becomes 
overt in adolescence or during the reproductive age period. It is surprising to note 
that some hemizygous males survive for many years despite of a low OTC activity. 
In a case involving a large five-generation family in which a Ala208Thr mutation 
was identified, the mutation was found to originate in the great-grandfather of the 
index patient, who never had dietary restrictions or hyperammonemic throughout his 
life and died at age 59 of liver carcinoma (van Diggelen et al.，1996). 
Table 1.3 lists the statistical data of the reported cases from 1969 to 2002, 
showing males subdivided into neonatal onset and late-onset group. 
1.6.3 OTCD in females 
Female OTCD heterozygotes exhibit wide clinical expression, ranging from 
being apparently asymptomatic to having the same profound neurologic impairment 
as observed in severely affected males. Because the OTC gene is located on the X 
chromosome, heterozygous females have a normal and an abnormal allele. 
Lyonization (Lyon, 1961) causes random inactivation of one of the two alleles and a 
mosaic pattern of expression in the liver of females (Ricciuti et al., 1976). Most 
* • 
affected females are asymptomatic carriers and appear to be normal until the disease 
is precipitated by some factors such as unusually high protein intake, intercurrent 
infections, trauma, anaesthesia, surgery, childbirth (Schimanski, 1996)，or other 
physiological stresses (Maestri et al., 1998). Treatment with sodium valproate, an 
anti-seizure medication was also found to precipitate OTCD (Tokatli et al., 1991). 
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As pregnancy may be a precipitating cause, it is important to take particular care of 
female carriers during the pregnancy and peripartum period. 
Neonatal onset of the disease in females is not common but is observed. Early 
onset does not correlate with lower OTC activities, but may have reflected the 
protein load that is fed to the infants, usually cow's milk formulas. Human breast 
milk, which is lower in protein, seems to be better tolerated. 
Table 1.3 lists the statistical data of the reported cases from 1969 to 2002, 
showing females subdivided into neonatal onset and late-onset group. 
M ^ Female  
Neonatal Late-onset Total Neonatal Late-onset Total 
Number 67 82 149 12 106 118 
Mortality rate, % 69 55 -- 33 - 29 
Age at onset 2.7±2.4d 8.0±10.5y -- 5.9±11y 
Age at death 43±145d 11.2±11.7y - 7.0±8.4y 
OTC activity, U/L 1.1±3.1 11.6±14.5 -- 16.1±17.2 
Remarks: data are shown as mean +/- SD. 
Keys: d for days; y for years. 
(Extracted from Snodgrass, 2002) 
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1.7.1 Diagnosis 
Patients developing the symptoms mentioned in Chapter 1.61 may be suspected 
of having OTCD. In such cases, the following biochemical tests can be used to 
confirm the diagnosis. 
The first step is to measure plasma or blood ammonia in plasma or whole blood. 
If the newborn is premature and has respiratory distress before 24 hours of age, the 
diagnosis is more likely to be transient hyperammonemia. 
To distinguish OTCD from other types of ureagenesis defects, the next step is to 
measure plasma amino acids by amino acid analyzer or by filter paper blood spot 
amino acid analysis with tandem mass spectrometry. In OTCD, glutamine and 
alanine levels are elevated as storage forms of nitrogen; while citmlline and arginine, 
which are products of OTC, are absent or trace in amounts. 
The next recommended measurement is for urinary orotate and / or orotidine. 
In OTCD, carbamyl phosphate, which is the substrate of OTC, is not rapidly utilized 
for citmlline formation during acute hyperammonemic episodes. It escapes from 
mitochondria into the cytoplasm, and stimulates the synthesis of carbamyl aspartate, 
a precursor of orotate and orotidine. As a result, orotate and orotidine accumulate 
in the urine. The most widely used colorimetric method for measurement of both 
orotate and orotidine is that of Harms and Oberholzer (Hams and Oberholzer, 1980). 
The final proof of OTCD is an assay of OTC in liver or intestinal mucosal 
tissue. � 
The use of molecular genetic methods to confirm OTCD will be discussed in 
Chapter 2.4. 
In addition, as OTCD is a genetic disease, the taking of a detailed patient's 
history and the corresponding family history is important. 
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1.7.2 Differential diagnosis 
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There are several other illnesses that may give similar results in one or more o f 
the biochemical tests mentioned in Chapter 1.7.1. Fig 1.9 shows a diagram for 
diagnosing OTCD and distinguishing the disease from other metabolic defects that 
also result in hyperammonemia. 
2 4 
AM Ahn,»fr nx r ^ ^ 
1.7.3 Carrier testing by protein loading test or allopurinol test 
It is important to establish the carrier status of females at risk of OTCD in order 
to determine the medical and reproductive strategy. 
The protein loading test measures ammonia disposal in the liver by stressing the 
urea cycle with a high protein load. NH4CI (Levin et al.’ 1968)，protein or alanine 
loading test (Cathelineau et al.’ 1972; Pelet et al., 1990) had been used for testing 
carriers of OTCD before. However, these loading tests were associated in some 
subjects with nausea, vomiting, or even hyperammonemic episodes. 
Allopurinol test (Hauser et al., 1990; Climent et al., 1999) is a preferred 
substitute for protein loading test because its side effects are less and sensitivity and 
accuracy are equal. Upon ingestion, allopurinol is converted to oxypurinol 
ribonucleotide, which inhibits orotidine monophosphate decarboxylase from 
converting orotidine 5'-phophate to uridine 5'-phosphate in the pyrimidine synthetic 
pathway, resulting in the accumulation of orotidine and orotate. Carbamyl 
phosphate, the substrate of OTC, is not rapidly utilized for citrulline formation. It 
will also finally lead to orotate and orotidine formationn as mentioned in Chapter 
1.7.1 before. The ingestion of allopurinol will further amplify this formation and 
will reflect in urine excretion. The dose of allopurinol varies in different studies but 
it was shown that the dose adjusted for body weight works well from infants to adults 
(Riudor et al； 2000). 
Though protein loading test and allopurinol test can serve as a quick and 
noninvasive screening for OTCD carriers, it must be noted that occasionally, 
asymptomatic heterozygotes may have normal urinary orotate excretion even when 
given a protein loading test or allopurionol test (Spada et al., 1994)，giving false 
negative results. As a result, some carrier conditions are missed. 
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1.7.4 Prenatal diagnosis 
Prenatal diagnosis is important for families with patients or carriers of OTCD. 
In OTCD, prenatal diagnosis is mainly performed by molecular genetic methods, 
which will be discussed in Chapter 2.5.3. 
1.7.5 Preimplantation genetic diagnosis 
Preimplantation genetic diagnosis (PGD) is a pre-pregnancy test to pre-select 
mutation-free embryos created through in vitro fertilization (IVF) before transferring 
into the uterus of the mother. PGD is particularly useful in obviating prenatal 
diagnosis and pregnancy termination for patients or carriers of genetic diseases. 
PGD has been performed successfully in several OTCD cases, resulting in the birth 
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TmatnifintS Of OTCD 
Current treatment of OTCD involves dietary protein restriction to limit nitrogen 
intake, alternative pathway therapy to remove waste nitrogen, dialysis, and liver 
transplantation. When plasma ammonia levels are found to be elevated, treatment 
can be given with a low-protein diet supplemented with arginine, and with sodium 
phenylbutyrate / phenylacetate and sodium benzoate and to remove excess nitrogen. 
In acute hyperammonaemic episodes, dietary protein is stopped, alternative pathway 
therapy is given intravenously, and dialysis is needed urgently. In severe cases, 
liver transplantation is used as a curative form of treatment. 
In OTCD, asymptomatic carriers outperform symptomatic patients on all tested 
domains of neuropsychological functioning. Therefore, it is important to maintain 
meticulous metabolic control in asymptomatic carriers (Gyato et al., 2004). For 
symptomatic patients, although normal plasma ammonium levels can be maintained, 
they are vulnerable to episodic hyperammonemia that may result in coma and death. 
Successful therapy of episodic hyperammonemia plays an important part in these 
patients (Brusilow et al., 1984). 
1.8.1 Diet and supplements 
Infants with OTCD are placed on a low-protein, high-caloric diet supplemented 
by essential amino acids. This involves combining small amounts of a high 
biological value natural protein, such as breast milk or cow's milk formula, with an 
essential amino acid formula, and a calorie supplement without protein. However, 
micronutrient deficiencies of iron and zinc may occur on a low protein diet. 
In OTCD, arginine becomes an essential amino acid. It helps replace 
mitochondrial ornithine to optimize the remaining OTC function, and to maintain a 
normal rate of protein synthesis. Its precursor, citrulline can be used instead. 
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For asymptomatic patients, voluntary adoption of a vegetarian diet is 
recommended. 
1.8.2 Alternative pathway therapy 
1.8.2.1 Sodium phenylbutyrate / phenylacetate 
The only FDA (Food and Drug Administration) approved drug for treatment of 
OTCD by alternative pathway therapy is sodium phenylbutyrate (Brusilow and 
Finkelstien, 1993). Phenylbutyrate is converted to phenylacetate (PA) after 
beta-oxidation, and PA is activated by an acylating enzyme to • phenylacetylCoA 
(PACoA). PACoA is then joined to glutamine by a second enzyme to form 
phenylacetylglutamine (PAG) (Moldave and Meister, 1957), which is rapidly 
excreted in the urine, thus removing 2 moles of nitrogen for every mole of PA. The 
use of phenylbutyrate instead of PA avoids the unpleasant smell and taste of PA. 
In a retrospective study with nine OTCD patients who had previously been 
treated with sodium benzoate and a low protein diet, switching the treatment to 
sodium phenylbutyrate resulted in no hyperammonamic episodes needing hospital 
admission, and no significant side effects in a follow-up duration of 2 years (Burlina 
et al, 2001). 
1.8.2.2 Sodium benzoate 
Sodium benzoate is also used to treat OTCD. Sodium benzoate is activated by 
CoA to benzoylCoA. BenzoylCoA reacts with glycine and alaninie to produce 
benzoylglycine and benzoylalanine respectively, which are rapidly excreted by the 
kidneys. This provides a pathway for the disposal of waste nitrogen (Tremblay and 
Qureshi, 1993). However, excessive doses of benzoate can be toxic. 
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1.8.3 Dialysis 
Acute hyperammonemia is a medical emergency, for which immediate 
management should be undertaken to minimize permanent brain damage, especially 
in neonates. Dialysis can be used to lower serum ammonia concentration. The 
effectiveness of different form of dialysis, such as blood exchange transfusion, 
peritoneal dialysis, hemodialysis (HD) or continuous renal replacement therapy 
including continuous arteriovenous hemofiltration (CAVH), continuous venovenous 
hemofiltration (CVVH) (Ring and Zobel, 1992; Chang et al., 1999)，continuous 
arteriovenous hemodialysis (CAVHD), continuous venovenous hemodialysis 
(CVVHD) and continuous arteriovenous hemodiafiltration (CAVHDF) The 
effectiveness of these dialysis methods have been compared in different studies. 
Peritoneal dialysis has a slow rate of ammonia clearance (Nyhan et al., 1985) 
and is not usually recommended (Snodgrass PJ, 2004). In a study of the treatment 
of ten hyperammonemic neonates, a comparison of HD, CAVHD, and CVVHD 
revealed that CVVHD achieved the highest ammonium clearance. HD provided the 
highest ammonium extraction but homeostasis was difficult to maintain if continued 
for more than a few hours, a limitation which hampered sustained clearance (Picca et 
al” 2001). In another study of the treatment of three hyperammonemic neonates 
with OTCD, a comparison between peritoneal dialysis, blood exchange transfusion, 
CAVH, CAVHD, and CAVHDF was made and it was shown that CAVHDF provided 
the best ammonia clearance (Chen et al., 2000). Yet another study revealed that 
hemodialysis driven by an extracorporeal membrane oxygenation pump achieved an 
ammonia clearance rate of 170-200 ml/min and was the most effective dialysis 
(Summar, 2001). 
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1.8.4 Liver transplantation 
Total liver transplant or auxiliary partial orthotopic liver transplantation 
(APOLT) should be considered when the diagnosis of OTCD is confirmed and 
life-threatening or injurious symptoms are still occurring despite other means of 
treatment. Males with neonatal onset OTCD are often considered for liver 
transplantation after 6 months of age. Some late-onset males and females who have 
been poorly responsive to alternative pathway therapy have also undergone liver 
transplantation. 
Liver transplantation can result in marked improvement. A girl, whose liver 
biopsy showed a reduced OTC activity at 30% of normal received APOLT, and the 
subsequent liver biopsy showed improvements. The patient had a normal recovery 
(Inui et al., 1996). The earlier the liver transplantation can be performed, more 
episodes of hyperammonemia will be prevented and more likely a OTCD child will 
develop normally. 
The scarcity of liver donors and the problem of transplant size for small children 
lead to the use of split-liver cadaver transplant by replacing the left lobe and leaving 
the original right lobe of the recipient. A partial liver segment with normal enzyme 
activity from the donor is sufficient to correct hyperammonmia in the patient. It has 
even been shown that retaining the native liver brought several advantages. The 
native liver can serve as an available backup for other liver functions in case of graft 
failure and rejection and it has the ability to recover function. As long as 
living-related donors serve as the main source of donor organs, APOLT is a safe 
approach to liver transplantation in OTC (Kasahara et al., 1998). 
Before transplantation, potential donors have to be evaluated with the 
allopurinol loading test to exclude heterozygotes. Recent advances in organ 
procurement, surgical technique, and immunosuppression have significantly 
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decreased morbidity and mortality. However, it should be noted that the mortality 
rate of liver transplantation is still around 10%, and there can be significant 
complications associated with the transplantation. In the short term, thrombosis and 
haemorrhage can occur, and in the long term viral and bacterial infections are a 
common problem. There is also the possibility that graft rejection in spite of 
immunosuppression will occur (Lee and Goss, 2001). After liver replacement, 
plasma citrulline levels may remain deficient, probably because of the persistent 
intestinal mucosa defect, so this amino acid should continue to be provided (Busuttil 
etal, 1998). 
The transplantation of a liver from an asymptomatic carrier mother to her 
daughter resulted in normal metabolism in the recipient and no adverse effects in the 
donor (Nagasaka et al.，2001). However, it should be noted that living-donor 
transplantation raises ethical questions. 
1.8.5 Other medications 
Intravenous flumazenil, a drug that competitively inhibits benzodiazepine 
binding to the GABA^enzodiazapine receptor complex in the brain, has been given 
for the treatment of the acute encephalopathy of OTCD with good results (Meyer and 
Gavrilova, 2002). 
L-camitine therapy can be used to prevent secondary carnitine deficiency 
developed from OTCD (Mori et al., 1990). Also, carnitine can be used to minimize 
the adverse effects of sodium benzoate treatment in hyperammonemia (Sakuma, 
1991; Michalak and Qureshi, 1995). 
In hyperammonemia, elevated levels of quinolinic acid have been found in the 
cerebrospinal fluid of affected children. Quinolinic acid acts as a neurotoxin by 
activating the N-methyl-D-aspartate subclass of glutamate receptors and causing 
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dysfunction and later irreversible damage to neurons. N-methyl-D-aspartate 
blocking agents such as dextromethorphan or competitive inhibitors such as 
kynurenic acid can be considered to ameliorate quinolinic acid toxicity. 
1.8.6 Counseling 
Although OTCD heterozygous females often present milder symptoms, the 
clinical course in a fraction of children can include manifestations similar to those in 
affected males. OTCD carrier families should be counseled regarding the 
possibility of significant hyperammonemia, neurologic deficit, and the need for 
pharmacologic and dietary intervention in their carrier daughters (Fries et al., 1994). 
The possibility of gonadal mosaicism needs to be considered when counseling 
couples, who have a previously affected child with OTCD but both of them are not 
carrier of the disease (Bowling et al., 1999). 
A survey of families who have a child with a urea cycle defect revealed that 
their three greatest sources of stress were financial problems, fear of the child's death, 
and the restrictions imposed by the diet. An inter-disciplinary team of 
geneticist-physicians, nephrologists, nurses, social workers, psychologists, and 
financial/insurance advisors is needed to cope with the illness for the patients and 
their families (Cederbaum et al.，2001). 
1.8.7 Gene therapy 
After early success in the correcting of OTCD in spf mice, a murine model of 
the disease (Stratford-Perricaudet et al., 1990; Ye et al., 1996; Ye et al., 1997) by 
adenovirus (Ad) vectors, OTCD was once regarded as one of the genetic diseases 
'likely to be among the first treated' with gene therapy (Raper et al., 1995). 
However, despite various achievements made in developing gene therapy for 
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OTCD, the results of the phase I clinical trial (Raper et al., 1998) were a great 
disappointment. Although the toxicity associated with administration of the vector 
was investigated in non-human primates including baboons (Raper et al； 1998) and 
rhesus monkeys (Nunes et al., 1999)，one of the patients, a 18-year-old male with 
late-onset OTCD experienced lethal complications due to a generalized cytokine and 
immune response to the vector. This event forced the FDA to put a 'clinical hold' 
on enrolling any new patients and provoked a civil lawsuit against all involved 
parties (Fox, 2000). Among the other 18 patients, 7 showed transgene expression 
but none showed more than 1% of hepatocytes affected. Only 3 subjects showed 
modest increase in urea cycle metabolite activity, and that was not statistically 
significant. In addition, most of the subjects experienced significant side effects, 
included myalgias, fever, flulike symptoms, increased hepatic transaminases, 
thrombocytopenia, and hypophosphatemia (Raper, 2002). 
The outcome of this clinical trial has been controversial and has unleashed a 
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2.1.1 lype of mutations 
Mutations in OTC include point mutations resulting in missense mutations or 
premature stop mutations, small insertions or deletions, and large deletions. The 
majority of OTCD cases arise from point mutations and small deletions/insertions in I B 
the gene. About 10 percents of cases are due to partial gene deletions. Deletion of 
the entire gene and contagious regions of the X chromosome (Francke, 1984) are 
uncommon. 
2.1.2 How mutations cause OTCD? 
Mutations in the OTC gene promoter or other regulatory elements can lead to 
low transcriptional activity and underexpression of the gene. 
Mutations involving the intron splice sites, e.g. the invariant AG at the 3'-end of 
the acceptor splice site and the invariant GT at the 5' end of donor splice sites, will 
affect the correct splicing of the introns and processing of the primary transcript. 
Mutations in the exons affect the protein in various ways. Missense mutations 
can cause substitution of a conserved, essential residue and crucial for the function of 
the protein. Nonsense mutations result in premature translational termination. 
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PrnnRrtifts of QTC Mutations 
2.2.1 Heterogeneity 
Mutations of OTC are scattered throughout the gene, and nearly every family 
affected has a unique mutation. Up to now, more than 278 mutations have been 
identified. Table 2.1 summarizes the mutations found in OTC, which are I H 
subdivided into exon mutations and intron splice site mutations. 
2.2.2 Neonatal vs late-onset 
Clinically, patients with OTCD ean be classified into two groups according to 
the onset of disease. For neonatal onset, the disease onset is within the first month 
after birth; the OTC mutants have no enzyme activity. For late-onset, the disease 
onset is after the first month of life; the OTC mutants have residual enzyme activity. 
Generally, mutations causing neonatal disease affect amino acid residues that are 
’buried’ in the interior of the enzyme, especially around the active site; while those 
associated with late-onset tend to be located on the surface of the protein (Tuchman 
et al, 1998). 
2.2.3 Recurrent mutations 
Recurrent missense mutations seem to be equally distributed among most CpG 
dinucleotides. No single missense mutation has a relative frequency of more than 
6.4% (Tuchman et al., 1996). 
* 
i 
2.2.4 Gonadal mosaicism 
Gonadal mosaicism has to be considered when OTCD recurs in the offspring of 
couples with normal genotype in the peripheral blood. The rate of gonadal 
mosaicism in OTCD is unknown but is probably low (Bale AE, 1999). 
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2.2.5 Sporadic mutations 
De novo mutations can occur in the OTC gene during paternal spermatogenesis 
or maternal oogenesis (Liechti-Gallati et al., 1991). New mutations occur more ^ H 
often in father's sperm than in mother's ova (Snodgrass, 2004). In a study with 28 
males and 15 females with OTCD, 7% of males but 80% of females had sporadic H 
mutations. Because of the difference in mutation rates between male and female 
germ cells, the risk of having carrier status in a mother with an affected son is 
estimated to be 9/10 or higher; while the risk of a mother with an affected daughter is 
much lower, approximately 2/10 (Tuchman et al.’ 1995). 
2.2.6 Polymorphic Presentation 
Even with the same mutation, different individuals can have a different 
presentation of the disease. In a case involving a four-generation family, the index 
patient, a 10-year-old boy died of late-onset OTCD. He was found to have an 
Ala208Thr mutation in the OTC gene. The mutation was further detected in several 
clinically healthy male and female relatives, the oldest male being 97 years old 
(Ausems et al., 1997). The cause for variable expressivity of this and other OTC 
mutations is currently unknown but is likely to be involved in a combination of 
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Some base changes cause no functional effects and appear to be polymorphisms. 
Table 2.2 summarizes all the polymorphisms found in OTC. 
When specific mutations cannot be located in an affected family, 
polymorphisms can serve as a tool for tracking deleterious OTC alleles and for use in I H 
carrier identification and prenatal diagnosis in these families (Plante and Tuchman, 
1998). 
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Diagnosis of OTCD can be established by different methods as mentioned in 
Chapter 1.7. Here, we will focus on direct and indirect DNA-based diagnosis of 
OTCD. The methods involved include restriction fragment length polymorphisms 
(RFLP) (Schwartz et al” 1986)，single-strand conformation polymorphism (SSCP), H B 
denaturing gradient gel electrophoresis (DGGE) (Finkelstein et al.’ 1990), chemical 
mismatch cleavage (CMC) (Grompe et al., 1989), linkage analysis and mutation 
analysis. 
2.4.1 Restriction fragment length polymorphisms 
The use of RFLP in detecting 
carriers of OTCD began in 1986. In ^ ^ ^ ^ t M i M M d m m ^ ^ ^ ^ ^ M 
DMA • rrrtnctioo Kc»tr»ctkHt 
«n7ymc fragntmH _ _ _ _ _ 
RFLP analysis, extracted DNA is H i t M 剛‘""； 
I I m — I N I mil m i l 
J. , . , , i f f I" IB limn I III 
digested with restriction endonucleases, , „ ; 
NiltcwUuloK .1'jp.T ( ~ 
followed by separation of the digested : \ 
fragments by electrophoresis, transfer 
tolutum ^ ^ " ‘ ‘ 
of the bands to a nitrocellulose 工 ： \ \ ^ � � � 
membrane, and hybridization of the —' 
DNA fragments to radioactive probe 
by Southern blot. The probe, which is a full-length cDNA of a gene, hybridizes to 
restriction fragments by complementary base pairing. Finally the result is 
visualized, by autoradiography. By using appropriate restriction endonucleases, 
patients carrying the mutations that affect the relevant restriction site will result in 




2.4.2 Single-strand conformation polymorphism 
In SSCP or single-strand 
conformational analysis (SSCA) (Orita 
\ ' \ Hoirozygole A Heleiozygota Honnoiygote 8 
et al.y 1989)，the exons and adjacent 
introns of a gene are amplified by PCR. ^ ^ 
Dduatuf« wrth t>e«t fofmamtdft or NaOH 
The PCR products are denatured to • 
separate into single strands, rapidly 
cooled to maintain their conformation, ^ ^ ^ ^ ^ ^ ^ 
, , , CMI in ic9C«1h an<J run nwiw PAG ©i»«rophofow» 
and electrophoresed on a 12% • 
polyacrylamide gel containing 10%  
glycerol, using a Tris-borate-EDTA 
buffer at pH 8.0. Each denatured 
Double eiranda single-stranded DNA molecule forms = =  
Silver SUinmg 
intrastrand base pairing and other Adaptedfwm Amersham Biosciences K.K.. 2004 
bonds based on the nucleotide 
sequence, resulting in a unique three-dimensional conformation, and thus giving a 
different rate of migration in the gel electorphoresis. As a result, a mutant with 
single base alteration can be distinguished from the wild-type in SSCP. The 
sensitivity of SSCP is close to 85% (Climent and Rubio, 2002) and most studies 
using SSCP for diagnosis require further confirmation by DNA sequencing (Tsai et 
al, 1993; Reish et al.，1993; Garcia-Perez et al.’ 1995). 
> 
2.4.3 Denaturing gradient gel electrophoresis 
In the DGGE method, the exons in a gene are amplified by PCR, and the PCR 
products are then separated in an acrylamide gradient gel containing 40% formamide 
and 7 M urea. When dsDNA electrophoreses through the gel, they are subjected to 
4 0 
Introduct— 
an increasingly denaturing environment and partially melt. Partially melted 
fragments have single-stranded regions and migrate much more slowly through the 
gel than double-stranded fragments. As the denaturing environment increases, the 
DNA fragments will dissociate completely and almost stop migrating. The position 
in a gel where the dsDNA fragments melt and become ssDNA depends on the H I 
nucleotide sequence in the melted region. As a result, a single base alternation in 
the mutant can be distinguished from the wild-type in DGGD by gel position. 
2.4.4 Chemical mismatch cleavage 
In the CMC method (Cotton et al., 1988)，mispaired nucleotides within 
heteroduplexes are modified by chemical agents, in which mispaired cytosine 
residues react with hydroxylamine and mispaired thymidine residues react with 
osmium tetroxide. The sites of chemical modification are cleaved by piperidine, 
and the molecules are then separated by size and stained to identify the location of 
the mismatched positions. 
2.4.5 Linkage analysis 
Linkage analysis is an indirect method of genetic diagnosis based on the 
cosegregation of markers and phenotypes in a pedigree. The error rate of diagnosis 
of genetic diseases based on linkage analysis depends on the recombination of the 
markers and the gene locus (Liechti-Gallati et al., 1991), i.e., the recombination 
fraction.� 
2.4.6 DNA sequencing 
DNA sequencing involves amplification of the exons and intron-exon 
boundaries of a gene, followed by direct DNA sequencing of the gene to identify any 
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abnormality. After sequencing of all 10 exons and flanking introns was achieved in 
1996，this method becomes more widely used in the diagnosis of OTCD. DNA or 
RNA samples for mutation analysis can be extracted from peripheral blood, ^ H 
leukocytes, lymphoblast (Giorgi et al； 2000; Bisanzi et al.’ 2002) or fibroblasts 
(Rapp et al., 2001). For prenatal diagnosis, DNA samples can be isolated from H U 
amniotic fluid cells, cultured amniocytes, chorioic villi (Yoo and Kim, 1998) or 
single fetal nucleated erythrocyte isolated from maternal blood (Watanabe et al., 
1998). 
DNA sequencing has been regarded as ‘the most reliable way，of detecting 
carrier status in females, and for performing prenatal diagnosis in families with an 
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In addition to clinical diagnosis, molecular genetic analysis can be used for 
carrier testing and prenatal diagnosis in families with OTCD. Furthermore, genetic ^ H 
analysis provides other advantages over alternative methods in diagnosis, carrier ^ H 
testing and prenatal diagnosis. H U 
2.5.1 Diagnosis 
Molecular genetic methods provide a non-invasive and reliable detection of 
mutants. Liver biopsy is commonly used in diagnosis of OTCD. However, false ！ 
positive results were reported in two cases, in which the subjects manifest symptoms | 
i 
of OTCD despite normal enzyme activity in the liver. Both cases were later found | 
1 ) r to have mutations in OTC, namely Hisl36Arg (Vella et al., 1997) and His202Pro ！ I 
(Staudt et al., 1998) respectively by mutation analysis. Also, tissue assays are ！ 
fraught with possible sampling errors (Snodgrass, 2002). i 
j 
1 I I 
2.5.2 Carrier testing 
Protein loading test or allopurinol test are traditionally used for carrier testing of 
OTCD, however, the tests sometimes give rise to false negative results. In families 
with partial enzyme deficiencies and have borderline results in such tests, carrier 
status can be clarified easily by molecular genetic methods (Wendel et al., 1988; 
Grunewald et al., 2004). 
> 
2.5.3 Prenatal diagnosis 
Prenatal diagnosis is important as it provides an early detection of the disease, 
allowing prospective treatment starting from birth. As discussed in Chapter 1.9，the 
prognosis of the neonatal onset group is grave; patients usually succumbed rapidly or 
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may have developmental disabilities even if survived. In a study of 8 OTCD infants 
who were identified by prenatal diagnosis and treated shortly after birth, 5 subjects 
avoided severe hyperammonemia and survived the neonatal period. These ^ H 
surviving patients had a more favorable neurological outcome than patients rescued ^ H 
from neonatal hyperammonemic coma (Maestri et al, 1991). | H I 
However, OTC is not expressed in amniocytes and there are no unusual 
metabolites found in the amniotic fluid. Assay of OTC activity from fetal liver 
biopsies (Holzgreve and Golbus, 1984) is possible, however, the procedure is risky 
and associated with fetal loss (Shulman and Elias, 1990). Therefore, molecular 
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Exon Nucleotide Change Amino Acid Change Onset References 
Exon mutations - Males | | | | 
1-10 del exons 1-10 N Tuchman et al., 2002 ^ H 
1-3 del exons 1-3 del exons 1-3 N Tuchman etal., 1997 ^ H 
1 CAC—delA H18, frameshift, early ter N Tuchman et al., 2002 ^ U 
1 CGA—TGA R 23 ter, Leader sequence N Grompe etal., 1991 
1 CGG 一 CAG R 26 Q, Leader sequence N Grompe etal., 1989 
2 GGC—TGC G39C N Calvas etal., 1989 
2 CGT-TGT R40C L Oppligeretal., 1995; PloechI et 
al., 2001 
2 CGT—CAT R40H L . Davis, 1986： | 
Oppliger et al., 1995; Tuchman 丨 
and Plante, 1995; 
Matsuda etal., 1996; i 
Gilbert-Dussardier et al., 1996; ^ 
Nishiyori et al., 1997; Galloway 
et al., 2000; PloechI et al., 2001 
2 CTA—CCA L45P N Grompe etal., 1989 
2 del A, CTA frameshift. 63 ter N Calvas etal., 1998 
2 AAC一ATC N471 N Tuchman etal., 1997 | 
2 ins G, frame shift K 54 ter N Matsuda and Tanase 1997; | 
Shimadzu etal., 1998 I 
‘ "'““ • • I 
2 GGA—AGA G 50 R L Tuchman etal., 1997 j 
2 GAA->AAA E 52 K N McCullough et al., 2000 
2 GAA—GAT E 52 D L McCullough et al., 1992 
2 ATT->AGT 1 53 S N Tuchman et al., 2002 
2.. TAT-^ GAT Y 55 D L Matsuda and Tanase, 1997 
2 ATG—ACG M56T L Tuchman etal., 1997 
3 del exon 3 N Tuchman, 1992 
3 , TTA—TCA L76S N Genet et al., 2000 
3 TTG-^ TTT - L77 F L Youssoufran et al., 1986 
3 GGG—GAG G 79 E N Tuchman etal., 1992 
3 AAG-»AAT K 80 N L Galloway et al., 2000 
3 GGC—CGC G83R N Tuchman etal., 1997 
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Exon Nucleotide Change Amino Acid Change Onset References 
3 GGC-GAC G83D N Bartholomew and McClellan, H j M 
1998 ^ H 
3 GAG—AAG E 87 K N Feldmann etal., 1992 
3 AAA—AAT K 88 N N/L Reish etal., 1993： Oppligeref | | U 
al., 1996 
3 AGT—AAT S 90 N N McCullough et a/., 2000 
3 CGA—TGA R 92 ter N Grompe etal., 1991 
3 CGA—CAA R92Q N Grompe etal., 1991 
3 ACA—GCA T93A L Garcia Perez et al., 1995 
3 AGA—ACA R94T L Tuchman etal., 1992 
4-10 del exons 4—10 del exons 4—10 N Tuchman etal., 1997 | 
4 GCA—GAA A102 E N Reish et al.. 1993; Tuchman et  
al., 1997 
4 del T, TGT frameshift, 120 N Calvas etal., 1998 
4 CTT—CCT L111P L Grompe etal., 1989 
4 CAT—CTT H 117L L Tuchman etal., 1994 ‘ 
4 CAT—CGT H117 R L Matsuda and Tanase, 1997 
4 ACG一ATG T125M N Gilbert Dussardier et al., 1996 
4 GAC—GGC D126G N Matsuura ef a/., 1994 
4 CGT—CTT R129, L + donor splice error L Strautnieks and Malcolm, 1993 
4 CGT—CAT R129H L Matsuura et al., 1994, Garcia 
+donor splice error Perez et al., 1995 ‘ 
Gilbert Dussardier et al., 1996 
5-8 del exons 5—8 L Maddalena etal., 1988 
5 del exon 5 N Genet et al., 2000 
5" TCTinsT frameshift, 132ter N Maas. 1991 
5 GCA—deIG A135 frameshift, early ter N Tuchman etal., 1992 
5 CGA—TGA R141 ter N Grompe et al., 1991, Maddalena 
‘ etal., 1988 
• Matsuura et al., 1993, Oppliger 
et al., 1996 
“ 4 6 ‘ 
Introductp^" 
Exon Nucleotide Change Amino Acid Change Onset References 
5 CGA^CAA R141 Q N Grompe etal., 1991, Maddalena H j M 
Suess et al., 1992, Matsuura et 
al.. 1993 
5 GTG—GAG V 142 E L Tuchman et al., 2002 
5 TCA—TGA S146 ter N Genet etal., 2000 
5 GAA->TAA E 154 ter N Grompe ef al.. 1989 
5 ATT—ACT 1 159 T L McCullough et a/., 2000 
5 AAT-^ GAT N 161 D N Genet et a/., 2000 
一 ' ~ ‘ 二 
5 GGG—AGG G 162 R N Feldmann etal., 1992 
5 TCA->TGA S 164 ter N Hoshide etal., 1993 
5 GAT—TAT D165Y L Genet et al., 2000 
5 TAC—TAG Y 167 ter N Matsuda and Tanase, 1997 
5 TAC—TAA Y 167 ter N Garcia Perez et al., 1995 
5 CAT->CAA H 168 Q L Tuchman et al., 1997 
5 CCT—CTT P169L N Genet etal., 2000 
5 ATC—ATG I172M N Matsuura et al., 1994, Tuchman 
et al., 1995 
5 GAT->GGT D175G L Genet etal., 2000 
5 TAC—CAC Y176H N Tuchman etal., 2002 
5 TAG—TGC Y176C L Oppliger et al., 1996 
5 del ACGCTC del T178+L, 179 N Matsuda and Tanase, 1997 
I 
5 ACG—ATG T178 M N Oppliger ef al., 1995 
5 dupTCAC frameshift N Gilbert Dussardier et al., 1996 
5 CAG—CAC Q 180 H + donor splice error N, L Tuchman et al., 1995, Matsuda 
and Tanase, 1997 
6 GAA—GGA E181 G N Tuchman etal., 1998 
6 CAC—CTC H182 L N Tuchman etal., 1995 
6 TAT^TGT Y183 C N Satoh et al., 1992,260 
6 GGT—CGT •• G188 R N Oppliger etal., 1996 
6 CTC—TTC L191F L Climent and Rubio, 2002 
6 AGC—AGG s 192 R N Matsuura ef al.. 1993 
6 TGG—TAG W193 ter N Matsuda and Tanase, 1997 
6 GGG-^AGG G195 R N McCullough et a/., 2000 
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Exon Nucleotide Change Amino Acid Change Onset References 
6 GAT一TAT D196Y N Tuchman et al., 1998 H | | 
6 GAT—GTT D196 V N Tuchman etal., 1998, Matsuura ^ H 
6 AAT->AGT N 199 S N Tuchman etal., 2002 
6 delTA N199 frameshift, early ter N Davis, 1986 
6 CTG一CCG L201 P N Matsuda and Tanasel, 1997 
6 CAC—_TAC H202Y L Tuchman etal., 1997 
6 ATG^GTG M205V N Genet etal., 2000 
6 ATG—ACG M一205T N Yoo and Kim, 1998 
6 ATG—AGG M 206 R N Tuchman etal., 1997 
6 AGC—AGA S 207 R N Matsuda andTanase, 1997 
6 GCA—ACA A208T L van Diggelen etal., 1996, 
Tuchman et al., 1997; Ausems 
et al., 1997 
6 GCG—GTG A 209 V N Gilbert Dussardier et al., 1996, 
！ 
Matsuda and Tanase, 1997 ！ 
6 CAC—TAC H 214 Y N Yoo et al., 1996, Yoo and Kim, 
1998 
6 CAG一GAG Q216E N Grompe etal., 1989 
6 insT, CAG—TCA Q 216 S, frameshift. early ter N Tuchman et al., 1994 
6 CCA—GCA P220A L Oppliger etal., 1996 
6 AAG—AAA K221 K. L Matsuda andTanase, 1997 
I 
donor splice error 
7-9 del exons 7~»9 del exons 7-^9 L Legius etal., 1990 
7-8 del exons 7—8 del exons 7—8 N Suess et al., 1992 
7- CCG—ACG P 225 T L Tuchman et al., 1994 
7 CCG^CTG" P225L N Hentzen etal., 1991, Matsuda  
and Tanase, 1997 
7 , CCG—CGG P225R N Garcia-Perezetal., 1997 
8 ACC—ATC ’ T242l L Tuchman etal., 1997 
8 CTG—CAG L244Q N Calvas etal., 1998 
8 ACA—AAA T247K N Tuchman and Plante, 1995 
8 ACA—AAA T262K L Giorgi etal., 2000 
8 ACT—GCT T264A L Matsuura et al.. 1993 
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Exon Nucleotide Change Amino Acid Change Onset References 
8 ACT—GATT T 2641 L Matsuda andTanase, 1997 H | | | 
8 TGG—TTG W 265 L L Giorgi et al., 2000 ^ H 
8 AGC—CGC S267R L McCullough ef a/., 2000 ^ H 
8 ATG—ACG M268T L Matsuura ef a/., 1993 j j ^ 
8 GGA-^GAA G 269 E N Tuchman and Plante, 1995 
8 CAA—TAA Q 270 ter N McCullough et a/., 2000 
8 del AG>insC frameshift, 288 ter N Khooefa/., 1999 
8 del G, G,A del E 272—273, in frame L Segues et al., 1996 
8 CGG—TGG R277W L Finkelstein etal., 1990, Hata et 
• al., 1991 J 
Matsuura et al., 1993’ Oppliger 
et al., 1995 
8 CGG—CAG R277Q L Tuchman etal., 1994, Gilbert 
Dussardier et al., 1994 
8 CGG—CTG R277L L Tuchman et al., 2002 
—  i 
8 CAG—TAG Q 279 ter N McCullough et a/.. 2000 -
8 AAG—AAC K289N N McCullough etal., 2000 
9 del exon 9 del exon 9 N Suess et al., 1992 
> 
9 GCT—delT A 294, frameshift, early ter N Tuchman, 1993 
9 TTA->TTT L 301 F L Capistrano—Estrada ef a/., 
J J 
1994, Climent and Rubio, 2002; ‘ I 
Barshop et al., 2001 _ 
9 CAC-^TAC H 302 Y N Oppliger etal., 1996 
9 CAC~>CGC H 302 R N Genet etal., 2000 
9 CAC—CAG H302Q L Tuchman etal., 1997 
9.. TGC-^CGC C303 R N Calvas etal., 1998 
9 TGC—GGC C303G N Tuchman etal., 2002 
9 TTG—TTT L 304 F + splice error L Tuchman, 1992. Hoshide et al., 
. 1993 
9 del GAA ‘ del E 309, in frame deletion L Tuchman et al., 1994 
9 GAA->TAA E 310 ter N Tuchman. 1993, Reish etal., 
1993 
9 CGA—一TGA R 320 ter N Matsuda and Tanase, 1997; Yoo 
and Kim. 1998 
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Exon Nucleotide Change Amino Acid Change Onset References 
9 CGA—CTA R320 L N Grompe etal., 1991 • • [ 
9 TCA-TAA S 321 ter N Tuchman et al.. 2002 
9 AGA—GGA R 330 G N McCullough et a/., 2000 ^ H 
9 TGG—AGG W 332 R N Rapp efa/..2001 f j ^ 
9 TGG—TGA W 332 ter N Matsuura ef a/., 1994 
1 0 ATG一ATA M335 1 N Tuchman e�a/., 2002 
10 GGT—TCT A336S L Tuchman ef a/., 1998 
10 GTC—CTC V337 L L Matsuda andTanase, 1997 
10 GTG—CTG V_339 L N Tuchman et al., 1997 
10 ACA一AAA T343K L Tuchman etal., 1997 
10 TAC—TGC Y345C N Tuchman et al., 1998 
10 TTT—TGT F354C L Tuchman etal., 1997 
Exon mutations-Females ！ I 
1 ATG—GTG M 1 V L Oppliger et al., 1997 
1 ATG->ATA M1 I L Climent and Rubio, 2002 
1 CGA—TGA R 23 ter L Matsuda andTanase. 1997 
1 CGG—CAG R26Q N, L Oppliger ef a/.. 1997 
备 
2 CAA-.TAA Q 32 ter L Oppliger ef a/., 1997 
‘ 丨••‘ •‘ • i 2 LAG—TAG Q 36 ter L Genet etal., 2000 
• ^ i 
2 CGT~0"GT, R40C L Oppliger ef a/.. 1995 : 
— j 
2 CTC->TTC 1-43 F L Oppliger etal., 1997 i 
2 ACT->ATT ^ L Yoo et al.. 1996 
2 CTA—GTA • L 45 V L Tuchman et al., 1998 
2 AAC—ATC N471 L McCullough et a/., 2000 
2•‘ TTT-TCT F48S L Genet etal., 2000 
2 GGA-^ TGA G 50 ter L Feldmann etal., 1992 
2 GAA-^ TAA E 52 ter L McCullough et al., 2000 
2 �TCA—TTA S60L L Tuchman etai, 1995, Tuchman  
^ et al., 1997 
2 CTG—CCG L63P L Oppliger ef a/., 1997 
2 CAG—TAG 0 69 ter L Climent et al., 1999 
3 AAG—GAG K 80 E L Schultz and Salo, 2000 
3 del CTT del L 82 L Tuchman and Plante, 1995 
5 0 
Introductp^" 
Exon Nucleotide Change Amino Acid Change Onset References 
3 TTA—TGA L 82 ter L McCulIough et a/., 2000 | | | | 
3 AGT—AGG S 90 R L Tuchman efa/.. 1998 
3 ACT—CT T 91 del A L Genet et al., 2000 
3 CGA—TGA R 92 ter N. L Gilbert Dussardier etal., 1996, H i 
Oppliger et al., 1997, 
Bogdanovic et al., 2000 
3 CGA—CAA R92Q L Schultz and Salo, 2000 
3 TTG—TCG L95S L McCulIough et a/., 2000 
4 GGC—GAC G jOOP L Oppliger et al., 1997 
4 GGA—AGA G106 R L McCulIough et a/., 2000 i  
i 
4 CGT—CTT R 129L + donor splice error L Strautnieks et a/., 1991 
•-丨丨丨 • • I 
4 CGT 一 CATa R 129 H + donor splice error L Tuchman etal., 1994, 
Garcia Perez et al., 1995 
5 insTTA V130 ins L L Tuchman etal., 2002 
5 TTG-^ TCG L139S L Tuchman etal., 1997 
5 CGA—TGA R141 ter L Matsuda etal., 1989, 
Maddalena et al., 1988 
Hata et al., 1989, Matsuura et 
al., 1993 
Gilbert Dussardier et al., 1996 
5 CGA—CCA R141P L Tuchman etal., 1997 
5 CGA—CAA R141 Q L Strautnieks etal., 1991, 
Matsuura et al., 1993 
Yoo etal., 1996, 
Yoo and Kim, 1998 
” Hasegawa et al., 1995 
5 AAA—TM L144 ter L Tuchman and Plante, 1995 
5 TTG—TGG L148W L McCulIough et a/.. 2000 
5 , TTG—TTC L148F L Komaki etal., 1997 
5 ACC~^delC .. T 150 frameshift, early ter L Tuchman et al., 2002 
5 GCT-.GTT A152 V L Satoh etal., 1992. 
Kogo et al., 1998 
5 GCA—TCA A155S L Tuchman et al., 2002 
5 1 
IntroduH-inn 
Exon Nucleotide Change Amino Acid Change Onset References 
5 ATT—ACT I 159 T L Garcia Perez etal., 1995 H H 
5 ATC—AGC 1 160 S L Climent and Rubio et al., 2002 ^ H 
5 AAT—AGT N161 S L Tuchman and Plante, 1995, ^ H 
Perpoint et a/., 2001 H U 
^ 丁CA—TGA S 164 ter L Matsuda and Tanase, 1997 
5 CAT—CGT H168R L Vella et al., 1996 
5 CCT—GCT P 169A L Tuchman etal., 2002 
^ ATC—TTC 1172 F L Climent et al., 1999 
5 GCT->CCT A174P L Tsai etal., 1993 
5 GAT—GTT D175 V L Tuchman etal., 1997 + 
5 ACG—ATG T178M L Oppliger et al., 1995 
6 TAT—GAT Y 183 D N Oppliger etal., 1997 
6 TAT—TGT Y183C L Reish ef a/., 1993 
6 GGT—GTT G188V L Climent et al.. 1999 
6 GGG—AGG G195 R L Satoh et al., 1992, Tuchman and 
Plante, 1994 
Matsuura et al.. 1994, Oppliger 
et al., 1997 
Kogo et al.. 1998 
I 
Genet et al., 2000, Legras et al., 
J 
2002 '‘ 
6 GAT 一 AT, deIG D196, frameshift, early ter L Climent etal., 2002 丨 ‘ ‘ — I 
6 GGG-.AGG G197R L Climent et al., 1999 
6 GGG—GAG G 197 E L Tuchman et al., 1998 
6 AAC-^ AAA N 198 K L Popowska et al.. 1999 
CAC—CCC H202P L Staudt et al.’ 1998 
6 TCC—TGC S 203C L Tuchman etal., 1994 
6 ATG—ATC M2061 L Climent et al., 2002 
6 . GCA—ACA A 208 丁 L Ausems et al.. 1997 
6 GCG—GTG • A 209 V L Garcia Perez ef a/., 1995, 
Popowska etal., 1999 
6 ATG—AAG M213 K L Oppliger et al.. 1997 
6 CAC^TAC H214Y L Yooefa/., 1996, 
Yoo and Kim, 1998 
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Introdurt-inn 
Exon Nucleotide Change Amino Acid Change Onset References 
7 deIG del G 222, frameshift, ter L Tuchman etal., 1997, H | | 
Keller etal., 1998 
I CCG—CTG P225L L Oppliger ef a/., 1997 H 
7 GAG->GAA E 239 E, donor splice error L Tuchman etal., 1997 K 
8 del 9 nt del L244-248, frameshift L Calvas etal., 1998 
^ CAT—CCT H255P N Tuchman etal., 1998 
^ GAC—AAC D263 N L Tuchman e�a/., 1997 
8 GAC—GGC D263G L Tuchman etal., 1998 
8 ACT—GCT Tg64A L Giorgi etal., 2000 
8 AGC->CGC S267R L Matsuda and Tanase. 1997 
8 CGG—-TGG R277W L Finkelstein etal., 1990 
^ TGG->delTG W298. frameshift L Schimanski ef a/., 1996 
9 CAC—TAC H 302Y L Genet ef a/., 2000 
9 CAC—CTC H 302 L L Gilbert Dussardier et al., 1996 
9 TGC—TAC C303Y L Tuchman etal., 1997 
9 CCC一CAC P305H L Climent et al., 2002 
9 GAA-^ TAA E 310 ter L Giorgi etal., 2000 
^ GTC—GGC V315G L McCullough ef a/., 2000 
9 GTC—GAC V315D L McCullough e�a/., 2000 
9 丁C丁 F316S L McCullough e�a/., 2000 
9 TCT-^ TTT S318F L Genet etal., 2000 
9 CGA—TGA R 320 ter L Yoo etal., 1996, Matsuda and 
Tanase, 1997 
Yoo and Kim, 1998 
9 GAG—AAG E 326 K L Popowska etal., 1999 
^ AGA-^ GGA R 330 G L Tuchman et al., 1997 
9 delAGA, insT R 330, frameshift, early ter L Climent et a/., 2002 
遍 10 TCC—CCC S340P L Oppliger e�a/., 1997 
10 �C T G - . C C G L341 P L Climent e�a/., 2002 
_ 10 aCA—AAA ^ T343K L Tuchman etal., 1995 
^ TAC^GAC Y345D L Tuchman et al., 1992 
10 CAG—TAG Q 348 ter N Oppliger etaf., 1997 
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Other Bxon mutations H | 
1 GCTTTT—T A13—F14, frameshift Hwu et al., 2003 ^ H 
delGCTTT 
1 42delT F14, frameshift Huang et al., 2003 ^ ^ 
GAA^AAA E98K Bisanzi S et al., 2002 
4 GAA—GGA E122G Gao et al., 2003 
5 TCT^CTT S132P Bisanzi S et al. 2002 
6 AAC—CAA K210Q Valik etal., 2004 
6 GCA—ACA A218T Hwu et al., 2003 
Huang et al., 2003 
8 ACT—AAT T264N Hwu ef a/., 2003 
Huang et al., 2003 
Intron Splice Errors 
IVS1nt+1 g->t donor splice site error L Tuchman etal., 1997 
IVS1 nt+4 a—c splice error, tow mRNA N Hoshide et al., 1996 
IVSInt+5g—a donor splice site error N Tuchman etal., 1997 
lVS1nt+3-6 del aagt, donor splice error L Tuchman et al., 2002 
IVS2nt+1: g—t donor site error Azevedo L et al., 2002 
IVS2nt+1 g-^a donor site error, ？skip E2 N Oppliger et al., 1996. 
Matsuda and Tanase, 1997 
IVS2nt-1 g->a acceptor site lost N Tuchman etal., 1992 
IVS3nt+1 g—a 16 aa's added to exon 3 N Garcia Perez et al., 1995 
IVS3nt+1 delgtaag donor splice site L Tuchman etal., 1997 
IVS4nt-2 a—t acceptor site. 4 aa's lost N Carstens et al., 1991 
IVS4nt-2a—c acceptor site error N McCullough et al., 2000 
IVS4nt-2 a—g acceptor site error N McCullough et al., 2000 
IVS4nt-12 g—a acceptor site error L Hoshide et al., 1993 
A . 
‘IVS5nt+1 g—c donor site error N Oppliger et al., 1996 
IVS5nt+2 t->c exon 5 deleted N Matsuura etal., 1995 
IVS5nt+3 t->tt donor splice site error L Tuchman and Plante, 1995 
IVS5nt-2 a->g acceptor site error N Genet et al., 2000 
IVS6nt+1 g—t donor site error L Tuchman and Plante, 1995; 
Oppliger et al., 1996 
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IVS6nt+1 g—a donor site error L Tuchman etal., 1997 
IVS6nt-1g—a acceptor site error N, L Climent et al., 2002; Tuchman et 
2002 
IVS6nt+2 t-»c donor site error L Tuchman etal., 1997 
IVS6nt+3 del g donor site error L McCullough et al., 2000 
IVS6nt+3 t—tt donor site error L Tuchman and Plante, 1995 
IVS7nt+1 g->a donor site error N Genet et al., 2000 
IVS7nt+1 g—t donor site error L Tuchman et al., 2002 
IVS7nt+21—c donor site, exon 7 lost N Carstens et al., 1991; 
McCullough et al., 2000 
IVS7nt+3 a->g ""” N Carstens etal., 1991 
IVS7nt7-22 dellSnt splice error N Calvas etal., 1998 
IVS7nt-2 a-^ g^ acceptor site error L Popowska etal., 1999 
IVS8nt+1 g—t ？E8 skipping N Oppliger etal., 1996 
IVS8nt+1 g—a "“ L Hoshide etal., 1993; 
McCullough et al., 2000 
IVS9nt+1 g 一t donor splice error N Tuchman etal., 1997 
IVS9nt+2t—c donor splice site error N Tuchman et al., 2002 




Amino Acid Allele 
Exon Codon Nucleotide Change References 
Change Frequency ^ H 
Exon polymorphisms 
0.64/0.36 
2 46 AAA—AGA K^R 
0.68/0.32 Climent C et al., 2002 H K 
4 101 TTT—TTA L—F 0.99/0.01 
4 111 CTT—CCT L—P 1.00/0.00 
5 143 TAT—TAC Y—Y 0.98/0.02 
6 193 TGG-^ TGT W->C 
6 194 ATC—TTC I—F 
6 195 GGG—GGA G—G 1.00/0.00 
0.875/0.125 
8 270 CAA—CGA Q—R 
0.97/0.03 Climent C et al., 2002 
9 333 ACA—GCA T—A 
Intron polymorphisms 
2 IVS2-54nt Ins a(ac^aac) 
3 IVS3-8nt a—t 0.50/0.50 
0.34/0.66 Climent C et al., 2002 
3 IVS3-17nt lnst(ct—ctt) 
3 IVS3-39_40insT 0.66/0.34 Climent C et al., 2002 
4 IVS4+8nt a—g 0.98/0.02 
4 IVS4-7nt a—g 0.71/0.29 Plante and Tuchman, 
1998 
5 IVS5-63nt g—a Azevedo et al., 2003 
6 IVS6+3nt Ins t(gta—gtta) 
8 IVS8 + 35 nt g—t 0.62/0.38 Azevedo L et al., 2002 
.,9 IVS9-12nt g—t 1.00/0.00 
9 IVS9-70 c—t Azevedo et al., 2003 
Regulatory elements 
Amino Acid Allele 
Region Position Nucleotide Change References 
Change Frequency 
5'UTR -512nt Ins ttct Azevedo et al., 2003 
5'UTR -441 nt g—a Azevedo et al., 2003 
5'UTR -365nt g—a Azevedo et al., 2003 
5'UTR -359nt a—g Azevedo et al., 2003 
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Materials & Mpfrhnric 
Biinnmifi ni|A Bttractlon from OTCD Patients hy QIAamp® DNA 
Bloofl Mini Kit 
Genomic DNA was isolated from the peripheral blood of eight OTCD patients MM 
and family members by QIAamp® DNA Blood Mini Kit. Informed consent was 
obtained prior to blood collection. 
> 
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Materials 路 MPfrhnric 
3.1.1 Materials 
3.1.1.1 Patients 
Five male and 3 female unrelated patients identified or suspected of having OTCD 
were investigated for OTC mutations. The patients were from different hospitals • 
located in Hong Kong, Canada, and Mainland China. A summary of the patients' • 
information can be found in Appendix A5. 
3.1.1.2 QIAamp® DNA Blood Mini Kit 
QIAamp® DNA Blood Mini Kit (Qiagen, Hilden, Germany) consists of QIAGEN® 
protease, protease solvent, buffer AL, buffer ATL, buffer AWl, buffer AW2, buffer 
AE, QIAamp® spin columns and 2 mL collection tubes. Protease is supplied 
lyophilized and need to be dissolve in Protease solvent before use. The kit is stored 
at room temperature (RT) while dissolved protease is stored at -20°C. The kit 
claims to have a yield of up to 12 ^g DNA from 200 |iL whole human blood. The 
purified DNA is from 200 bp up to 50 kb depending on the age and storage of 
samples, with majority of 20-30 kb. 
Ethanol absolute GR for analysis (Merck KGaA, Darmstadt, Germany) C2H5OH, 





Materials & Mpfrhnric P 
3.1.2 Methods 
3.1.2.1 Genomic DNA extraction 
Four hundred microlitres whole blood ^ ^ HH 
S a m p l e g e n o m i c ^ H 
was added to 40 i^L Protease. 400 i^L ^ orv丨oIdna • 
buffer AL was then added to the mixture. • 
, ：忍 w w The mixture was vortexed for 15 sees ， ^ 
\ ^ 
and incubated at 56 °C in a heating block ^ ^ 
for 10 mins. 400 ^L absolute ethanol Bind g Eiute 
was added, and the tube was vortexed for ^ 
15 sees. The mixture was then applied 
W a s h n | f u . i l W a s h 
. . ^ T A ® C • 1 ^ M f e r A W l l ^ (BU«TAW21 to the QIAamp Spin Column and  
, QIAamp® DNA Blood Mini Kit isolates centnfuged at 6000 x g for 1 min. 500 
DNA from blood and other body fluids. 
i^L buffer AWl was added, and the Samples are lysed to release the DNA 
, .^  , content, which binds specifically to the column was centnfuged at 6000 x g for 1 
silica-gel membrane in the QIAamp 
min. 500 i^L buffer A W 2 was added, spin column during centrifugation. Salt 
J 1 , … ， " … and pH conditions in the lysate are and the column was centnfuged at 16100 
adjusted to allow optimal binding of the 
X g for 3 mins. The column was further DNA to the membrane, while 
• p contaminants pass through. Any centnfuged at 16100 x g for 1 min to 
residual contaminants which can act as 
remove any residual buffer AW2. 50 PCR inhibitors, such as divalent cations 
and proteins are completely removed in M-L buffer AE was then added to the 
two subsequent wash steps, leaving 
column, and the column was incubated at pure DNA ready to be eluted. 
4 
RT for 5 mins. DNA was eluted by 
centrifugation at 6000 x g for 1 min. The DNA yield and purity were determined 
spectrophotometrically with a BioPhotometer (Eppendorf AQ Hamburg, Germany) 
by measuring absorbance at A260 and calculating the A260/A280 ratio respectively. 
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iiTn mnnQ Ampinication By PCB 
The ten exons with their flanking introns in the OTC gene were amplified by 
polymerase chain reaction (PCR) (Mullis et al., 1986) from genomic DNA extracted • 
from the patients. The PCR products were further purified by MicroSpin™ S-400 • 
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3.2.1 Materials 
3.2.1.1 Chemicals and reagents for agarose gel electrophoresis 
1 kb DNA ladder (Invitrogen Corporation, Carlsbad, California, USA) is supplied in • 
a concentration of 1 \ig/\iL. It is diluted to 100 ng/^iL by loading buffer and TE • 
buffer. It is stored at 4°C. Detailed information can be found in Appendix A. 17. H i 
Ethidium Bromide (Invitrogen Corporation, Carlsbad, California, USA) is supplied 
in a concentration of 10 mg/mL. It is stored at RT. It is carcinogenic and is an 
irritant. 
SeaKem® LE agarose (FMC Bioproducts, Rockland, Maine, USA) is in powder 
form and stored at RT. 
Tris-Acetate-EDTA (TAE) Electrophoresis Buffer (Invitrogen Corporation, Carlsbad, 
California, USA) is supplied in lOx solution. It is diluted to Ix with dHsO. It is 
stored at RT. 
2% agarose gel was prepared by dissolving 1.2 g SeaKem® LE agarose in 120 mL 
Ix TAE electrophoresis buffer and heating in microwave oven. The solution was 
cooled under running tap water to 55°C. 60 ^g ethidium bromide was added. The 
mixture was poured into a gel cast with the suitable comb inserted. It was let stand 
at RT until set. 
3.2.1.2 Chemicals and reagents for PCR 
100 mM dNTP Set (Invitrogen Corporation, Carlsbad, California, USA) is supplied 
in a concentration of 100 mM. It is diluted to 10 mM with dHaO. It is stored at 
-20°C. 
AmpHTaq GolcF DNA Polymerase (Applied Biosystems, Foster City, California, 
USA) is supplied together with Buffer II and MgCl?. The enzyme is stored at -20°C 
while the other components are stored at 4°C. 
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3.2.L3 MicroSpin™ S-400 HR columns 
MicroSpin S-400 HR columns (Amersham Biosciences, Uppsala, Sweden) are 
pre-packed with Sephacryl™ resin and equilibrated in TE buffer. They are stored at • 
4 � C . • 
« • 
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3.2.2 Methods 
3.2.2.1 Primer design and synthesis 
Ten pairs of OTC primers, namely OTCexonlF to OTCexonlOF and OTCexonlR to 
OTCexonlOR, were designed using a web-based software program, Primer3. All 
the exons and flanking introns of the OTC gene were included by the primers. The H 
primers were synthesized by QIAGEN (QIAGEN, Hilden, Germany). The 
sequence of the primers and the corresponding amplified regions in the exons can be 
found in Appendix A.5. 
3.2.2.2 Polymerase chain reaction 
One hundred nanograms genomic DNA 
was amplified in a reaction mixture 
AmpliTaq Gold DNA Polymerase is a 
containing 5 pmol forward primers, 5 chemically modified form of AmpliTaq® 
DNA Polymerase, with a chemical pmol reverse primers, 5 pmol dNTPs, 50 , 
moiety attached to the enzyme. 
nmol MgCb, 1 x Buffer II and 0.5 U When the chemical moiety is attached, 
the enzyme is inactive. By a heat AmpliTaq Gold® DNA Polymerase, 
activation step, the chemical moiety is 
adjusted to a final volume of 25 |xL with cleaved and active AmpliTaq® DNA 
enzyme is released. Thus, during dH20. PCR was carried out in a MJ 
reaction set-up and the first ramp of 
PTC-200 (MJ Research, Waetham, thermal cycling, the enzyme is inactive 
and mis-primed primers cannot be Incorporated, Massachusetts, USA) with GXIGnQSQ. 
the following parameters: 94°C for 12 
‘ mins for denaturation of DNA and activation of the polymerase, followed by 40 
cycles of denaturation at 94°C for 45 sees, annealing for 1 min, and extension at 72°C 
for 1 minute, with a final elongation at ITC for 7 minutes. For exon 1 to exon 7， 
the annealing temperature was 60°C while that for exon 8 to exon 10 was 58°C. The 
amplified PCR products were then analyzed by 2% agarose gel electrophoresis to  
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ensure they are in correct sizes. 
3.2.2.3 PGR product purification • 
MicroSpin™ S-400 HR column was • 
vortexed to resuspend the resin inside. 
MicroSpin旧 S-400 HR columns utilize 
The cap was then loosened one-fourth spin-colomn chromatorgrapy to purify 
DNA for a wide range of applications, turn and the bottom closure was snapped 
such as purification of PGR products 
off. The column was centrifuged at 735 from unincorporated primers and 
“ nucleotides. Spin-column X g for 1 min to remove the storage . . 
chromatorgrapy enables desired 
buffer. The PCR product was then product passing through the gel while 
retaining smaller impurities, applied to the top-center of the resin.  
The column was then centrifuged at 735 
X g for another 2 mins to collect the purified products. 
I 
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The amplified exons were sequenced to screen for mutations by the 
dideoxynucleotide method (Sanger et al, 1977). The sequencing reaction products • 
were purified by genCLEAN Dye Terminator Removal Columns to remove residual • 
dye-labeled dideoxynucleotide terminators that may interfere with sequencing. • 
Sequencing was performed in an automated sequencer. The sequencing of the ten 
exons was first performed by the forward primers. If a mutation was found, the 
mutation will be confirmed by sequencing with the reverse primer. 
» 
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3.3.1 Materials 
3.3.1.1 Chemicals and reagents for sequencing 
BigDye® Terminator v3.1 Cycle Sequencing Kit (Amersham Biosciences, Uppsala, • 
Sweden) consists of BigDye® Terminator v3.1 cycle sequencing mix and BigDye® • 
vl.1/3.1 sequencing buffer (5x). It is stored at -20°C while the buffer can be stored • 
at 4 � C . 
genCLEAN Dye Terminator Removal Columns (Genetix, Hampshire, UK) consists 
of genCLEAN columns, collection tubes and column caps. It is stored at RT. 
TVl/f 一 
MegaBASE Loading Solution (Amersham Biosciences, Uppsala, Sweden) is 
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3.3.2 Methods 
3.3.2.1 Sequencing reaction 
Six microlitres PGR product was added to a reaction mixture containing 3.2 pmol • 
primers, 2 \iL BigDye® Terminator v3.1 cycle sequencing mix and Ix BigDye® • 
vl.1/3.1 Sequencing Buffer, adjusted to a final volume of 10 [iL with dHsO. • 
Cycle sequencing reaction was carried out in a GeneAmp PGR System 9700 Cycler 
(Applied Biosystems, Foster City, California, USA), with the following parameters: 
9 6 � C for 1 min, followed by 24 cycles of 9 6 � C for 10 sees, 5 0 � C for 5 sees, 6 0 � C for 
4 mins. 
3.3.2.2 Sequencing product purification 
genCLEAN Dye Terminator Removal Column was vortexed to resuspend the gel 
inside. The cap was then removed and the tip was snapped off. The column was 
centrifuged at 1000 x g for 2 mins to remove the buffer. 200 ^L distilled H2O was 
added to the columns and centrifuged at 1000 x g for another 2 mins. The 
sequencing product was added to the centre of the resin. The column was then 
centrifuged at 1000 x g for 2 mins to collect the purified product. 
3.3.2.3 Sequencing 
The purified sequencing product was added to 12 |liL MegaBase™ loading solution 
and heated at a 95°C heat block for 5 mins. The direct sequencing was performed 
• in an ABI PRISM® 3100-Avant Genetic Analyzer (Applied Biosystems, Foster City, 
California, USA). The mutation site was identified manually and using BLAST. 
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^ ^ 7 Miitfliinns and 1 Qucstionaftle Polymorplilsms were Identified 
In OTCD Patients 
By DNA sequencing, patients 1 to 8 were found to carry the following mm 
substitutions: Arg26Gln, LeulllPro, Glul22Gly, Argl29His, Lysl44Term, • 
Thrl78Met, Asnl98Ile, and IVS5+1G^T (Fig 4.1a, 4.3a, 4.4a, 4.6a, 4.8a-4.11a). • 
Of these substitutions, Asnl98Ile and IVS5+1 G—T are novel mutations. 
Leul 11 Pro is a known polymorphism. The others are known mutations. 
In some patients, identification of the mutation led to a further screening of 
carriers in the corresponding f a m i l y . -
Patient 1 carried a transition of G to A at nucleotide position 77, causing a 
substitution of arginine by glutamine at residue 26 (Fig 4.1a). The patient came 
from a large family and the disease was found to span four generation (Fig 4.2). 
III6-10 were identified as OTCD patients, while II, 12 and III were identified as 
obligate carriers of the disease. All the male children of II died in early infancy. 
The patient's grandmother (III) was also an obligate carrier. She died at age 63 
from diabetes mellitus, renal disease and cerebrovascular accident. Following 
confirmation of an Arg26Gln mutation in patient 1 (IV3), an extensive screening of 
carriers was performed in the family. Individuals IB, 1111，III3, and III5 were 
shown to be normal. Individual III2 was found to be a carrier. Further analysis 
was performed in her son and daughter. The son (IV1) was shown to be normal. 
The daughter (IV2), who refused fresh milk but drank chocolate milk and tolerated 
. meat, was shown to be a carrier. 
I 
Patient 3 carried a transition of A to G at nucleotide position 365, causing a 
substitution of glutamic acid by glycine at residue 122 (Fig 4.4a). His mother was 
found to be a carrier of the mutation (Fig 4.5). 
Patient 4 carried a transition of G to A at nucleotide position 386, causing a 
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substitution of arginine by histidine at residue 129 (Fig 4.6a). Further mutation 
analysis showed that the patient's father and mother do not have the mutation (Fig 
4.7). In a subsequent pregnancy of his mother, the fetus was also shown to be • 
normal. 
Patient 8 carried a donor splice site mutation at IVS5+1 position with a H 
transversion of G to T (Fig 4.11a). His mother was found to be a carrier of the 
mutation. She also transmitted the disease to the offspring in her second pregnancy 




4.11 Patient 1 carried an Arg26Gln mutation 
a Pat ient 1 b • 
C G A A A T T T i C A G ： A A G T G CA T C A C T T A C T G A A A A T T T C GA • 
F T - T I ImwlMtm 
c Control d Carrier (1112,1114, and IV2) 
G A A ' ^ T T T T C G G T aTG T G A T C ' G A A A T T T T C A G T A A G T G A 
1F IF 80 90 
In 
Fig 4.1 Patient 1 carried an Arg26Gln mutation 
DNA sequencing results of exon 1 of the OTC gene in a and b) patient 1 (rV3); c) 
normal subject; d) heterozygotes (1112，1114，and IV2) sequenced by either 
OTCexonlF or OTCexonlR as indicated. The base involved is arrowed and the 
corresponding codon underlined. 
In 4.1a, the patient was shown to carry a transition of G to A at nucleotide position 77， 
causing a substitution of arginine by glutamine at residue 26. This was further 
confirmed by sequencing in the reverse direction shown in 4.1b. In 4.1d, some 






“ D ^ Q O O I 
Arg 滅 In/- • 
.i.coaO.Q s O m m Hifii 
Arg平In/- Arg平In/- ^ ^ ^ ^ A ^ ^ l n ^ ^ ^ ^ 
'V Am . 6 
Arg26Gln/- Arg26Gln 
Fig 4.2 Pedigree of patient 1，s family 
Black: Affected males; Dotted: Female carriers. 
Patient 1 (IV3) was the index patient. Individuals 113，1111’ III3, and III5 were 
shown to be normal. Individual III2 was found to be a carrier. Her son (IV1) was 
shown to be normal and her daughter (IV2) was shown to be a carrier. Individuals 




4.12 Patient 2 carried a Leull lPro subsitution 
a Patient 2 b • 
C T T G T T T T C C T A C CA C A C A I I T G T G T G G T A G G A A A A C A A G I • 4F m 80 4R 160 170 • 
i i i y Ia/wwvwWJ 
c Control . d 
I 66 T T T T N C l T A C C A C A C A " o i7o 
F T G T G T G G T A A G A A A A C A A G 4F 70 I 4R  kkliJ I f e i l V 
Fig 4.3 Patient 2 carried a Leull lPro subsitution 
DNA sequencing results of exon 4 of the OTC gene in a and b) patient 2; c and d) 
normal subject sequenced by either OTCexon4F or OTCexon4R as indicated. The 
base involved is arrowed and the corresponding codon underlined. 
In 4.3a，the patient was shown to carry a transition of T to C at nucleotide position 
332，causing a substitution of leucine by proline at residue 111. This was further 
confirmed by sequencing in the reverse direction in 4.3b. 
7 2 
Results_H| 
4.13 Patient 3 carried a Glul22Gly mutation 
a Patient 3 b Control • 
1 1 0 1 2 0 I I ^ H 
G T G A G A C T T C C A T T C A C A C C ' 2 0 1 3 0 r G A G A C T T T C A T T C A C A C 
c Mother 一 rnj n 
！ T G A G A C T T N C A T T C A C A C c 4R  
w W 
Fig 4.4 Patient 3 carried a Glul22Gly mutation 
DNA sequencing results of exon 4 of the OTC gene in a) patient 3; b) normal subject; 
c) patient 3's mother sequenced by OTCexon4R. The base involved is arrowed and 
the corresponding codon underlined. 
In 4.3a, the patient was shown to carry a transition of A to G at nucleotide position 
265，causing a substitution of glutamic acid by glycine at residue 122. In 4.3c, his 




I E F ^ 
Glul22Gly/- • 
II M I 
Glul22Gly 
Fig 4.5 Pedigree of patient 3's family 
Blacked: Affected males; Dotted: Female carrier. 
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4.14 Patient 4 carried an Argl29His mutation 
a Patient 4 b • 
C A C G G C C C A G T T N G T A A A T T T A C A A A C ^ G G G C C G ^ G ^ ( • IR i f f • 
MA/vJkj I M M 
c Control 一 d 
A C AC G G C C C G G T T N G T A A A | I T T T A C A A A C C G G " ° C C G T G T 
4F?0 130 4 R 
n 
Fig 4.6 Patient 4 carried an Argl29His mutation 
DNA sequencing results of exon 4 of the OTC gene in a and b) patient 4; c and d) 
normal subject sequenced by either OTCexon4F or OTCexon4R as indicated. The 
base involved is arrowed. The site is located next to the splice donor site of intron 4. 
One of the bases in the codon is located in exon 5, that cannot be viewed in this 
result. 
In 4.6a，the patient was shown to carry a transition of G to A at nucleotide position 
386，causing a substitution of arginine by histidine at residue 129. This was further 
confirmed by sequencing in the reverse direction in 4.1b. 
» 
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Argl29His 
Fig 4.7 Pedigree of patient 4，s family 
Black: Affected males. 
Patient 4 (II) parents did not carry the mutation and were shown to be normal. 
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4.15 Patient 5 carried a Lysl44Term mutation 
a Patient 5 b • 
C G A G T G T A T A A A C A A T CA G |T C T 6 A T T G T T A A T A C A C T C I 
5F 60 70 5R 150 160 
A A • 
jyywM Lf t iWi 
c Control - d 
C G A G T G T a ' t ° A A A C A A T C A ' g r G A T T G T T T T T A C A C T C G 
5F 5R 一 
( i k i J U l t W 
Fig 4.8 Patient 5 carried a Lysl44Term mutation 
DNA sequencing results of exon 5 of the OTC gene in a and b) patient 5; c and d) 
normal subject sequenced by either OTCexonSF or OTCexonSR as indicated. The 
base involved is arrowed and the corresponding codon underlined. 
In 4.8a, the patient was shown to be heterozygous for a transversion of A to T at 
nucleotide position 430，converting codon 144 encoding lysine to a stop codon TAA. 




4.16 Patient 6 carried a Thrl78Met mutation 
a Patient 6 b • 
T T A C ( T G A N G C T C C A G G T A C C T G G A G C N T G A G G T A A T 
5F 5R S0 H j 
c Normal Control 一 d 
A T TAG C T C A C G CTCCAGGT A C C T G G A G C GT G A G G T AA T 
5F 2 9 ^ 30 琳 I I i 
(tmmfrA IVmUtlft 
Fig 4.9 Patient 6 carried a Thrl78Met mutation 
DNA sequencing results of exon 5 of the OTC gene in a and b) patient 6; c and d) 
normal subject sequenced by either OXCexonSF or OTCexonSR as indicated. The 
base involved is arrowed and the corresponding codon underlined. 
In 4.9a, the patient was shown to be heterozygous for a transition of C to T at 
nucleotide position 533, causing a substitution of threonine by methionine at residue 
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4.17 Patient 7 carried an Asnl 98Ile mutation 
a Patient 7 b • 
G C G A r G G G A T CA A T A T C C T I |A G G AT A T T C C CA T C C C I • 
6F 90 — 100 6R _ dklkJ 
c Control — 
m m  
G G G A T G G G A A C A A T A T C C T 
6F 一 
Fig 4.10 Patient 7 carried an Asnl98Ile mutation 
DNA sequencing results of exon 6 of the OTC gene in a and b) patient 7; c) normal 
subject sequenced by either OTCexon6F or OTCexon6R as indicated. The base 
involved is arrowed and the corresponding codon underlined. 
In 4.10a，the patient was shown to carry a transversion of A to T at nucleotide 
position 593, causing a substitution of asparagine by isoleucine at residue 198. This 
was further confirmed by sequencing in the reverse direction in 4.10b. 
« • 
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4.18 Patient 8 carried an IVS 5 + 1 G->T mutation 
a Patient 8 b • 
320 330~~ ” n nn ^ H 
: a c g c t c c a g t t t g g t t t a t . a ' ^ a a a C C A a a c ' t ° G G A G C G T 
5R I • 
c Control __ d 
C G C - T C C A G G T T G G T T T A T A A T A A C C A A " C C T G G A G C G T 
5F 300 5R 40 SK 
I . Jjl I 
mlnAlS^ IMVmt 
e Mother f 
亦C G C T C c f c G T T G G T T g j ^ A A A C C C T G G AG C'G°T C 
i M M ' M W 
Fig 4.11 Patient 8 carried an IVS5 + 1 G->T mutation 
DNA sequencing results of exon 5 of the OTC gene in a and b) patient 8; c and d) 
normal subject; e and f) patient 8，s son sequenced by either OTCexonSF or 
OTCexonSR as indicated. The base involved is arrowed. 
In 4.11a，the patient was shown to carry a transversion of G to T at position IVS5+1, 
causing a splicing defect at the donor splice site of intron 5. This was further 
confirmed by sequencing in the reverse direction in 4.11b. In 4.11c, the patient's 
mother was shown to be heterozygous for the mutation. 
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IVS5+1G^T IVS5+1G->T 
Fig 4.12 Pedigree of patient 8，s family 
Black: Affected males; Dotted: Female- carrier. 





S J ^ HBtfirnffi inqtB of OTC MUtatiOnS 
The 8 unrelated OTCD patients had different mutations. This fully 
demonstrates the allelic heterogeneity of OTC in our local Chinese population. 
Mutations of OTC are well-known to be private in nearly every affected family. As 
shown in Table 2.1, more than 278 mutations have already been identified in the H i 
o r e gene. 
) 
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, ^ ^ TwnIinwsiMiitatlonsWereUentlfieil：Asnt98ileandIWS5+1 
G ^ T 
5.2.1 Asnl98Ile • 
Patient 7 showed a transversion of A to T at nucleotide position 592, causing a 
substitution of asparagine by isoleucine at residue 198. This is a novel mutation. 
The sample came from Children's Hospital of British Columbia in Vancouver and the 
patient was a Chinese male with neonatal onset. 
In this codon, another disease-causing mutation, Asnl98Lys, has been identified 
(Popowska et al., 1999) in Polish patients. From the multiple alignments of a 
known OTC protein sequences shown in Appendix A.4，34 out of 42 species are 
shown to have an asparagine in residue 198，indicating that this residue may have 
importance to the protein functions. The conservation of asparagine in residue 198 
and the presence of a different mutation at the same residue in another family suggest 
that Asnl98Ile is probably a disease-causing mutation. 
5.2.2 IVS5+1G-^T 
Patient 8 was shown to have a transversion of G to T at IVS5+1. This is also a 
novel mutation. The sample came from Tsan Yuk Hospital in Hong Kong, and the 
patient was a Chinese female who was asymptomatic. As the mutation is located at 
the donor splice site of intron 5, it would probably affect the splicing of the 
pre-mRNA, resulting in OTCD. 
‘ Of 278 mutations found in OTC, 33 results in splicing errors. At this same 
> 
nucleotide, another substitution IVS5+1G->C had been identified in Switzerland 
before (Oppliger Leibundgut et al., 1995). 
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^ ^ fiifft icnnwn Mutations were Identified, Four of which were 
identified in Chinese tor the First Time 
Of the eight substitutions identified, five are known mutations, supporting their jjjjjjH 
likelihood as being disease-causing factors. Four of the five mutations are reported 
for the first time in Chinese, namely Arg26Gln, Argl29His, Lysl44Tenn, and 
Thrl78Met. 
5.3.1 Arg26Gln 
Arg26Gln was identified in patient 1 (IV3), who was a male with neonatal onset. 
Arg26Gln has previously been identified in United States, in both male (Grompe et 
al.’ 1989) and female patients (Oppliger Leibundgut et al., 1997). This is the first 
reported case in Chinese. 
The affected codon is located in the leader peptide of the protein. It is quite 
unusual as proportionally, much fewer mutations have been found in the leader 
peptide than in the mature enzyme. As the mutation is located in the leader peptide 
of the gene, it may be disease-causing by affecting the uptake of protein into 
mitochondria, or by altering the processing of pOTC into mature protein. 
5.3.2 Glul22Gly 
Glul22Gly was identified in patient 3 who was a male with neonatal onset. 
His mother was shown to be a carrier of the disease in further analysis. This 
• mutation had been reported in Chinese before (Gao et al.’ 2003). 
> 
5.3.3 Argl29His 
Argl29His was identified in patient 4，who was a male with late-onset. The 
mutation had been reported in Japan (Matsuura et al., 1994), Spain (Garcia-Perez et 
— - _ 
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al.’ 1995) and France (Gilbert-Dussardier et al., 1996) before. It was found in 
males with late-onset of disease. This is the first time reported in Chinese. The 
mutation resulted in loss of a unique Mspl restriction site which can be used for 
restriction analysis. 
Both patient 4's father and mother were shown to be normal. There may be H 
two possibilities account for this result. First, the mutation in patient 4 may be a de 
novo mutation in the patient or maternal oogenesis. Secondly, gonadal mosaicism 
may be present in either his father or his mother. In a subsequent pregnancy of the 
mother, prenatal diagnosis was performed using DNA extracted from cultured 
chorionic villi. The fetus was shown to have a normal genotype. The reason for 
the occurrence of Argl29His in patient 4 can be found out by sequencing with the 
parents' gonads. 
The same mutation (Hodges et al., 1989) was found in the mouse strain sparse 
fur with abnormal skin and hair (spf-ash), a rodent model of mild OTCD. The 
mutation decreases OTC expression to 10% of the normal level, with resultant 
4%-7% residual OTC activity. 
The effect of this mutation was well-studied in spf-ash mouse. As the 
mutation is located near to the exon 4 - intron 4 junction, it plays a role in the 
recognition of the adjacent splice donor site. The mutation results in inefficient 
splicing of pre-mRNA, both at this site and at a cryptic splice donor site 48 bases into 
the adjacent intron, which results in the synthesis of two distinct OTC precursor 
polypeptides, one normal in size and the other distinctly elongated. The 
normal-sized protein is correctly spliced and constitutes only 12% mRNA produced 
when compared with the control (Ohtake et al., 1987). 
In the 12% correctly spliced mRNA, the mutation results in a substitution of 
arginine to histidine at residue 129 of pre-OTC. This missense transition has no 
8 5 
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discemable effect on mitochondrial import, subunit assembly or enzyme activity 
(Hodges et al” 1989). For the rest of mRNA that has not been correctly spliced, the 
elongated mRNA is also translated into a protein with insertion of 16 amino acids 
and further imported and proteolytically processed by mitochondria, but it fails to 
assemble into an active trimer and results in a dysfunctional protein (Rosenberg et al., H 
1983). The disease-causing factor investigated in spf-ash mice is likely to be the 
same as that of OTCD patients carrying the Argl29His mutation. 
Though the spf-ash mouse carries the Argl29His mutation, the affected mice are 
only slightly hyperammonemic and develop quite well by utilizing a few major 
adaptations (Cohen et al” 1989). Firstly, the liver of spf-ash mouse contains about 
33% more mitochondrial protein per g than normal liver. Secondly, the specific 
activity of carbamyl phosphate synthetase of the spf-ash mouse is about 15% lower 
than normal, resulting in less formation of carbamyl phosphate, which is the 
substrate of OTC. Thirdly, at lower concentration of external ornithine, a smaller 
fraction of the carbamyl phosphate synthesized is converted into citrulline in spf-ash 
mouse than in normal mitochondria. Finally, it was observed that spf-ash mice are 
capable of synthesizing citrulline at an unexpectedly high rate of up to 44 nmol/min 
per mg in the presence of 10 mM-omithine and the substrates for carbamyl 
phosphate synthesis. Though this rate is still lower than the corresponding rates 
obtained with normal mitochondria, the difference does not arise from the deficiency 
in OTC, but from the lower carbamyl phosphate synthetase activity. These four 
adaptations together may contribute to the survival of spf-ash mouse in spite of 
carrying the Argl29His mutation. It would be interesting to investigate whether 
some of these adaptations do occur in humans. The adaptations may explain why 
the two Spanish patients carrying the Argl29His mutation (Garcia-Perez et al., 1995) 





Lysl44Term was identified in Patient 5，who was a female with late-onset. 
The mutation had been reported in United States (Tuchman et al.’ 1995) in a female 
with late onset of disease. This is the first time reported in Chinese. 
The transition leads to a premature termination of the protein, and resulted in a 
truncated protein with loss of the ornithine binding site in H270-C271-L272-P273, 
resulting in OTCD. 
5.3.5 Thrl78Met 
Thrl78Met was identified in Patient 6，who was a female with late-onset. The 
mutation had been reported in Switerzerland (Oppliger Leibundgut et al.’ 1995) in 
both male and female patients. This is the first time reported in Chinese. From 
the multiple alignments of OTC protein sequences shown in Appendix A.4，all 42 
species are shown to have a threonine at residue 178. The strictly-conserved 
residue among the 42 species indicates that threonine 178 may be important for 
enzymatic function of OTC. 
I 
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^ ^ fl niifistinnaMc Polymorphism was Idcntltleil： IculllPro 
In patient 2，no mutation was found in all the 10 exons and the flanking introns. 
However, Leul 11 Pro, which was a known polymorphism was identified. 
In the study of structure and expression of OTC, an OTC clone from a human 
cDNA library (New Haven, Conn) gave a proline at residue 111 (Horwich et al., IH 
1984). While in another study, an OTC cDNA gave a leucine at residue 111 (Hata 
et al., 1988). As both cDNA sources were presumably come from normal 
individuals, Hata et al. suggested that the difference should be account for a 
polymorphism but not a mutation. 
In a study of OTC polymorphism frequency, all 67 normal subjects showed to 
have a leucine at residue 111 (Oppliger Leibundgut et al’ 1996), giving rise to an 
allele frequency of 1.00/0.00 to this polymorphism. 
The proline substitution has been found in United States (Grompe et al., 1989). 
The individual had tuberous sclerosis, very mild symptoms and no OTC activity on a 
liver biopsy specimen, indicating that he is suffering from OTCD. Mutation 
analysis showed that the patient did not have any mutation found in all the 10 exons 
and the flanking introns, but only the subsitution LeulllPro. 
The rediscovery of Leull lPro in an OTCD patient in this study supports the 
assertion that this substitution may be a disease-causing mutation rather than a 
polymorphism. And the identification of proline at residue 111 by Horwich may be 
due to a sequencing artifact, a transcription error or the presence of this mutation in 




^ ^ Bnifi nf UNA Sequencing as a Direct Diagnosis of OTCD 
Of the eight cases, some had already been diagnosed as having OTCD or as 
being carriers of OTCD by other methods as mentioned in Chapter 1.8. DNA 
sequencing confirmed the diagnosis in each of these cases in a more specific and 
direct way. I H 
Patient 1 (IV3 in Fig 4.2) presented with collapse two days after birth, and 
ultimately resulted in global delay and spastic cerebral palsy. Subsequently, he had 
recurrent metabolic decompensation with coma at 2，3, and 6 year old. He was 
diagnosed of having OTCD with liver biopsy showing a decreased OTC activity of 
0.6 unit. This was further confirmed by mutation analysis showing an Arg26Gln 
mutation in the OTC gene. And the identified mutation led to a screening of 
carriers in his family. His mother (III4 in Fig 4.2) had shown a positive allopurinol 
loading test before and was suggested to be an asymtomatic carrier of OTCD. 
Mutation analysis further showed that she was a heterozygous for Arg26His mutation 
and confirmed the allopurinol loading test result. 
Patient 4 showed an increase in urinary orotic acid, suggesting that he may 
suffer from OTCD. The clinical results were further confirmed by mutation 
analysis, showing that the patient carried an Argl29His mutation. 
The sons of Patient 8 (III and 112 in Fig 4.12) were shown to be affected in a 
previous linkage analysis study. Both of them were later shown to have the 
IVS5+1G—T mutation, inherited from their mother. 
Combined with the advantages that DNA sequencing has well-established 




fl m丨Bstin明ute Polymorphism： LculOlPlic with Allele Frequency 
0.01/0.99 
In a study of OTC polymorphism frequency, no leucine but all phenylalanine • • 
was found at residue 101 in 67 normal subjects (Oppliger Leibundgut et al, 1996)，in 
contrast to a previous reported allele frequency of 0.01/0.99. We suggested 
LeulOlPhe might be a dubious polymorphism like Leul 11 Pro. And so, we decided 
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JB^ siift-nirftRted Mutagenesis 
Although up to 278 mutations have been identified in the OTC gene, the 
mechanisms of how these mutations in affecting the enzyme function are not 
well-studied. 
Site-directed mutagenesis followed by in vitro expression can serve as a method 
to establish the relationship between a mutation and its phenotype in OTC. In 
addition, as mentioned in Chapter 5.4 and 5.7，the assignment of two reported jHH 
substitutions as polymorphisms may be doubtful. Expression studies could be ^ H 
definitive in this regard. Further, a dominant negative effect, has been identified in H i 
homomultimeric proteins, including OTC. This refers to the effect of endogenous 
mutant protein presented in patients in the activity of a delivered recombinant 
wild-type protein in gene therapy or enzyme replacement therapy. Mutagenesis can 
serve as a tool for investigating the dominant negative mechanism of OTC mutations. 
This may be useful for patient selection in gene therapy or enzyme replacement 
therapy trials (Morsy et al, 1996). Finally, a better understanding of how the 
mutant enzymes function may also help in the development of new and better 
therapies for OTCD. 




No Mutation Expression Findings References  
method  
1 Arg40His E.coli. Morizono et 
al., 1997 
2 Arg40His Cos1 28% activity; lower protein expression Nishiyori A et 
al., 1997 
3 Arg40His CHO 26-35% activity Augustin et 
No dominant negative effects a/., 2000 
4 Arg40His CHO Enhanced degradation of preprotein in Mavinakere 
cytosol et al., 2001 
5 Leu148Phe Cos1 0% activity Komaki et al., ^ T 
1997 
6 Ala152Val Cos? 3.7% activity Kogo et al., 
29% protein expression 1998 
Rapid degradation of mature protein in 
mitochondrial matrix 
7 Arg109Gln Cos1 100-fold lower activity Lee and 
Nussbaum, 
^  
8 Arg141Gln CHO 0% activity Augustin et 
No dominant negative effects al., 2000 
9 Glu154Ter Cos1 0%-activity Matsurra et 
al., 1994 
10 Gly195Arg Cos1 0% activity Matsurra et 
al., 1994 
11 Gly195Arg Cos7 2.5% activity Kogo et al., 
12% protein expression 1998 
12 Asp196Val Cos1 3.7% activity Matsurra et 
al., 1994 
. 13 Thr264Ala Cos1 8.9% activity Matsurra ef 
\ 
al., 1994 
14 Arg277Gln £ coli. Morizono et 
al., 1997 
15 Arg277Trp E. coli. Morizono et 
al., 1997 
“ 9 3 
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No Mutation Expression Findings References  
method  
16 R277W E.coli. 70-fold lower affinity for L-omithine; no Morizono H et 
substrate inhibition; reduced thermal al., 1997 
stability 
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^ ^ prniftin gwpression Systems 
There are several ways to express proteins in vitro, mainly by bacteria, yeast, 
baculovirus, and mammalian cells. Each expression system has its advantages and 
drawbacks, and the choice of expression system should depend on the aim of the 
study and also the protein to be expressed. 
As seen from Table 6.1, E.coli. and mammalian cells, including CHO, cosl, and 
COS? have been used in mutagenesis study of OTC. Active OTC can also be 
expressed in the baculovirus system (Lithrow et al., 1991) and bacteria expression 
system with the addition of GroE to assist folding, • 
6.2.1 Bacteria 
The bacterial expression system is a common way of expressing recombinant 
proteins. The advantages of using bacteria as a vehicle for protein expression is that 
bacteria can be easily transformed and selected for positive transformants. Also, 
the bacterial system is an economic way to express a protein, as bacteria grow 
rapidly and express high levels of recombinant proteins; yet the cost is relatively low. 
The main drawback when expressing protein by bacteria expression is that 
many proteins may be insoluble and trapped in inclusion bodies. This may be 
partly solved by the addition of chaperones to assist folding. One of the major 
chaperones was GroE, which is cytoplasmic chaperone in E.coli. The addition of 
GroE has been shown to assist folding of many different proteins as listed in Table 
6.2. , Another disadvantage is that bacteria cannot provide any eukaryotic 
post-translational modification. 
6.2.2 Yeast 
The yeast expression system can partly solve the problem in bacteria expression 
“ ^ 
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systems. Some of the proteins that are insoluble in bacteria expression systems are 
soluble when expressed in yeast, which have a more complex protein processing. 
Also, yeast can provide most of the eukaryotic post-translational modifications. 
However, it is quite difficult to handle yeast expression, especially transfecting 
and lysing the yeast cells. 
6.2.3 Baculovirus WM 
Baculovirus vectors are a viral system for expressing proteins in cultured insect 
cells. Baculovirus serves as a good expression system for expressing mammalian H 
proteins since insect cells can recognize most mammalian protein-targeting 
sequences and perform many of the post-translational modifications. 
Using baculovirus may be challenging because it may be difficult to infect 
insect cells with baculovirus vectors efficiently, especially for large vectors. 
Another drawback is that insect cells grow more slowly than bacterial and yeast 
cells. 
6.2.4 Mammalian cells 
Mammalian cells have the advantages of producing necessary post-translational 
modifications and recognizing the same synthesis and processing signals found in 
human. 
However, the transfection efficiency of mammalian cells is low, resulting in a 
low expression level of protein in mammalian cells. Another drawback is that 
mammalian cells grow more slowly than bacteria and yeast cells. This makes 
mammalian cells a relatively expensive method for protein expression. 
Transfection of mammalian cells can be done in many different ways, including 
calcium phosphate coprecipitation (Chen and Okayama, 1987; Wigler et al., 1977), 
— -
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electroporation (Wong et al., 1982，Neumann et al” 1982)，complex formation with 
DEAE-dextran (Kawai and Nishizawa, 1984), microinjection (Capecchi, 1980), 
biolistic particle delivery (Klein et al., 1987) and cationic lipid addition. 
6.2.5 Cell-free expression 
Cell-free expression system usually utilizes bacterial extract for expressing a 
protein. Cell-free expression is efficient and easy to handle, but it shares the 
common disadvantages with the bacterial system in the formation of inclusion bodies 
and inability to give eukaryotic post-translational modifications. K 
Molecular 
Enzyme/Protein . “ Origin References  
weight  
monomer 
dihydrofolate reductase 20 kDa (a1) chicken Martin et al. 
mouse Viitanen et al. 
Laminet and 
pre-p-lactamase 30 kDa (a1) Escherichia coli 
Pluckthun 
^ Martin et al. 
rhodanese 33 kDa (a1) bovine 
Mendoza et al. 
ribonuclease {in vivo) 40 kDa (a1) human granulocyte Rosenberg et al. 
6-hydroxy-D-nicotine oxidase 48 kDa (a1) Escherichia coli Brandsch et al. 
Schmidt and 
Fab fragment 60kDa(a1) mouse 
Buchner 
Holl-Neugebauer 
a-glucosidase 68 kDa (a1) yeast 
and Rudolph 
dimer 
‘ Xenopus laevis, 
Cu, Zn-superoxide dismutase 32 kDa (a2) Battistoni et al. 
human 
citrate synthase 50 kDa (a2) pig Buchner et al. 
non-glycosylated invertase 59 kDa (a2) yeast Kerm et al. 
Bacillus 





Enzyme/Protein . Origin References  
weight  
malate dehydrogenase 70 kDa (a2) pig Hartman et al. 
luciferase {in vivo) 74 kDa (a1 (31) Vibrio harveyi MAV Escher and Szalay 
enolase 94 kDa {a2) yeast Kubo et al. 
Goloubinoff et al. 
ribulose bisphosphate Rhodospirillum 
110 kDa (a2) Viitanen et al. 
carboxylase rubrum WM 
van der Vies et al. 
{in vivo) Anacystis nidulans Goloubinoff et al. 
phytochrome photoreceptor 248 kDa (a2) oat Grimm et al. 
3-mer • 
ornithine transcarbamylase 108 kDa (a3) rat Zheng et al. 
Salmonella phage 
tailspike protein 216 kDa (a3) Brunschier et al. 
P22 
4-mer 
branched-chain a-keto acid 
160 kDa (a2p2) mammalian Wynn et al. 
decarboxylase Ei {in vivo) 
tryptopharase 208 kDa _ Escherichia coli Mizobata et al. 
12-mer 




^ ^ nTR tnyymB Assay 
DAMO/TSC 
Acid 
B j M l ^ ^ ^ ^ M ^ ^ H E ^ B a B ^ ^ ^ S ^ ^ ^ B i i M i t f f i B 15 mins 
Chromophore 
with absorbance • 
The OTC enzyme assay measures the amount of OTC in a sample, based on the 
enzymatic activity of OTC to form citrulline, followed by a colorimetric reaction of 
citrulline with a chromogen. Thus, the assay can be separated into two parts, the 
enzymatic reaction and the colorimetric reaction. 
The enzymatic reaction of the assay is based on the catalytic property of OTC, 
in which the substrate, ornithine and carbamyl phosphate are condensed to citrulline. 
Urease is added to prevent urea interference when the assay is used for determining 
OTC activity in serum (Snodgrass and Parry, 1969). After the enzymatic reaction, 
acid ferric solution is added to denature the enzyme, and diminish its catalytic 
activity. 
The colorimetric reaction of the assay is based on the reaction of citrulline with 
diacetylmonoxime- thiosemicarbazide (DAMO/TSC) which results in the production 
of a pink-colored chromophore, giving an absorbance peak at 515-530nm. 
Thus, there are two limiting factors in the OTC enzyme assay. The enzymatic 
reaction is limited by the amount of ornithine and carbamyl phosphate, while the 
colormetric reaction is limited by the amount of DAMO/TSC. 
It should be noted that ornithine and carbamyl phosphate also form citrulline by 
9 9 
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a non-enzymatic reaction, which may give rise to a background absorbance value 
(Snodgrass, 1968). Therefore, a sample blank has to be included in the assay to 
account for this. 
In addition, a reagent blank can be included to determine the endogenous 
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nhaininff tHe ^ T g C l o n e 
A GeneStorm® Expression-Ready Clone, with the OTC gene cloned into 
pcDNA3.1/GS® was purchased. The clone was supplied transformed in GeneHogs 
chemically competent E.coli. The plasmid was extracted form the bacteria by 
QIAprep® Miniprep Kit. 
Though the manufacturer claimed that the GeneStorm® clone was already 
sequence verified, we re-verified the sequence of the clone by subjecting the isolated • 
plasmid to TempliPhi™, which amplify the plasmid for subsequent sequencing. • I 
I 
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7.1.1 Materials 
7.1.1.1 Chemicals for preparing low salt LB medium / agar with Zeocin^"^ 
Agar bacterialogical (Agar No.l) (Oxoid Ltd., Basingstoke, Hamsphire, UK) is 
supplied in powder form. It is stored at RT. 
Sodium chloride (Sigma-Aldrich, St. Louis, Missouri, USA) NaCl, with molecular 
weight (MW) 58.44, is supplied in powder form. It is stored at RT. 
Sodium hydroxide pellets (BDH Laboratory Supplies, Poole, UK) NaOH, with MW • 
40.00, is supplied in pellet form. It is stored at RT. It is corrosive. It is dissolved • 
in dHzO for use. • 
Tryptone (Oxoid Ltd., Basingstoke, Basingstoke, Hamsphire, UK) is supplied in 
powder form. It is keep tightly closed and stored at RT away from bright light. 
Yeast extract (Sigma-Aldrich Co., St. Louis, Missouri, USA) is supplied in powder 
form. It is cell-culture tested and insect cell culture tested. It is stored at RT. 
Zeocin™ (Invitrogen Corporation, Carlsbad, California, USA) C55H83N19O21S2CU, 
with MW 1137.41，is supplied in a concentration of 100 mg/mL in autoclaved dHaO. 
It is stored at -20 °C in dark. 
Low salt Luria Bertani (LB) medium with Zeocin™ was prepared by adding 10 g 
tryptone, 5 g NaCl, and 5 g yeast extract to 950 mL deionzied H2O. pH was 
adjusted to 7.5 with NaOH. The volume was brought up to 1 L with deionized H2O. 
The medium was autoclaved at 121 °C for 20 mins. It is stored at 4 °C. Zeocin^^ 
was added at a concentration of 25 |ig/mL prior using. 
Low salt LB agar with Zeocin™ was prepared as LB medium, supplemented with 
15 g agar before autoclaving. The autoclaved agar was cooled in a 55 °C water bath. 
ZeocinTM was added at a concentration of 25 |ig/mL. The agar was poured into 
plates and allowed to stand at RT overnight. The plates are stored at 4 °C in dark. 
1 0 2 
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7.1.1.2 AutoSeqTM G-50 
AutoSeq™ G-50 (Amersham Biosciences, Uppsala, Sweden) are MicroSpin™ 
columns prepacked with Sephadex™ G-50 DNA Grade F, equilibrated in water 
containing 0.05% Kathon™ CG/ICP biocide as a preservative. They are stored at 
RT. 
7.1.1.3 GeneStorm® expression-ready clone m 
GeneStorm® Expression-Ready Clone (Invitrogen Corporation, Carlsbad, California, • 
USA) is supplied with supercoiled pcDNA3.1/GS® (lyophilized in Tris-EDTA, pH • 
8.0) and Anti-V5-horseradish peroxidase (HRP) antibody conjugate (in 
filter-sterilzed PBS). The clone has the OTC gene cloned into pcDNA3.1/GS® It 
is supplied transformed in GeneHogs chemically competent E.coli in the form of a 
16-hour bacterial culture in low salt LB media with 25 |ig/mL Zeocin™. The 
GeneStorm® Expression-Ready Clone is stored at -80 °C while the other items are 
stored at 4 °C. A detailed map of pcDNA3.1/GS® can be found in Appendix A. 11. 
The genotype of GeneHogs chemically competent E.coli can be found in Appendix 
A.16. 
7.1.1.4 QIAprep® Miniprep Kit 
Miniprep Kit (QIAGEN, Hilden, Germany) consists of buffer PI, buffer 
P2, buffer N3, buffer PB, buffer PE, buffer EB, RNase A, QIAprep spin columns and 
2 mL collection tubes. It is stored at RT. RNase A is added to Buffer PI before 
use. With RNase A, Buffer PI is stored at 4 � C . The DNA binding capacity of the 
membrane in a QIAprep spin column is 20 |ig. 
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7.1.1.5 TempliPhi™ 100 Amplification Kit 
TempliPhi™ 100 Amplification Kit (Amersham Biosciences, Uppsala, Sweden) 
consists of Sample buffer, Reaction buffer and Enzyme mix. Sample buffer 
contains random hexamers. Reaction buffer contains salts and deoxynucleotides, 
adjusted to a pH that supports DNA synthesis. Enzyme mix contains 029 DNA 
polymerase and random hexamers. pUC19 (2 ng/jiL) is included as a positive 
control of the kit. It is stored at -70 °C. The kit claims to have an amplification of • 
1.5 |Lig DNA. • 
I 
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7.1.2 Methods 
7.1.2.1 Small-scale preparation of pcDNA3.1/OTC by QIAprep® Miniprep Kit 
A GeneStorm® Expression-Ready 
s 
Clone, with the OTC gene cloned into ^^。阳“邮, ? 
»« aa'-icf yjcyx-ryaooatc...如 one ctt coa cot cat;... 
noqa'3oy>a^ -T03TAc,. • jrrc cca ctc oaa oct CCA ；jtj ,.. 
pcDNA3.1/GS® was purchased. It is \ 如…卜“U AI, «IY HI.... 
supplied transformed in GeneHogs — 
chemically competent E.coli in the form ^ ^ L • • 
of a 16-hour bacterial culture. m 雙 
置 pcDNA3.1/GS^ S • 
The bacterial culture was streaked ^ L .. ^ ^ • 
onto a low salt LB agar plate with 25 ^ •嶋 
fig/mL Zeocin™ so that a single colony Adaptedfrom invitrogen, 2004 
could be isolated. The plate was pcDNA3.1/GS® utilizes strong 
. u ^ J ^ T7 00 ^ 1 0 1 A immediate-early cytomegalovirus incubated at 37 °C for 18 hours. A 
(CMV) promoter for high-level, 
single colony was then picked and constitutive expression in mammalian 
. , , . n T , , … ，. cell lines. K contains a V5 epitope for inoculated in 2 mL low salt LB medium 
detection with Anti-V5-HRP Antibody. 
with 25 jLig/mL Zeocin™. The It also has a Zeocin™ resistance gene 
. , , , for selection of transformants in E.coli inoculum was shaken at 37 °C，200 rpm 
and for the creation of stable 
for 18 hours. mammalian cell lines. Zeocin™ is an 
1 T /^ i . „ antibiotics which is only active when the 2 mL 01 bacteria cells were pelleted 
salt concentration of the medium is 
by centrifugation at 4500 x g for 15 mins lower than 90mM with pH 7.5. A 
^ . or. 11 1 detailed map of pcDNA3.1/GS® can be at 4 °C. The cells were then 
found in Appendix A.11. 
‘ resuspended in 250 i^L Buffer PI. 250 
I^ L Buffer P2 was then added and mixed by gently inverting the tube 6 times and 
incubated at RT for not more than 5 mins. 350 i^L Buffer N3 was then added and 
mixed by gently inverting the tube 6 times. The mixture was centrifuged at 16100 
X g for 10 mins. The supernatant was applied to the QIAprep® Spin Column and 
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centrifuged at 16100 x g for 1 min. 500 
|liL Buffer P B was added and centrifuged Ovemight cultures 
at 16100 X g for 1 min. 750|NL Buffer T PURE PIOSMID DNA 
PE was added and centrifuged at 16100 x 
g for 1 min. The column was C， 
centrifuged at 16100 x g for an 宫 
B i n d 1 I E l u t e 
additional 1 min to remove any residual • 场 ， • 
wash buffer. 50 ^L deionized H2O was ^ 舊 ^ ^ I 
added to the center of the QIAprep Spin wosh • 
QIAprep® Miniprep Kit utilizes a Column and incubated at RT for 1 min 
modified alkaline lysis method of 
and the eluate was collected by bacteria cells (Birnboim and Doly, 
1979), in which Buffer P2 contains SDS, 
centrifugation at 16100 x g for 1 min. 
which solubilizes the phospholipids and 
The D N A yield and quality were protein components of the cell 
. membrane, leading to lysis and release determined spectrophotometrically with 
of the cell contents. Buffer N3 was 
a BioPhotometer (Eppendorf AG, then used to neutralize the lysate and 
its high salt concentration precipitates 
Hamburg, Germany) by measuring 
- denatured proteins, chromosomal DNA, 
absorbance at A260 and calculating the cellular debris, and SDS. The 
optimized lysis time allows maximum A260/A280 ratio respectively. 
release of plasmid DNA without release 
of chromosomal DNA. The lysate is 
then loaded into a QIAprep® columns 
with a silica-gel membrane which 
absorbs plasmid DNA in high-salt buffer 
• and elutes in low-salt buffer. 
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7.1.2.2 Amplification of pcDNA3.1-OTC by TempliPhiTM 
One nanogram of plasmid was added to 5 
i^L sample buffer. The mixture was ^ f ^ ^ 
then heated at 95 °C for 3 mins for 
template denaturation and primer - t ^ n A 
i ^ annealing, and then cooled to 4 °C. 5 _ 
/ T ^ f \ j • 
\xL reaction buffer was added followed ‘ , — ^ • 
KJ) �\J^ I 
by 0.2 |iL. The amplification was ^ H carried out at in a water bath at 30 °C for zrrr. • 
TempliPhi™ utilizes bacteriophage 029 _ 
18 hours. The enzyme was DNA polymerase to exponentially 
amplify DNA by rolling circle heat-inactivated at 65 °C for 10 mins to �， ^ , 
amplification (RCA) (Dean et al., 2001) prevent potential interference with (Lizardi etal., 1998). The proofreading 
activity of 029 DNA polymerase subsequent cycle sequencing reactions. 
ensures high fidelity DNA replication 
(Esteban et al., 1993). The starting 
material for amplification can be any 7.1.2.3 Primer design and . , 
circular DNA sample, such as a small synthesis for sequencing amount of bacterial cells containing a 
plasmid or an isolated plasmid. As the OTC cDNA is 1065 bp, four pairs ^ 
Random hexamer primers anneal to the 
of OTC c D N A primers, namely circular template DNA at multiple sites. 
029 DNA polymerase extends each of OTCclonel to 4 were designed by a ,… ^^  … * 
these primers. When the DNA web-based software program, Primer 3 to polymerase reaches a downstream 
extended primer, strand displacement amplify the whole gene， with _ 
synthesis occurs. The displaced 
OTCclonelR covering the 5'-end and strand is single-stranded and available 
to be primed by more hexamer primers. OTCclone4F covering the 3'-end. The 
The process continues, resulting in 
primers were synthesized by Q I A G E N exponential, isothermal amplification. 
The product is high molecular weight, (QIAGEN, Hilden, Germany). The ‘ 
double-stranded concatemers of the 
circular template. 
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sequence of the primers and the corresponding amplified region in OTC can be found 
in Appendix A.6. 
7.1.2.4 DNA sequencing 
One microlitre TempliPhi^'^ product was added as template to carry out the 
sequencing reaction as described in Chapter 3.3.2.1. The sequencing products were 
purified by AutoSeq^^ G-50. AutoSeq^"^ G-50 was vortexed to resuspend the resin • 
inside. The cap was then loosened one-fourth turn and the bottom closure was • 
snapped off. The column was centrifuged at 2000 x g for 1 min to remove the • 
buffer. The sequencing product was added to the centre of the resin. The column 
was then centrifuged at 2000 x g for 1 min to collect the purified products. 
Sequencing was done as described in Chapter 3.3.2.3. 
I 
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fntftrinff i明o the Gateway SvstBm 
The OTC gene was cloned into 
DNA tfagminlt from. 
pENTR/D-TOPO for entering into the p J f P 鄉 = 
ciwitRtactfon 咖 Lib,«nf 
Gateway system, which enabled ^ ^ ^ ^ 
enormous convenience in subsequent ^ ^ 
V u ^ 
experiments. •(游 A 对 
• 
Adapted from Invitrogen, 2004 
Gateway® - technology allows • 
transferring DNA fragments into 
different vectors by lambda phage 
site-specific recombination (Landy, 
1989). A detailed description of 
lambda phage site-specific 
recombination can be found in Fig 7.9. 
Directional TOPO® Cloning technology 
is incorporated into Gateway 
technology. A detailed description of 
directional cloning and TOPO® cloning 
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7.2.1 Materials 
7.2.1.1 Chemicals and reagents for PCR 
PfuUltra™ High-Fidelity DNA polymerase (Stratagene, La Jolla, California, USA) 
is supplied with 10 x reaction buffer. It is stored at -20 °C. 
7.2.1.2 Chemicals and reagents for preparing LB medium / agar with 
kanamycin • • 
LB Agar (Lennox L agar) (Invitrogen Corporation, Carlsbad, California, USA) is 
supplied in powder form and stored at RT. For preparation, 32 g was added to 1 L • ] 
distilled water and autoclaved at 121 °C for 15 mins. The agar was cooled in a 55 
°C water bath. Appropriate antibiotics were added. The agar was poured into 
plates and allowed to stand overnight. The plates were stored at 4 °C in dark. 
LB Broth Base (Lennox L Broth Base) (Invitrogen Corporation, Carlsbad, 
California, USA) is supplied in powder form and stored at RT. For preparation, 20 
g was added to 1 L distilled water and autoclaved at 121 °C for 15 mins. 
Appropriate antibiotics were added just prior to using the medium. 
Kanamycin sulfate (Invitrogen Corporation, California, USA) C18H36N4011 •H2SO4, 
with MW 583, is supplied lyophilized. It is reconstituted to 10 mg/mL with sterile 
dHiO and stored at -20°C. 
7.2.1.3 pENTR Directional TOPO® Cloning Kit 
“ pENTR Directional TOPO® Cloning Kit (Invitrogen Corporation, Carlsbad, 
California, USA) consists of pENTR TOPO® reagents and TOP 10 Chemically 
Competent E.coli. 
pENTR TOPO® reagents include pENTR/D-TOPO® vector, dNTP Mix, salt solution 
and sterile water. Ml3 Forward (-20) sequencing primer and Ml3 reverse 
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sequencing primer are included for sequencing verification of the insert. Control 
PCR Template (0.1 |^g/|iL in TE buffer, pH 8.0) and control PCR primers (0.1 \ig/[iL 
each in TE buffer, pH 8.0) are included as positive control of the kit. 
pENTR/D-TOPO® vector is supplied in a concentration of 5-10 ng/^iL. A detailed 
map can be found in Appendix A. 14. 
TOP 10 Chemically Competent E.coli consists of SOC Medium and TOP 10 cells. 
pUC19 Control DNA (10 pg/|iL in TE buffer, pH 8.0) is included as the positive • 
control. OneShot® TOP 10 Competent Cells yield 1 x 10^cfu/|agDNA in a 50 [iL • 




Materials & MPthnrU J 
7.2.2 Methods 
7.2.2.1 Primer design and synthesis 
The primers, namely OTC-Topo-F and 
OTC-Topo-Rl and OTC-Topo-R2 were 
designed by a web-based software c c t t t aal;c.« 
•^•.>nc;AA<»Oa TTCCC� 
program, PrimerS. The forward primer, i S S ^ 
OTC-Topo-F contained the sequence W J ^ 
CACC at the 5' end so that it can base T M • 
pair with the overhang sequence, GTGG, ^ ^ m 
in the pENTR TOPO® vector to enable 
directional cloning. Two reverse Adapted firm invumgen, 2004 
primers, OTC-Topo-Rl and Directional TOPO® Cloning vectors 
. contains a single-strand GTGG OTC-Topo-R2 were designed. 
overhang on the 5'-end and a blunt end 
OTC-Topo-Rl removed the native stop on the 3'-end. This four-nucleotide 
, p , , , overhang invades the double-strand codon from the gene, enabling the 
DNA of the PCR product and anneals 
expression of a gene product with a to the CACC sequence that was 
^ . , _ _ _ _ incorporated into the 5' PCR primer, so C-termmal tag. OTC-Topo-R2 ^ 
that the insert is in a desired 
re-introduced back the stop codon to the orientation, 
gene, enabling the expression of a native 
protein. The primers were synthesized by QIAGEN (QIAGEN, Hilden, Germany) 
with High Performance Liquid Chromatography (HPLC) purification. The 
sequences of the primers can be found in Appendix A.7. 
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7.2.2.2 Polymerase chain reaction 
One nanogram of pcDNA3.1-0TC was 
PfuUltra™ HF polymerase was a amplified in a reaction mixture containing . •_ 
genetically engineered mutant of Pfu 
25 pmol of OTC-Topo-F, 25 pmol of DNA polymerase and the 
Archaemaxx™ polymerase-enhancing OTC-Topo-Rl or OTC-Topo-R2, lOnmol , , , 
factor. It claims to be able to amplify a 
dNTPs, 1 X P/wUltra™ HF reaction buffer, 500 bp fragment with less than 0.5% 
errors. The Archaemaxx™ ^ ^ 2.5 U Pfu HF polymerase, adjusted to a • • 
polymerase-enhancing factor 
final volume of 50 ^L with dHzO. PGR eliminates PGR inhibition due to dUTP • 
一 poisoning by converting poisonous H | | was carried out in a MJ PTC-200 (MJ � • .丁。 • 
dUTP to harmless dUMP and inorganic I H 
Research, Incorporated, Massachusetts, pyrophosphate. This promotes PGR 
with shorter extension times, higher USA) with the following parameters: . . , . 
yield, and greater target length 
denaturation at 95 °C for 2 mins， capabilities.  
followed by 30 cycles of denaturation at 
95 °C for 30 sees, annealing at 59 °C for 1 min 30 sees, and extension at 7 2 � C for 1 
min 30 sees, and a final extension at 72 °C for 10 mins. 
The PGR products were analyzed by 1% agarose gel electrophoresis to ensure that 
sharp and distinct bands were produced. The concentration was determined 
spectrophotometrically with a BioPhotometer (Eppendorf AG, Hamburg, Germany) 
by measuring absorbance at A260. It was then further diluted to 9 ng/|iL with dHzO. 
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7.2.2.3 TOPO® cloning reaction 
Nine nanograms PCR product was ligated 
into 1 nL pENTR/D-TOPO® vector in a 
reaction mixture containing 1 |iL salt ^ • 
声 ® - ~ ~ .V phosphate 
solution, adjusted to a final volume of 6 _ I 
HL with sterile d H � � . The ligation was ( � ' � _ ' • 
carried out in a water bath at 23 °C for 5 
Blum-end P C K Pruduc丨 • (designed with C'ACC ui the 5 ‘ end. no nKxifkmitMi ^^H ihe ."^  'cnd) mins, ^ H 
room tcinpcruturc 
•各 ， • 
7.2.2.4 Transformation 
Z lupoisomerasc I C-'iom is released 
The product was then transformed into _ 
Li call on complete 
OneShot® TOPIO Competent Cells. 50 Adaptedfn>mmvurvgen. 2004 
\iL OneShot® TOPIO Competent E.coli Traditional cloning uses DNA ligase in 
, , A T … . the ligation process. TOPO® Cloning was thawed on ice. 2 ^L of the ligation 
utilizes the enzyme topoisomerase I 
product was added and the mixture was (Shuman, 1994) in place of ligase. 
, , . p 严 ,, , Topoisomerase I is isolated from incubated on ice for 5 mins to allow the 
' vaccinia virus. It specifically 
ligation product to attach onto the cell recognizes the sequence 
^ , 5'-(C/T)CCTT-3' and forms a covalent surface. The cells were then heat 
bond with the phosphate group of the 
shocked in a water bath at 42 °C for 30 3,-thymidine. It can function both as a 
. restriction enzyme and a ligase. It seconds and immediate transferred to ice, 
cleaves one DNA strand, enabling the 
so that the ligation product could enter DNA to unwind. The enzyme then 
' . ,, _ religates the ends of the cleaved strand into the competent cells. 250 \iL SOC 
and releases itself from the DNA. 
medium was added and the cells were 
recovered with shaking at 37 °C, 200 rpm for 30 minutes. 
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7.2.2.5 Spreading plates 
The transformed cells were then spread 
onto LB plates containing 50 ^ig/rtiL - ^ ^ ^ wrmm -
kanamycin and incubated at 37 °C for 16 
,ottL 1 art 
hours. A single colony was then picked •於 令� 
and inoculated into 5 mL LB medium \ 
• pENTR 
containing 50 fxg/mL kanamycin. The S 2,6 kb 
inoculum was shaken at 37 °C, 200 rpm 
for 16 hours. The plasmid was extracted H ^ 
from the bacteria by QIAprep® Miniprep Adaptedfmm invumgen. 2004 
. pENTR/D-TOPO vector is linearized Kit as described in Chapter 7.1.2.1. A 
with topoisomerase I covalently bound 
total of 5 colonies were picked for to each 3'-phosphate at both ends for 
, TOPO® Cloning. It contains a subsequent experiments. 
single-strand GTGG overhang on the 
5'-end and a blunt end on the 3'-end. 
This four-nucleotide overhang invades 
the double-stranded DNA of the PGR 
product and anneals to the CACC 
sequence that is incorporated into the 
5' PGR primer, so that the insert is in a 
desired 5'->3' orientation, it contains 
the attL recombination sites flanking 
the PGR product insertion site for 
efficient recombination with other 
Gateway® destination vector; flanking 
universal M13 sequencing sites for 
‘ sequence verification of the insert; 
kanamycin resistance gene for 
selection in E.coli. 
j — 
M a t e r i a l s & M^i-hnHc J 
inuRstiffatinn oi suftceHu丨ar Localization of OTC 
OTC was swapped into another vector, pcDNA-DEST47 to allow fusion with a 
C-terminal GFP protein by the LR Clonase™ Reaction. Site-Directed Mutagenesis 
(Zoller and Smith, 1982) was carried out to bring about amino acid changes, 
including Arg26Gln, PhelOlLeu, LeulllPro, Glul22Gly, Argl29His, Lysl44Term， 
Thrl78Met and Asnl98Ile by QuikChange® II XL Site-Directed Mutagenesis Kit. 
The resulting plasmids were sequenced to ensure that they carried the desired MM 
mutation, in the correct orientation, and without any other mutations. The fusion 
protein was transiently expressed in HepG2 and Hep3B cells by transfection with • 
Lipofectamine™ 2000 and the subcellular localization of the GFP fusion protein was 
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7.3.1 Materials 
7.3.1.1 Chemicals and reagents for cell culture 
Dulbecco，s Modified Eagle Medium (D-MEM)，powder (high glucose) (Invitrogen 
Corporation, Carlsbad, California, USA) is in standard formulation, containing 4500 
mg/L D-glucose, and L-glutamine, but no sodium pyruvate or sodium bicarbonate. 
To prepare Ix liquid medium, the powdered medium was added to 950 mL 
autoclaved deionized water with gentle stirring until dissolved. 3.7 g NaHCOs was • • 
added. The medium was adjusted to pH 7.1-7.2 with 1 N HCl or 1 N NaOH, which ^ ^ 
was 0.2-0.3 below desired final working pH as pH units will usually rise 0.1-0.3 • 
upon filtration. The final volume was brought up to 1 L with autoclaved deionized 
water. In the biological safety cabinet, the medium was steriled by filtration with a 
4.5 nm filter. 
Minimum essential medium (MEM), powder (Invitrogen Corporation, Carlsbad, 
California, USA) is in standard formulation containing Earle's salts and L-glutamine, 
supplemented with non-essential amino acids. It is prepared as shown in DMEM 
above, but 2.2 g NaHCOs was added instead. 
Phosphate Buffered Saline (Sigma-Aldrich, St. Louis, Missouri, USA) contains 
NaCl (120 mmol/L), KCl (2.7 mmol/L) and phosphate buffer (10 mmol/L), pH 7.4. 
It is provided in powder form and stored at RT. To prepare PBS solution, the 
.powder was dissolved to 1 L deionized water and autoclaved at 121 °C for 15 mins. 
Trypsin-EDTA (0.5% Trypsin, EDTA • 4Na) (lOx), liquid (Invitrogen Corporation, 
• Carlsbad, California, USA) contains 5.0 g /L trypsin (1:250), 2.0 g/L EDTA*4Na and 
8.5 g/L NaCl. It was porcine parvovirus tested and mycoplasma tested. It was 
provided in lOx solution and stored at -20 °C. To prepare Ix Trypsin-EDTA, 10 
mL Trypsin-EDTA was added to 90 mL HBSS. 
Sodium Pyruvate Solution lOOmM (lOOx), liquid (Invitrogen Corporation, Carlsbad, 
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California, USA) is provided in a concentration of 100 mM. It is stored at 4 °C and 
should be protected from light. 
Fetal Bovine Serum, Certified (US) (FBS) (Invitrogen Corporation, Carlsbad, 
California, USA) is stored at -20 °C. It is tested to have endotoxin level lower than 
10 EU/mL and hemoglobin level lower than 15 mg/dL. It is heat-inactivated at 
55°C for 30 mins. 
Hanks，Balanced Salt Solution (HBSS) (10 x)^ liquid (Invitrogen Corporation, • • 
Carlsbad, California, USA) is in standard formulation containing no calcium chloride, 
magnesium chloride, magnesium sulfate, or sodium bicarbonate. It is stored at 4 • 
�C. 
Sodium hydrogen carbonate (May & Bayer Ltd, UK) NaHCOs, with MW 84.01，is 
in powder form and stored at RT. 
Reduced Serum Medium (Invitrogen Corporation, Carlsbad, 
California, USA) contains HEPES buffer, 2400 mg/L sodium bicarbonate, 
hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace elements, growth 
factors, and 1 .Img/L phenol red. It is stored at 4 °C. 
7.3.1.2 4% Paraformaldehyde in PBS 
Paraformaldehyde (Sigma-Aldrich, St. Louis, Missouri, USA) is in powder form 
,and stored at RT. It is an irritant and combustible. To prepare 4% 
paraformaldehyde in PBS, 2 g of paraformaldehyde was dissolved in 20 mL PBS by 
heating in a waterbath at 60°C. 
7.3.1.3 Ampicillin 
Ampicillin (Invitrogen Corporation, Carlsbad, California, USA) CisHigNsCUSNa， 
with MW 371.4, is supplied lyophilized. It is reconstituted to 10 mg/mL with sterile 
n i 
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dH20. It is then aliquoted and stored at 4 °C. 
7.3.1.4 Cells 
HepG2 cells (American Type Culture Collection, Manassas, Virginia, USA) are 
supplied frozen in dry ice. Upon receipt, the cells were thawed quickly in a water 
bath at 37 °C. 10 mL complete medium was added dropwise. The cells were then 
centrifuged at 1000 rpm for 5 mins to remove the cryopreservative. The cells were • 
resuspended in 9 mL complete medium and plated. • 
Hep3B cells (American Type Culture Collection, Manassas, Virginia, USA) are • 
supplied frozen in dry ice and thawed as HepG2 cells as above. 
7.3.1.5 pcDNA-DEST47™ 
pcDNA-DEST47™ (Invitrogen Corporation, Carlsbad, California, USA) is supplied 
lyophilized in TE, pH 8.0. pcDNA/GW-47/CAT™ (lyophilized in TE，pH 8.0) is 
supplied as a positive control. Both vectors are resuspended to 150 ng/|LiL with 
RNase-free dUjO. A detailed map of pcDNA-DEST47™ and 
pcDNA/GW-47/CAT™ can be found in Appendix A.9 and A. 10. 
7.3.1.6 QuikChange® II XL Site-Directed Mutagenesis Kit 
QuikChange® IIXL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California, 
USA) consists of 10 x reaction buffer, QuikSolution™ reagent, dNTP mix, 
‘ P/wUltra丁M high fidelity DNA polymerase (2.5 U/|iL) and Dpnl restriction enzyme 
(10 U/i^L). pWhitescript™ 4.5-kb control plasmid (5 ng/|LiL) with oligonucleotide 
control primer #1 and oligonucleotide control primer #2 are included in the kit as the 
positive control. It is stored at -20 °C. The kit claims to have an efficiency 
greater than 80%. 
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7.3.1.7 Lipofectamine™ 2000 
Lipofectamine™ 2000 (Invitrogen Corporation, Carlsbad, California, USA) is stored 
at 4 °C. 
7.3.1.8 LR clonase reaction mix 
LR Clonase Reaction mix (Invitrogen Corporation, Carlsbad, California, USA) 
consists of Gateway™ LR Clonase™ enzyme mix, LR reaction buffer and proteinase • 
K solution. GatewayTM LR Clonase™ enzyme mix contains bacteriophage lambda • 
recombination proteins Int (Integrase) and Xis (Excisionase), and the £:.co/z-encoded • 
protein IHF (Integration Host Factor). It is stored at -70 °C. 
7.3.1.9 MitoTracker® Red CMXRos 
MitoTracker® Red CMXRos (Invitrogen Corporation, Carlsbad, California, USA) 
C32H32CI2N2O, with MW 531.52，is stored at -20 °C. It is supplied lyophilized and 
stored desiccated at -20 °C. To prepare a stock solution, it is dissolved to ImM 
with high quality, anhydrous dimethylsulfoxide (DMSO). Dissolved MitoTracker® 
was stored at -20 °C. 
7.3.1.10 Nikon Optiphot-2 compound microscope 
Nikon Optiphot-2 compound microscope (Nikon, Melville, New York, USA) is 
equipped with a ColorView 12 Camera. The microscope has B-2A filter, G-2A 
. filter and a triple D API / FIFTC / Rhodamine (D-F-R) filter 
) 
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7.3.2 Methods 
7.3.2.1 Swapping the OTC gene from pENTR/D-TOPO to pcDNA-DEST47™ 
by LR Clonase Reaction 
Three hundred nanograms of the entry 
clone pENTR/D-TOPO-OTC and 300 ng 
of the destination vector, V J V 一 ) 
pcDNA-DEST47服 were recombined in a 咖 � r ^ �抓 人 • 
广 , ^ f 1 們， • 
reaction mixture containing 1 x LR V J fl 
reaction buffer, adjusted to a final volume • 
Adapted from Invitrogen, 2004 of 16|LIL with TE buffer (pH 8.0)，  
Traditional cloning involves restriction 
followed by the addition of 4 \ iL endonuclease and ligase to insert a 
^ 丁 M , TM gene into a vector. Gateway® Gateway LR clonase enzyme mix. 
technology utilizes lambda phage 
The mixture was incubated in a water site-specific recombination (attL x attR 
u .u . oc or- ^A • o T — — attP X attB) in place of bath at 25 °C for 60 mins. 2 |LIL 
endonuclease and ligase. Any DNA 
Proteinase K Solution was added and the fragment flanked by a recombination 
. ^ , , site (attL) can be transferred into any mixture was further incubated at 37 °C 
- vector that has a corresponding site 
for 10 mins to terminate the reaction. (attR) by LR Clonase™ enzyme mix. 
> 
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1 |iL LR clonase reaction product was 
|T7 B S a•圳画胁謝 c a i transformed into OneShot® TOP 10 I 
Competent Cells as described in Chapter . ，、 / ^ 7.2.2.4. / \ I pcDNA-DEST47'^ jm 
The cells were then spread on LB plates \ 8.0 kb _ 
containing 100 ^g/mL ampicillin and v 
incubated at 37 °C for 16 hours. A wicoi - 一 • 
Adapted from Invitrogen, 2004 single colony was then picked and 7r: • 
一 pcDNA-DEST47"^ has a human CMV • 
inoculated in 5 m L LB medium promoter for high-level expression in • 
. . 嘴八八 , ^ mammalian cells and a bovine growth containing 100 ng/mL ampicillin. The 
hormone (BGH) polyadenylation 
inoculum was shaked at 37 °C, 200 rpm sequence for proper termination and 
r 1 , 1 , processing of the transcript. It has a tor 16 hours. The plasmids were 
C-terminal ‘cycle 3 mutant' of the green 
extracted from the bacteria by QIAprep® fluorescent protein (GFP) gene, in 
、 广 . T,. which the codon usage was optimized Mmiprep Kit as described in Chapter 
by three cycles of DNA shuffling to 
7.1.2.1. It was sequenced as described generate a mutant form of GFP that 
. 一 ， has over 40-fold increase in fluorescent in Chapter 3.3.2. 
' yield over wild-type GFP (Crameri et 
al., 1996). It contains the attL 
recombination sites flanking the PCR 
product insertion site for efficient 
recombination with pENTR/D-TOPO®. 
I 
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7.3.2.2 Site-directed mutagenesis of 
pcDNA-DEST47-OTC by ^ ^ i i a y i i a a ^ j y i i y ^ i i i i a i i i i i a 
QuikChange® II XL ^ ^ 
Site-Directed Mutagenesis • 
Q ^ 
7.3.2.2.1 Primer design and synthesis 
Mutagenic primers, containing the desired ^ ^ ^ X • 
mutations of OTC, including Arg26Gln, ^ ^ s i f • 
• • I 
PhelOlLeu, LeulllPro, Glul22Gly, / F ^ 参广、, • 
Argl29His, Lysl44Term，Thrl78Met, V-；? 
Asnl98Ile, were designed by a web-based J ^ ^ k 
primer design software program at ^ ^ ^ f 
http://labtOOls.Strata^ene.COm/QC. T h e Adapted from Stratagene. 2004 primers were synthesized by QIAGEN QuikChange® II XL Site-Directed 
Mutagenesis Kit replaces, inserts, or (QIAGEN, Hilden, Germany) with HPLC 
deletes nucleotides from a 
purification. double-stranded vector. Two 
synthetic oligonucleotide primers 
containing the desired mutation, each 
7.3.2.2.2 Mutant strand synthesis complementary to opposite strands of 
the vector, are extended to generate a Five nanograms dsDNA template was 
mutated plasmid. The product is then 
amplified in a reaction mix containing treated with Dpn\ endonuclease (target 
sequence: 5'-Gm®ATC-3'), which is 62.5 ng of the corresponding 
specific for methylated and 
oligonucleotide primer and 62.5 ng of its hemimethylated DNA (McClelland and 
Nelson, 1992). The parental DNA anti-sense oligonucleotide primer, 0.5 jiL 
template, isolated from E.coli is dam 
dNTPs, 1.5 \ i L QuikSolution and I x methylated, thus is digested by Dpn\ 
endonuclease, leaving the mutated reaction buffer, adjusted to a final volume 
vector intact. 123 
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of 25 i^L with dH20, followed by the addition of 1.25 U P/wUltra™ HF DNA 
polymerase. PGR was carried out in a MJ PTC-200 (MJ Research, Incorporated, 
Massachusetts, USA), with the following parameters: denaturation at 95 °C for 1 min, 
followed by 18 cycles of denaturation at 95 °C for 50 sees, primer annealing at 60 °C 
for 50 sees, extension at 68 °C for 9 mins, and a final extension at 68 °C for 7 mins. 
For Leull lPro and Glul22Gly, 25 ng dsDNA template was added and 2 |LIL 
QuikSolution was used. The PCR conditions are: denaturation at 95 °C for 2 mins, • 
followed by 18 cycles of denaturation at 95 °C for 1 min, primer annealing at 60 °C • 
for 50 sees, extension at 68 °C for 9 mins, and a final extension at 68 °C for 7 mins. • 
7.3.2.2.3 Dpnl digestion of parental strand 
Ten units Dpnl restriction enzyme was added to the amplification product and the 
reaction was incubated in a water bath at 37 °C for 1 hour to digest the parental 
dsDNA. 
Five microlitres £)/?«I-treated product was analyzed by 1% agarose gel 
electrophoresis. A sharp band indicated successful mutant strand synthesis. 
7.3.2.2.4 Cloning 
Two microlitres Z)p«I-treated DNA was transformed into OneShot® TOP 10 
•  Competent Cells as described in Chapter 7.2.2.4. Small-scale preparation of 
plasmid DNA was performed by QIAprep® Miniprep Kit as described in Chapter 
7.1.2.1. The plasmid was sequenced as described in Chapter 3.3.2. 
124 
Materials & Mpfrhnric J 
7.3.2.3 Cell culture 
Hep3B and HepG2 were cultured in ^ ^ J ^ m ^ Q J ^ K H I ^ ^ ^ ^ ^ ^ ^ 
DMEM and MEM medium respectively, 
supplemented with 10% heat-inactivated 
FBS at 37 °C with 5% CO2. 
^^B I 
Adapted from ATTC, 2004 
Hep3B and HepG2 were isolated from 
two children with primary 
hepatoblastoma and hepatocellular 
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7.3.2.4 Transfection of OTC into Hep3B and HepG2 by Lipofectamine^"^ 2000 
Transient transfection of 
pcDNA-DEST47-OTC and mutants into 欢、 二； 
H :.'’二""““ 
Hep3B and HepG2 were performed by 
Lipofectamine™ 2000. 
各 pcDNA-GW47-CAT vector, which — ~ ~ ^ ，， 
/ 绍 J - O E M ! encodes for a cytoplasmic protein, was • 
also transfected as a control. Cationic lipid reagent-mediated • 
6 ‘ transfection (Feigner et al., 1987) • 0.12 X 10 cells were seeded on a cover • 
involves the formation of small • 
slip placed inside a 24-welled plate the unilamellar liposomes, which are 
J , ^ positively charged and are attracted day before transfection. 
electrostatically to the negative 
Lipofectamine™ 2000 was mixed by phosphate backbone of DNA, forming 
, … ， . A . , . jM DNA-cationic lipid reagent complexes, gently flicking. 2 i^L Lipofectamme 
The complexes are then attracted to 
2000 was diluted with 50 |iL the negatively charged surface of the 
八.��T 竹， , ^ cell membrane (Gershon et al., 1993) Opti-MEM®I Reduced Serum Medium, ‘ 
and enter the cells through endosomes 
mixed and incubated at RT for 5 mins. and lysosomes into the cytoplasm 
(Coonrod et al., 1997). 
In a second tube, 0.8 i^g plasmid was  
diluted in 50 i^L Opti-MEM®I Reduced 
Serum Medium. Diluted Lipofectamine™ 2000 and DNA were combined and 
incubated together at RT for 20 mins. While complexes were forming, the cells 
were washed with PBS twice to remove any FBS which may affect transfection, and 
then replaced with 500 i^L plain RPMI medium. The DNA- Lipofectamine™ 2000 
complexes were added to the cells dropwise and mixed by gently rocking the dish. 
The mixture was then incubated at 37 °C with 5% CO2 for 6 hours. After six hours 
incubation, the medium was replaced with 1 mL complete DMEM medium. The 
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transfected cells were further incubated at 37 °C with 5% CO2 for 36 hours. The 
cells were fixed 42 hours after transfection. 
7.3.2.5 Staining of mitochondria by MitoTracker® 
One millimolar Mitotracker® Red 
CMXRos was diluted 5000 fold to 200 r " ^ r - ^ ^ 
nM in complete medium. 0.5 mL 「丁 IT 丁 1 • 
medium with Mitotracker was added • 
r A I and the cells were incubated at 37 "C for , 
10 mins in the dark to stain the cells. 1 CH^Ci 
mL complete medium was added and the Adapted/mm invitrogen. 2004 
Conventional fluorescent stains for cells were incubated at 37 °C for 30 mins. 
mitochondria, such as 
The cells were then washed with 1 mL tetramethylrosamine and rhodamine 
123, are readily sequestered by PBS twice. 
functioning mitochondria, but easily 
washed out from the cells once the 
mitochondria experience a loss in 7.3.2.6 Fixation of cells 
- membrane potential. This limits the 
0.5 mL 40/0 paraformaldehyde in PBS was use of these stains to viable cells. 
MitoTracker® probe diffuses passively added and the cells were incubated at RT 
across the plasma membrane of the 
for 20 mins in dark. The cells were cells and accumulates in active 
mitochondria (Root et al., 1996). It -washed with 1 mL PBS twice. The 
contains a mildly thiol-reactive 
coverslips were mounted on microscope chloromethyl moiety that can keep the 
• dye associated with the mitochondria 
slides. 
after fixation. Thus, once their 
mitochondria are labeled, the cells can 
be treated with a fixative and the 
sample continues to exhibit the 
fluorescent staining pattern 
characteristic of live cells. 
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132.1 Fluorescence microscopy 
The fluorescent patterns were viewed 
under Nikon Optiphot-2 compound 
ExcltaMoo and EmlMion Sprctra for GFP 
microscope. "*] 
M* 507 
I Cycle 3 GFP has a primary excitation 
peak at 395 nm and a secondary I M 
I - \ 
excitation peak at 478 nm. Excitation at | 供 ‘― I • 
either o f these wavelengths yields a . / \ • 
^ , • . 1 - '2 s 3 s I I 3 3 s ! s 3 • 
fluorescent emission peak wi th a w.v.i«,9th(nm) • 
maximum at 507 nm. OTC and its Adapted from invitmgen. 2004 
mutants that fused wi th GFP were 
visualized in f ixed cells using a B -2A filter set. The filter set excites Cycle 3 GFP 
wi th l ight from 450 to 490 nm which covers the secondary excitation peak, and 
passes light f rom 505 to 520 nm, al lowing detection o f the Cycle 3 GFP 
fluorescence. 
Mitotracker® Red CMXRos has an excitation peak at 579 nm and an emission peak 
at 599 nm. Cells stained wi th Mitotracker® Red CMXRos were visualized by a 
G-2A fi lter set. The filter set excites Mitotracker® Red CMXRos w i th l ight from 
510 to 560 nm which is close to the excitation peak, and passes light from 575 to 590 
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•nufistiqation Of Enzyme Activity of OTC Mutants Expressed In a 
Cell-free System 
0TC2 was swapped from pENTR/D-TOPO to pEXPl-DEST by LR Clonase™ 
reaction. pEXP 1-DEST/0TC2 was mutated to bring about the following amino 
acid changes: Arg26Gln, PhelOlLeu, LeulllPro, Glul22Gly, Argl29His, 
Lysl44Term, Thrl78Met and Asnl98Ile by QuikChange® II XL Site-Directed 
Mutagenesis Kit. The gene was then expressed by cell-free expression by 
Expressway™ Plus Expression System. The analysis of the proteins by • 
SDS-PAGE was performed by using-NuPAGE® Novex Pre-Cast Gel System. To • 
confirm expression, His-tagged fusion protein was stained by InVision^'^ His-tag 
In-gel Stain. The activity of OTC was measured by a method developed by Ohshita 
M(Ohshita et al., 1976). 
* 
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7.4.1 Materials 
7.4.1.1 Chemicals and Reagents for His-tag protein stain 
In Vision™ His-tag In-gel Staining Kit (Invitrogen Corporation, Carlsbad, California, 
USA) consists of InVision™ His-tag In-gel Stain. BenchMark™ His-tagged 
Protein Standard is included as the marker and positive control of the kit. The kit 
claims to detect 0.5 pmol of a 6 x His-tagged fusion protein. It is stored at RT with 
BenchMarkTM His-tagged Protein Standard stored at -20 A detailed description • 
of BenchMarkTM His-tagged Protein Standard can be found in Appendix A. 17. • 
Potassium phosphate (Dibasic) K2HPO4 (Sigma-Aldrich, St Louis, Missouri, USA) • 
anhydrous approx. 98%, with MW 174.2. It is in powder form and stored at RT. 
Potassium phosphate (Monobasic) KH2PO4 (Sigma-Aldrich, St. Louis, Missouri, 
USA) anhydrous (99+%), with MW 136. It is in powder form and stored at RT. 
Fixing solution was prepared by mixing 50% methanol and 10% acetic acid with 
dHzO. 
7.4.1.2 Chemicals and reagents for OTC enzyme assay 
Carbamyl phosphate dilithium salt (Sigma-Aldrich Co., St. Louis, Missouri, USA) 
CH2NO5PL12, with MW 152.9，is supplied in powder form. It is stored desiccated 
at -20 oc. 
Diacetyl Monoxime (ICN Biomedicals, Irvine, Carlifomia, USA) with MW 101.1, is 
supplied in powder form. It is stored at RT. 
Iron(III)Chloride, Anhydrous (Wako Pure Chemical Industries, Ltd., Japan) FeCls, 
with MW 162.21, is supplied in powder form. It is stored at RT. 
L(+)-Omithine Monohydrochloride (Wako Pure Chemical Industries, Ltd., Japan) 
H2N(CH2)3CH(NH2)C00H-HCI，with MW 168.62, is supplied in powder form. It 
is stored at RT. 
L-Citrulline (Wako Pure Chemical Industries, Ltd., Japan) 
H2NC0NH(CH2)3CH(NH2)C00H，with MW 175.19，is supplied in powder form. 
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It is stored at RT. 
Ornithine Trascarbamylase from Streptococcus faecalis (Sigma-Aldrich Co., St. 
Louis, Missouri, USA) is supplied lyophilized and contains 80% protein in balanced 
Tris buffer salts. It is stored at -20 T . 
Thiosemicarbazide (Wako Pure Chemical Industries, Ltd., Japan) H2NCSNHNH2 
with MW 91.14, is supplied in powder form. It is stored at RT. 
Urease, from Jack Bean (Wako Pure Chemical Industries, Ltd., Japan) with activity 
124 units/mg, is supplied in powder form. It is stored at -20 °C. 
Reagent 1: 0.0IM L-ornithine in O.IMphosphate buffer’ pH 7.0 was prepared by • 
dissolving 337 mg of L-omithine monohydrochloride in 200 mL of 0.1 M potassium • 
phosphate buffer and adjust to pH 7.0 with potassium hydroxide. It is stored at 4 • 
� C . 
Reagent 2: Urease solution was prepared by dissolving 1 mg urease in 3.0 mL of 
Reagent 1. Reagent 2 has to be prepared just before used. 
Reagent 3: Dilithium carbamoyl phosphate was prepared by dissolving 5 mg of 
dilithium carbamyl phosphate in 1.5 mL Reagent 2. Reagent 3 has to be prepared 
just before use. 
Reagent 4: Acid ferric solution was prepared by adding 450 mL concentrated 
phosphoric acid and 40 mL of concentrated sulfuric acid and 400mg Iron(III) 
chloride. It is corrosive and should be stored in fume cupboard. 
Reagent 5: Diacetylmonoxime(DAMO)-thiosemicarbazide(TSC) solution was 
prepared by adding 500 mg of diacetylmonoxime and 3 mg of thiosemicarbazide to 
100 mL of dH20. It is stored at 4 T . 
. Reagent 6: Color Reagent was prepared by adding 20 mL Reagent 5 to 100 mL 
> 
Reagent 4. Reagent 6 has to be prepared just before use. 
7.4.1.3 Chemicals and reagents for NuPAGE® Novex Pre-Cast Gel System 
NuPAGE® Antioxidant (Invitrogen Corporation, Carlsbad, California, USA) is 
“ m “ 
Materia丨s & M对hnric [ J 
stored at 4 
NuPAGE® LDS Sample Buffer (4x) (Invitrogen Corporation, Carlsbad, California, 
USA) is stored at 4 
NuPAGE® MES SDS Running Buffer (for Bis-Tris Gels only) (20x) (Invitrogen 
Corporation, Carlsbad, California, USA) is stored at 4 °C. 
NuPAGE® MOPS SDS Running Buffer (for Bis-Tris Gels only) (20x) (Invitrogen 
Corporation, Carlsbad, California, USA) is stored at 4 • 
NuPAGE® Novex 4-12% Bis-Tris Gel 1.5 mm, 15 well (Invitrogen Corporation, I 
Carlsbad, California, USA) is stored at 4 I 
� 
NuPAGE Sample Reducing Agent (lOx) (Invitrogen Corporation, Carlsbad, 
California, USA) is stored at 4 T . 
7.4.1.4 Chemicals and Reagents for total protein stain 
GelCode® Blue Stain Reagent (Pierce Biotechnology, Inc., Rockford, Illinois, USA) 
is stored at 4 
Acetic acid glacial 100% GR (Merck KGaA, Darmstadt, Germany) CH3COOH, has 
a MW 60.05. It is corrosive and should be stored in fume cupboard. 
Methanol >99.8% GR (Merck KGaA, Darmstadt, Germany) CH3OH, has a MW 
32.04. It is highly flammable and toxic and should be stored in fume cupboard. 
-Fixing solution is prepared by adding 7 mL acetic acid and 50 mL methanol to 43 
mLdHzO. 
I 
7.4.1.5 Chemicals and Reagents for Tris-Glycine SDS-PAGE 
lOx Tris-Glycine-SDS Electrophoresis Buffer is prepared by dissolving 0.25 M 
Tris-HCl (pH 7.5)，1.92 M glycine and 1% SDS. It is stored at 4 It is diluted 
to Ix with dH20. 
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30% Acrylamide/Bis solution (Bio-rad Laboratories, Hercules, California, USA) is 
stored at 4 °C in dark. 
Ammonium persulphate (Sigma-Aldrich Co., St. Louis, Missouri, USA), APS is 
supplied in powder form. 10% APS solution is prepared by dissolving 0.5 g APS 
with 5 mL dHzO. Dissolved APS is stored at -20°C. 
NyNyN'yN'-tetrametylenediamine (Sigma-Aldrich Co., St. Louis, Missouri, USA) 
TEMED is stored at 4 � C in dark. • 
Kaleidoscope Prestained Standards (Bio-Rad Laboratories, Hercules, California, • 
USA) contains approximately 1.6 mg total protein in 33% (v/v) glycerol, 3% SDS, • 
10 mM Tris, pH 7.0，10 mM DTT, 2 mM EDTA, 0.01% NaN]. It is stored at - 2 0 � C . 
A detailed description can be found in Appendix A. 17. 
Sodium Dodecyl Sulfate (Sigma-Aldrich Co., St. Louis, Missouri, USA). SDS is 
supplied in powder form. 10% SDS is prepared by dissolving 10 g SDS with 100 
mL dH20. It is stored at RT. 
Tris Base (Sigma-Aldrich Co., St. Louis, Missouri, USA) is supplied in powder form. 
Tris-HCl buffer was prepared by dissolving Tris-base with dHsO to a desired 
concentration and adjusting the pH with HCl. Dissolved Tris-HCl buffer was stored 
at 4 oc. 
10% separating gel was prepared by mixing 4.3 mL water, 3 mL 30% 
-acrylamide/Bis solution, 2.5 mL of 1.5 M Tris-HCl (pH 8.8), 100 |LIL 10% SDS, 100 
\iL 10% APS and 4 i^L TEMED. 
‘ 5% stacking gel was prepared by mixing 3.64 mL water, 0.61 mL 30% 
acrylamide/Bis solution solution, 0.63 mL 1.0 M Tris-HCl (pH 6.8), 50 |liL 10% APS 
and 5 |iL TEMED. 
Bio-Rad Mini-Protein ™ II was set up by clamping two clean glass plates which 
were held apart by plastic spacers on the two sides. 10% separating gel solution 
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was pipetted into the space between the two glass plates until the liquid level reached 
a height of 1 cm below the lowest portion of the well-forming comb. Isopropanol 
was added to cover the meniscus in order to keep atmospheric oxygen away from the 
gel solution. Upon setting of the separating gel, isopropanol was drained and 
washed away with deionized water. 5% stacking gel solution was pipetted into the 
space just above the separating gel. Well-forming comb was put into the space 
— — : ‘ 一 " I 
7.4.1.6 ExpressWayTM expression system • 
Expressway™ Plus Expression System (Invitrogen Corporation, Carlsbad, 
California, USA) consists of IVPS plus E. coli extract, 2.5x IVPS plus E. coli 
reaction buffer, T7 enzyme mix, 75 mM methionine, DNase / RNase-free distilled 
water, RNase A (Img/mL in DNase/RNase-free H2O) and 2 mL screw-cap tubes. 
pT7/CAT and pEXPl-GW/lacZ are included as the positive control of the kit. It is 
stored at -80 The kit claims to have a production of up to 50 i^g protein in 50 
fj-L reaction. 
7.4.1.7 pEXPl-DEST vector 
pEXPl-DEST vector (Invitrogen Corporation, Carlsbad, California, USA) is 
supplied lyophilized in TE buffer, pH 8.0. It is resuspended to 150 ng/^iL with 
RNase-free 恥0 . pEXPl-GW/lacZ (lyophilized in TE buffer, pH 8.0) is supplied 
as a positive control. It is resuspended to 1 jug/^L with RNase-free dH20. A 
detailed map of pEXPl-DEST and pEXPl-GW/lacZ can be found in Appendix A. 12 
and A.13. 
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7.4.1.8 B-Gal assay kit 
ji-Gal assay kit (Invitrogen Corporation, Carlsbad, California, USA) consists of Ix 
lysis buffer, 10 x cleavage buffer, B-mercaptoethanol (14.3M), ONPG (4 mg/mL 
ONPG in sterile water) and stop buffer (1 M Sodium Carbonate). 
B-mercaptoethanol and ONPG is stored at -20°C while the other components are 
stored at 4°C. 
7.4.1.9 Rapid translation system RTS GroE supplement • 
Rapid Translation System RTS GroE Supplement (Roche Diagnostics GmbH，Basel, • 
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7.4.2 Methods 
7.4.2.1 Swapping OTC gene from pENTR/D-TOPO to pEXPl-DEST by LR 
Clonase Reaction 
0TC2 was swapped from 
pliXPl-DKST (4.6 kl>) 
pENTR/D-TOPO into pEXPl-DEST by . 1 I  
g j y RSS ^ Q Q Q S ^ ^ I Q ^ Q Cnr m ^ Q 
丁 I LR Clonase reaction as described in � \ Chapter 7.3.2.1. The gene had its stop / \ ^ • 
^ pEXP-DEST 9 • 
codon added so that transcription and j 等 • 
translation will be terminated properly, ^^^^ ^^^^ I 
producing pOTC with N-terminal His-tag Adapted fwm invitrogen. 2004 
and without any C-terminal tag. pEXP1-DEST vector contains 
transcription I translation regulatory 
elements, including a bacteriophage T7 
7.4.2.2 Site-Directed Mutagenesis of RNA polymerase promoter, prokaryotic 
Shine-Dalgarno ribosome binding site pEXPl-DEST-OTC by 
(RBS), ATG initiation codon, stop 
QuikChange® II X L codon, and T7 terminator, optimally 
spaced for protein expression with the Site-Directed Mutagenesis 
‘ system. The 15-20 nucleotide 
K i t sequence following the T7 promoter 
should form a potential stem-loop pEXPl-DEST-0TC2 was mutated to 
structure. A 6xHis sequence enables 
bring about the following amino acid rapid detection and purification of the 
fusion protein on nickel-chelating resin. changes: Arg26Gln, PhelOlLeu， 
It contains the attL recombination sites LeulllPro, Glul22Gly, Argl29His, flanking the PCR product insertion site 
• for efficient recombination with Lysl44Term, Thrl78Met and Asnl98Ile 
pENTR/D-TOPO. 
by QuikChange® II XL Site-Directed 
Mutagenesis Kit as described in Chapter 7.3.2.2. 
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7.4.2.3 Cell-free expression by ExpressWay plus expression system 
One microgram plasmid DNA was 
expressed in a reaction mixture 
containing 20 i^L IVPS plus E.coli extract, J _ ^ ^ i 
20 [lL 2.5X IVPS plus E.coli reaction ,,.•� ^ ^ ^ 
buffer, 1 ^L T7 enzyme mix, 1 |iL 75mM : L， ‘ 
W “ 
-rnmm^ methionine, and 6 i^L RTS GroE • 
Adapted from Invitrogen. 2004 
Supplement, adjusted to a final volume of — • 
Expressway Plus Expression • 
56 }aL with DNase/RNase-free water in a System utilizes extract from an S30 • 
E.coli strain (Zubay, 1973) to drive 2 mL screw-cap tube on ice. The 
coupled in vitro transcription and 
mixture was shaken by a shaking translation of target DNA to protein. 
S30 E.coli extract contains the cellular incubator at 290 rpm, 30 for 4 hours. 
machinery required to drive 
5 ^iL RNase A was added and the mixture transcription and translation. The 
IVPS reaction buffer contains an ATP was shaken at 290 rpm, 37 for 15 
regenerating system for energy (Lesley 
minutes. pIVEX control vector GFP etal., 1991; Kim etal., 1996) and all the 
required amino acids except and pEXPl-GW/lacZ, which expressed 
' methionine. T7 enzyme mix contains 
GFP and fi-galactosidase respectively, T7 RNA polymerase (Studier et al., 
1990). Methionine is provided were expressed simultaneously as 
separated from other amino acids to 
positive controls. p I V E X control vector allow generation of radiolabeled protein 
by addition of 扔S methionine. As the GFP has the advantage of being able to 
DNA template is transcribed, the 5' end 
detect expression easily by visualizing of the mRNA is bound by ribosomes 
‘ and undergoes translation, while the 3' under fluorescence light. 
end of the template is still being 
pEXPl-GW/lacZ has the advantage of transcribed. 
being able to detect expression 
quantitatively by assaying the activity, which is particularly useful for the activity 
assay. 
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7.4.2.4 Preparation of proteins for SDS 
PAGE m ^ ^ j y j y j j ^ j l l l ^ l l l ^ ^ ^ ^ ^ ^ 
10A 
Five microliters sample was centrifuged at GroEL:GroES with 
/ ^ j g ^ ^ y enclosed substrate 
10000 X g for 5 mins to separate soluble f ^ ^ S ^ A 
proteins which remained in the supernatant, y j j p ^ j ^ ^ ^ , 
and insoluble proteins which precipitated as a GroEL 
pellet. 20 ^L ice-cold acetone was added � -少 • 
Rapid Translation System RTS GroE • and incubated on ice for 5 mins for • 
Supplement contains GroEL and • 
precipitation of proteins. It was then GroES which are chaperonins of • 
E.coli. . GroEL is arranged in 2 centnfuged at 12000 rpm for 5 mins and the 
heptameric rings which in turn form a 
supernatant was discarded. The sample was cylindric complex. GroES forms 
, . , . 阅 p dome-shaped hepatmeric rings which dned in a SpeedVac for 15 mins. The 
cap the GroEL cylinder on one or both 
sample was resuspended in 20 ^L 1 x ends. The size of the cylinder allows 
�� proteins with a molecular mass up to SDS-PAGE sample buffer. It was heated at 
60kDa to be substrates for the GroE 
100 for 10 mins. system. It is believed that GroE are 
involved in the de novo folding of 
‘ 10-30% of all cytoplasmatic proteins in 
7.4.2.5 SDS-PAGE E. coli (Ewalt et al., 1997). 
The proteins were separated by SDS-PAGE with the NuPAGE® Novex Pre-Cast Gel 
System. 5 ^L pellet and 3 i^L supernatant were loaded per lane. 5 i^L 
Kaleidoscope Prestained Standards was loaded as a marker. 
After electrophoresis, the gel was shaken with 15 mL fixing solution for 15 mins at 
60 rpm to fix the protein. The gel was then washed with 100 mL dHsO for 5 mins 3 
times. The gel was shaken in 15 mL GelCode® Blue Stain Reagent for Ihour at 60 
rpm to stain the total protein. It was finally washed with 100 mL dHsO for 1 hour 
twice to enhance stain sensitivity. 
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7.4.2.6 Staining of his-tagged fusion protein by InVision^'^ his-tag In-gel stain 
The proteins were separated by 
SDS-PAGE with the Laemmli buffer 
L‘ system (Laemmli, 1970). 5|iL pellet and \ � 广 ii' 
3uL supernatant was loaded per lane. 广 —、丄?\ k I 
r r r 0.=/ ；>'. > � ™ , -ai, -ON'�<.K,..o 乡 
\ 厂f h、J 
TN/I CH—CH,-< ^ ---"'-^ o ii Z/ 
5|iL BenchMark™ His-tagged Protein L � 多 
K Standard was loaded as the marker and His-tag NI-NTA the positive control. AdaptedfromQiagen, 2003 
- Traditional method of detecting protein After electrophoresis, the gel was 
expression is to perform a western blot 
immersed in 15 mL for 1 hour to fix the with the corresponding antibody. The 
, InVision™ His-tag In-gel Stain is a stain protein. The gel was then washed with 
capable of visualizing His-tagged 
100 m L dH20 twice for 10 minutes to fusion proteins in a polyacrylamide gel 
after electrophoresis directly. It remove the fixative. It was stained by 
consists of a fluorescent dye 15 mL InVision™ His-tag In-gel Stain for 
conjugated to Ni^ "": nitrilotriacetic acid 
, , . ^ ^ ^ ^ (NTA) complex. The N ^ binds 1 hour. The gel was washed with 15 mL 
specifically to the oligohisitidine domain 
20 m M Phosphate Buffer (pH 7.8) for 10 of the His-tagged fusion protein, 
, , . allowing specific detection of minutes. The gel was visualized using a 
His-tagged fusion proteins from a 
302 nm U V transilluminator equipped mixture of endogenous proteins. 
BenchMark™ His-tagged Protein with an ethidium bromide filter and the 
Standard acts as a protein size marker 
• gel was imaged with a C C D camera using and a positive control. 
10 second exposure. 
> 
139 
Materia丨s & M p H w I c j ^ J j 
7.4.2.7 OTC enzyme assay 
OTC activity was assayed by the method developed by Ohshita (Ohshita et al, 1976). 
100 i^ L sample was added to 100 |iL reagent 3. A negative control was set up by 
just adding 200 |LIL deionized H2O. The enzymatic reaction was carried out at 37 °C 
for 20 mins. 0.5 mL acid ferric solution was added to stop the reaction, and 6.0 mL 
color reagent was added. The mixture was vortexed for 3 sees. The colorimetric 
reaction was carried out at in a water bath at 95 °C for 15 mins. The mixture was • 
then cooled with running tap water for 5 mins. The formation of colored product • 
was detected spectrophotometrically with a Beckman Du® 650 spectrophotometer • 
(Beckman Coulter, Inc., Fullerton, California, USA) by measuring absorbance at 515 
nm with the negative control as the blank. 
7.4.2.7.1 Validation of OTC enzyme assay by normal individual's sera 
The enzyme assay was validated by serum collected from 10 normal subjects. 
7.4.2.7.2 Determination of linear range by OTC and citrulline 
The linearity range of the assay to OTC was tested by applying 0.0005 U to 0.2 U 
Streptococcus faecalis OTC as the input material and that of citrulline was tested by 
applying 1 nmol to 200 nmol citrulline. 
7.4.2.7.3 Enzyme assay of cell-free expressed WT OTC 
The .volume of the cell-free expression product was made up to 100 |iL and assayed 
for its activity. 
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7.4.2.8 fi-Gal assay 
B-Gal activity was assayed by B-Gal 
assay kit. The sample volume was CH2OH 
• . . ^ 9 / N O 2 
made up to 30 jxL with deionized water. y^H y 
70 |NL O N P G and 200 |LIL 1 x cleavage H OH 
0 - N Itraphenyl - ft - Galactosld 
buffer with 6-mercaptoethanoL A 
negative control with H2O replacing the ch^oh oh • 
sample was set up simulatneously. The f + H 
mixture was mixed by gently flicking. H Iw- • 
Galactose 0 - Nitrophenol 
The reaction was carried out at 3 7 � C for   
The p-Gal Assay Kit measures the levels 5 mins. 500 \iL stop buffer was added 
of active fl-galactosidase expressed 
to stop the reaction. The absorbance of from /acZ. LacZ is a bacterial gene 
often used as a reporter construct in the sample was detected 
eukaryotic transfection experiments spectrophotometrically with a Beckman because the gene product, 
� fi-galactosidase, is resistant to Du 650 spectrophotometer (Beckman 
proteolysis in cellular lysates, is not 
Coulter, Inc., Fullerton, California, USA) normally found in mammalian cells and 
. is easily assayed. fi-galactosidase by measuring absorbance at 420 nm with 
catalyzes the hydrolysis of 
the negative control as the blank. ortho-nitrophenyl-p-D-galactopyranoside 
(ONPG) to the ONP anion, producing a 
bright yellow color with a peak 
absorbance at 420 nm that can be 
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^ ^ The ^igfienc In GencStorm® Expression-Beady Clone Showed 
3 Mismatches with Punilshed ^TgcDNA Sequence [GenBanK 
Accession Numftcr N W _ 0 0 5 ^ 
The sequence of the OTC gene in GeneStorm® Expression-Ready Clone 
matches with published OTC cDNA sequence (GenBank accession number 
NM_00531) with three mismatches (Fig 8.1). The first one is in codon 46，in which 
AAA in the reference sequence changes into AGA in the clone, substituting a lysine • 
with an arginine. This is a known polymorphism with an allele frequency of • 
0.68/0.32 (Climent et al., 2002). The second mismatch is found in codon 106’ in • 
which GGA in the reference sequence changes into GGG in the clone, with no amino 
acid substitution occurs. The third mismatch is found in codon 151, in which CTT 
in the reference sequence changes into CTG in the clone, also with no amino acid 
substitution occurs. Taken together, these three mismatches should not affect the 
subcellular localization and activity of OTC, which we intended to investigate in this 
study. And thus, the construct can be used to proceed in subsequent experiments. 
> 
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Query: 1 atgctgtttaatctgaggatcctgttaaacaatgcagcttttagaaatggtcacaacttc 60 I I M I M M I M I M I M I M I I I I I M I I I M I I I I I I M I I I I I I I I I I I I I I I I M I 
Sbjct: 589 atgctgtttaatctgaggatcctgttaaacaatgcagcttttagaaatggtcacaacttc 648 
Query: 61 atggttcgaaattttcggtgtggacaaccactacaaaataaagtgcagctgaagggccgt 120 M M M I I I I I I I I M I I I M I I I I I I M I I M I M I M I I I I M I I M I I I I I I I I I I I 
Sbjct: 649 atggttcgaaattttcggtgtggacaaccactacaaaataaagtgcagctgaagggccgt 708 
Query: 121 gaccttctcactctaagaaactttaccggagaagaaattaaatatatgctatggctatca 180 
11111 M 1111111 M I m 11111 m 111111 M 11 I I I I m I 丨 M 11111 M 111 
Sbjct: 709 gaccttctcactctaaaaaactttaccqqaqaaqaaattaaatatatqctataactatca 768 
Query: 181 gcagatctgaaatttaggataaaacagaaaggagagtatttgcctttattgcaagggaag 240 I I I I I M I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I • 
Sbjct: 769 gcagatctgaaatttaggataaaacagaaaggagagtatttgcctttattgcaagggaag 828 
I Query: 241 tccttaggcatgatttttgagaaaagaagtactcgaacaagattgtctacagaaacaggc 300 M I I I I M I I M M I I I M M I I I I I I I M I I I I M I I I I M I I M I I I I I I I I M I I I I 
Sbjct: 829 tccttaggcatgatttttgagaaaagaagtactcgaacaagattgtctacagaaacaggc 888 
Query: 301 tttgcacttctggga^^acatccttgttttcttaccacacaagatattcatttgggtgtg 360 II M 11 m II M I m I I I I I I I I I I I I I I I M I I I I I I I M I I I I I I I I I I I I I I I I 
Sbjct: 889 tttgcacttctgggag^acatccttgttttcttaccacacaagatattcatttgggtgtg 948 
Query: 361 aatgaaagtctcacggacacggcccgtgtattgtctagcatggcagatgcagtattggct 420 I 丨丨I I I I M 丨丨 I I I M I I M I I I M I I I M I I I III I I M I III I I I I I I I I I I I I I I I I 
Sbjct: 949 aatgaaagtctcacggacacggcccgtgtattgtctagcatggcagatgcagtattggct 1008 
Query: 421 cgagtgtataaacaatcagatttggacaccctggctaaagaaqcatccatcccaattatc 480 I I I I M M I M I I I I M I I I I I M I I I I I M I I III I I I III I I II I I I I I I I I M I I I 
Sbjct: 1009 cgagtgtataaacaatcagatttggacacccttgctaaaqaaqcatccatcccaattatc 1068 
Query: 481 aatgggctgtcagatttgtaccatcctatccagatcctggctgattacctcacgctccag 540 
丨丨丨丨 I I 丨 I I I M 丨丨 I I I M M I 丨 I I III I I I I I I I I I I I I I I I III I I I I I I I I I I I I I I 
Sbjct: 1069 aatgggctgtcagatttgtaccatcctatccagatcctggctgattacctcacgctccag 1128 
Query: 541 gaacactatagctctctgaaaggtcttaccctcagctggatcggggatgggaacaatatc 600 
丨 M 丨 M I m I I 丨 I I m M I I I I I M M I I M I I I 丨 I I I I I 丨 I 丨 I I I N I I I m 丨丨 I I 




Query: 601 ctgcactccatcatgatgagcgcagcgaaattcggaatgcaccttcaggcagctactcca 660 
I I M I M I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I 
Sbjct: 1189 ctgcactccatcatgatgagcgcagcgaaattcggaatgcaccttcaggcagctactcca 1248 
Query: 661 aagggttatgagccggatgctagtgtaaccaagttggcagagcagtatgccaaagagaat 720 
I I M I M I M I I I I M I I I I M I M I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I 
Sbjct: 1249 aagggttatgagccggatgctagtgtaaccaagttggcagagcagtatgccaaagagaat 1308 
Query: 721 ggtaccaagctgttgctgacaaatgatccattggaagcagcgcatggaggcaatgtatta 780 
111111111 m 11 m 111 M 1111111111 M 11111 m I m 111 M 11111 m I 
Sbjct: 1309 ggtaccaagctgttgctgacaaatgatccattggaagcagcgcatggaggcaatgtatta 1368 
Query: 781 attacagacacttggataagcatgggacaagaagaggagaagaaaaagcggctccaggct 840 
I I I I I I I I M I I I I I I M M I I I I I M I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I • 
Sb jct : 1369 attacagacacttggataagcatgggacaagaagaggagaagaaaaagcggctccaggct 1428 
I Query: 841 ttccaaggttaccaggttacaatgaagactgctaaagttgctgcctctgactggacattt 900 
I I I M I I I I 丨 M M I I I M I I I I I I I M M I I I I I M I I 丨 I I I I I I I I I I I I I I I I m I 
Sbjct: 1429 ttccaaggttaccaggttacaatgaagactgctaaagttgctgcctctgactggacattt 1488 
Query: 901 ttacactgcttgcccagaaagccagaagaagtggatgatgaagtcttttattctcctcga 960 
I I I M I I I I I M I I I M M I I I I I I I M i I M I I I I I I I I I I I I M M I I I I I I I I I I I I 
Sbjct: 1489 ttacactgcttgcccagaaagccagaagaagtggatgatgaagtcttttattctcctcga 1548 
Query: 961 tcactagtgttcccagaggcagaaaacagaaagtggacaatcatggctgtcatggtgtcc 1020 
I I I M I M 丨 M M I m I I I I M M I I I I I I I I 丨 I I I 丨 I I I I I I 丨 I I I m I I I I I I I I I 
Sbjct: 1549 tcactagtgttcccagaggcagaaaacagaaagtggacaatcatggctgtcatggtgtcc 1608 
Query: 1021 ctgctgacagattactcacctcagctccagaagcctaaattt 1062 
I I I I I I I I I M M I I I I I I M M I M I I I I I I I I M I I I I I I 
Sbjct: 1609 ctgctgacagattactcacctcagctccagaagcctaaattt 1650 
Fig 8.1 The OTC gene in GeneStorm® Expression-Ready Clone showed 3 
mismatches with published OTC cDNA sequence (GenBank 
accession number NM_00531) 
The sequence of the OTC gene in GeneStorm® Expression-Ready Clone matches 
with published OTC cDNA sequence (GenBank accession number NM_00531) with 
three mismatches (bolded), which are in nucleotide 137 (A->G), 318 (A—G), and 
452 (T—G). The substitutions are in codons 46, 106, and 151 respectively 
(underlined). In codon 46，in which AAA in the reference sequence changes into 
AGA in the clone, a substitution of lysine with arginine is resulted. Both the second 
and third mismatches do not have any amino acid change. 
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g.2 • flTH anil its Mutants snowed a Mitochondrial Dlstriautlon in 
Hcp3Band HcpB2 
To investigate the effect of mutations on the subcellular localization of OTC, the 
OTC gene with the stop codon removed, was cloned into the pcDNA3.1-DEST47 
vector. The vector has a mammalian CMV promoter for expression in mammalian 
cells and a GFP sequence fused in the C-terminal of the cloning site for visualization 
under fluorescence microscope. The removal of the stop codon from OTC would 
allow expression of a fusion protein, with OTC fused with GFP. I 
OTC carrying the mutations: Arg26Gln, Argl29His, Lysl44Term, Thrl78Met, I 
Asnl98Ile, and the two questionable polymorphisms: PhelOlLeu and Leul l lPro 
were constructed by site-directed mutagenesis. Successful mutagenesis was 
confirmed by sequencing, showing that the gene carried the desired mutation (Fig 
8.2a-g). The entire sequence of the gene was further sequenced to confirm that the 
gene was cloned in the correct orientation, and that it did not carry any other 
mutations, which may affect the results of the subsequent studies. 
The constructs were transfected into Hep3B and HepG2 cells. As OTC is 
mainly expressed in liver, Hep3B and HepG2 cells which are liver cell lines served 
as good choices for this study. The cells were then examined for GFP fluorescent 
patterns by fluorescence microscopy. As OTC was fused with GFP, these patterns 
reflected the subcellular localization of OTC. 
In both cells, transfection with OTC mutants carrying the substitution Arg26Gln, 
• PhelOlLeu, Leull lPro, Thrl78Met, and Asnl98Ile showed the same characteristic 
) 
particulate mitochondria pattern as cells transfected with the wild-type OTC (Fig 
8.3c-h; Fig 8.4c-h). The pattern was further confirmed to be mitochondria by 
staining the cells with the mitochondria-specific dye Mitotracker® Red CMXRos, 
which enabled visualization of the mitochondria pattern (Fig 8.3b; Fig8.4b). In 
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transfection with OTC carrying the Argl29His mutation, no GFP was visualized. 
Transfection with OTC carrying the Lysl44Term mutation served as a negative 
control of the study. It is because the lysine residue was mutated to become a stop 
codon which resulted in premature termination of OTC-GFR Thus, GFP, which 
located in the 3'-end of OTC would not be transcribed and translated, and the 






8.2.1 pcDNA-DEST47/OTC with desired mutations generated 
a Arg26Gln (CGG^CAG) b Phe101Leu (TTI->TTA) 
二 G J 厂 A 二 T T T C A A A C A G G C T T A G C A C T T C T 1R200 210 I F 240 250 
I q w v a I I 
C Leu111Pro(CIT^CCT) - d Arg129His (CGT^CAT) • 
C T T G T T T T C C T A C C A (TAI ACACGG C C C A T G T A T T G T C t\ H 
1F 270 280 IF 330 340 
e Lys144Term (AAA^JAA) f Thr178Met (ACG^AIG) 
G A G T G T AT T A A C AA T C A G A M ^ T A C C T C A T G C T C CA G G A 
2F 160 1"70 260 ~T~ 270 
2F 
^ V M V / w w w y v | \ntmhM 
g Asn198lle (AAC->AIC) 




Fig8.2 The OTC gene in pcDNA-DEST47 with desired mutations generated 
by site-directed mutagenesis 
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Sequencing results of pcDNA-DEST47/OTC after site-directed mutagenesis showed 
mutations of a) Arg26Gln; b) PhelOlLeu; c) LeulllPro; d) Argl29His; e) 
Lysl44Term; f) Thrl78Met; and g) Asnl98Ile sequenced by OTCclonelF, IR or 2F 
primers as indicated. 
The results showed generation of nucleotide changes (arrowed) in the designated 
codons (underlined), indicating successful site-directed mutagenesis. The whole 
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Fig 8.3 OTC and its mutants showed a mitochondrial distribution in 
Hep3B 
Hep3B cells cultured on coverslip in a 24-well plate were a) stained with 
Mitotracker® Red CMXRos; b) transfected with 0.8 |ig pcDNA-GW47/CAT; c) 
transfected with 0.8 \ig pcDNA-DEST47/OTC; d-h) transfected with 0.8 ^g 
pcDNA-DEST47/OTC carrying the indicated mutations. 
In 8.3a, the mitochondria pattern of Hep3B cells was visualized by staining with 
mitochondria-specific dye Mitotracker® Red CMXRos. In 8.3b，transfection with 
pcDNA-GW47/CAT, which encoded for a cytosolic protein showed a cytosolic 
distribution. This served as a negative control of the experiment. In 8.3c-h, 
transfection with pcDNA-DEST47/OTC and its mutants gave a punctate pattern, 
which is a characteristic mitochondria distribution and consistent with that stained 
with Mitotracker® shown in 8.3a. 
J 
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8.2.3 OTC and its mutants showed a mitochondrial distribution in HepG2 
• • 
e ^ m m ^ i d 
• • 
151 
Fig 8.4 OTC and its mutants showed a mitochondrial distribution in 
HepG2 
HepG2 cells cultured on coverslip in a 24-well plate were a) stained with 
Mitotracker® Red CMXRos; b) transfected with 0.8 ng pcDNA-GW47/CAT; c) 
transfected with 0.8 ng pcDNA-DEST47/OTC; d-h) transfected with 0.8 i^g 
pcDNA-DEST47/OTC carrying the indicated mutations. 
In 8.4a，the mitochondria pattern of HepG2 cells was visualized by staining with 
mitochondria-specific dye Mitotracker® Red CMXRos. In 8.4b，transfection with 
pcDNA-GW47/CAT, which encoded for a cytoplasmic protein showed a cytosolic 
distribution. This served as a negative control of the experiment. In 8.4c-h, 
transfection with pcDNA-DEST47/OTC and its mutants gave a punctate pattern, 
which is a characteristic mitochondria distribution and consistent with that stained 




PAiMmft iMnresslon is not a Feasible Method for Expressing 
Active OTC HomoTrlmer 
To investigate the effect of mutations on OTC activity, the OTC gene, with the 
stop codon re-introduced back to the original clone was cloned into the 
pEXPl-DEST vector. The pEXPl-DEST vector has a T7 promoter and a T7 
terminator for expression in a cell-free system. It has an N-terminal His-tag for 
easy detection of expression. ^ ^ 
OTC carrying the mutations: Arg26Gln, Glul22Gly, Argl29His, Lysl44Term， 
Thrl78Met, Asnl98Ile, and the two questionable polymorphisms: PhelOlLeu, and B f 
Leul 11 Pro, were constructed by site-directed mutagenesis. Successful mutagenesis 
was confirmed by sequencing, showing that the gene carried the desired mutation 
(Fig 8.5a-h). The entire sequence of the gene was further sequenced to confirm that 
the gene was cloned in the correct orientation, and that it did not carry any other 
mutations, which may affect the results of the subsequent studies. 
The constructs were expressed in a cell-free system. The expressed proteins 
were then analyzed by SDS-PAGE. As cell-free expression system cannot do signal 
sequence cleavage, the leading peptide of OTC should remain intact. Together with 
the 5' tag, and the protein should give a molecular mass of 43 kDa. The cell-free 
expression product was centrifuged to separate the insoluble and soluble fraction of 
proteins. 
SDS-PAGE analysis of the pellet fraction (Fig8.6a) showed a band of about 50 
kDa (boxed) compared with the negative control, indicating OTC may be expressed. 
For Lysl44Term, in which the lysine residue was mutated to become a stop codon, 
the protein should be truncated and expressed as a smaller protein. The absence of 
the 50 kDa band with this mutation further confirmed that the band was OTC and 
indicated successful synthesis of OTC and its mutants by the cell-free system. The 
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deviation in the expected size can be explained by reference to BSA, which should 
be 85 kDa but is also upshifled in the SDS PAGE. This up-shifting indicated that 
the size of other proteins, including OTC, may also be over estimated. 
In SDS-PAGE analysis of the supernatant fraction (Fig 8.6b), there was no 
specific band observed for OTC and its mutants when compared with the control. 
The expression of OTC and its mutants in the pellet was further confirmed by 
His-tag in-gel stain, which specifically stained His-tagged protein (Fig 8.7). The • • 
His-tag in-gel stain of OTC in the supernatant resulted in only non-specific bands, 
without the expected protein (result not shown). • 
Though the expressed OTC was found mainly in the pellet fraction, which 
indicated that it was likely to be trapped in inclusion bodies and was not active. 
Nevertheless, we still processed the activity assay as it should be more sensitive than 
protein stain to detect the presence of a protein. 
The OTC activity assay was set up according to Ohshita (Ohshita et al, 1976). 
This method was designed to estimate serum OTC activity as a test of liver injury. 
The OTC enzyme assay is composed of two parts as mentioned in Chapter 6.3, the 
catalytic reaction involving the conversion of ornithine and carbamyl phosphate into 
citrulline by OTC; and the colorimetric reaction involving the reaction between 
citrulline and diacetylmonoxime (DAMO)-thiosemicarbazide (TSC) to form a 
pink-colored product, giving an absorbance peak at 515-530 run. 
The assay was validated by measuring serum OTC activity from 10 normal 
individuals. All of the results lay in the range of 0-10 U/L which was the normal 
range of OTC activity. The mean of the ten individuals was 3.7 U/L, which was 
close to 3.0 U/L, as determined in 45 individuals in a previous study (Ohshita M et 
al., 1976). The wavelength scan of the enzyme assay product of serum showed an 
absorbance maximum at 515 nm, identical to that determined by Ohshita. 
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OTC from Streptococcus faecalis and standard citrulline were added to the 
assay to test the linearity of the enzymatic reaction and the colorimetric reaction 
respectively. The absorbance of the enzyme assay showed a linear relationship 
from 0-0.05 U of OTC. The reaction plateaued at 0.15 U OTC, indicating that at 
this point, the substrates ornithine and/or carbamyl phosphate in the enzymatic 
reaction were used up and the reaction was saturated. 
The absorbance of the enzyme assay showed a linear relationship from 0-200 
nmol of citrulline. The reaction did not yet saturate in the range of citrulline tested. 
The wavelength scan of both enzyme assay product from Streptococcus faecalis OTC • 
and citrulline gave an absorbance maximum at 530 nm, instead of 515 nm. 
After validation of the enzyme assay, the cell-free expression product was 
subjected to the assay in order to measure OTC activity. Before evaluating the 
effects of mutants to OTC activity, we had to ensure that wild-type OTC expressed 
was active. Thus, we first measured the activity of wild-type OTC. And 
considering that GroE may assist in folding of OTC to an active form, it was added 
to observe its effect. _ 
Wild-type OTC fused with a 5'-6 x His, either with or without GroE, did not 
give a significant value in the activity assay when compared with the negative 
control, implying that cell-free expressed OTC was not active (Fig 8 . 1 4 - 2 and 4). 
The addition of GroE to the cell-free system appeared to give a higher absorbance 
value in the assay. But this increase was not due to refolding of OTC by GroE, but 
to ‘ interference of GroE to the assay itself. This interference was proved by the 
addition of GroE alone to the activity assay, which also gave a substantial absorbance 
value (Fig 8.14-5). 
As the cell-free system failed to produce active wild-type OTC, the mutants did 
not subject to further activity assay. 
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8.3.1 pEXPl/OTC2 with desired mutations generated 
a Arg26Gln (CGG^CAG) b Phe101Leu (TTI^TTA) 
260 270 260 I 240 250 
C G A A A T T T T C A G T G T G G A C A A C A A A C A G G C T T A G C A C T T C T G G 
1F — 1F — 
ft/™ WM I 
c Leu111Pro(CIT^CCT) d Glu122Gly (G^->GGA) • 
50 60 I 90 100 I 
T C C N G T T T T C C T A C C A C A C A A C G G T G T G A A T G G A A G T C T C A C G 
e Arg129His (CGT->CAT) f Lys144Term (AAA^IAA) 
110 120 J 150 160 
G A C A C G G C C C A T G T A T T G T C 1 C T C G A G T G T A T T A A C A A T C A G i 
2F — 2F — iMkU kdmttJ 
g Thr178Met (ACG->AIG) h Asn198lle (AAC-^AIC) 
250 260 I I 310 320 3： GATTACCTC ATG CTCCAGG Ai :GGGGATGGG ATC AATATCCT( 
2F — 2F — 
Fig 8.5 The OTC gene in pEXPl-DEST with desired mutations generated by 
site-directed mutagenesis 
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Sequencing results of pEXPl/0TC2 after site-directed mutagenesis showed 
mutations of a) Arg26Gln; b) PhelOlLeu; c) LeulllPro; d) Glul22Gly; e) 
Argl29His; f) Lysl44Term; g) Thrl78Met; and h) Asnl98Ile sequenced by 
OTCclonelF or 2F as indicated. 
The results show generation of nucleotide changes (arrowed) in the designated 
codons (underlined), indicating successful site-directed mutagenesis. The whole 





8.3.2 OTC and its mutants were expressed by the cell-free system as shown 
in SDS-PAGE analysis 
a) Pellet 
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Fig 8.6 OTC and its mutants were expressed by the cell-free system as shown 
in SDS-PAGE analysis 
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SDS-PAGE stained with GelCode® Blue Stain Reagent of cell-free expression 
product of OTC and its mutants separated into a) Pellet and b) Supernatant. Lanes 
1-2，OTC wild-type with and without the addition of RTS GroE Supplement. Lanes 
3-11，OTC mutants carrying the mutation Arg26Gln, PhelOlLeu, Leull lPro, 
Glul22Gly, Argl29His, Lysl44Tenn, Thrl78Met, and Asnl98Ile with the addition 
of RTS GroE Supplement. A corresponding negative control includes only cell-free 
expression reagents but no input DNA template was set up with and without the 
addition of GroE. GFP is the positive control of the cell-free expression. M is the 
Kaleidoscope Prestained Standards. 
The cell-free expression products were centrifuged to separate the pellet and • 
supernatant, which contained the insoluble fraction and the soluble fraction of • 
proteins respectively. The two fractions were then loaded on to SDS-PAGE. In B 
Fig 8.6a, the expression of OTC and its mutants did show a band that cannot be 
found in the negative control. The presence of this band indicated the success of 
the cell-free expression in expressing the protein. This interpretation was 
confirmed by the absence of this band in the Lysl44Term expression product, a 
mutant that would result in a truncated protein. In Fig 8.6b，there was no specific 
band observed for OTC and its mutants. The presence of GroE showed no visible 
effect in wild-type OTC expression as viewed in SDS-PAGE. GFP was the positive 
control. It showed a band in both supernatant and pellet, which indicates successful 
protein expression by the cell-free system. As SDS-PAGE may have some 
deviations in the estimation of protein size, bovine serum albumin (BSA) was loaded 
to help to calibrate the size determination. BSA should be 85kDa and its up-shifting 
indicates that the size of the other proteins may also be over-estimated. 
> 
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8.3.3 OTC and its mutants expression were confirmed by His-tag in-gel stain 
Fig 8.7 OTC and its mutants expression were confirmed by His-tag in-gel stain 
His-tag in-gel stain of the cell-free expression products of OTC and its mutants • 
centrifuged into pellet. Lanes: Lane 1，OTC wild-type without the addition of GroE; • 
Lanes 2-10, OTC wild-type, Arg26Glu, PhelOlLeu, LeulllPro, Glul22Gly, • 
Argl29His, Lysl44Term, Thrl78Met and Asnl98Ile with the addition of GroE. A W 
corresponding negative control included only cell-free expression reagents but no 
input DNA template was set up with and without the addition of GroE. M is the 
BenchMark™ His-tagged Protein Standard. 
OTC and its mutants did showed a band that cannot be found in the negative control. 
The appearance of this band indicated the presence of His-tagged protein and further 
confirmed success of cell-free expression in expressing OTC. The absence of this 
band in Lysl44Tenn indicated the protein is truncated. BenchMark™ His-tagged 




8.3.4 Setup of OTC assay was validated 
8.3.4.1 Validation of OTC enzyme assay with normal subjects' sera 
One unit of OTC in serum is defined as one |imol of citrulline produced per liter of 
serum per minute at 37 °C. 
No of moles of citrulline (^mol) 
i.e. Activity of OTC (U/L) = — 
Volume of sample (L) x Time of reaction (min) 
In the enzyme assay, | |H 
No of moles of citrulline in sample No of moles of citrulline in standard (|Limol) • 
A-B-C D • 
where A is the absorbance of the sample; 
B in the absorbance of endogenous citrulline of the sample; 
C is the absorbance of spontaneously produced citrulline formed by 
non-enzymatic reaction of ornithine and carbamoyl phosphate; 
D is the absorbance of citrulline standard. 
Combining the two equations, 
A-B-C No of moles of citrulline in standard (^mol) 
Activity of OTC (U/L) = x  
D Volume of sample (L) x Time of reaction (min) 
A-B-C 
Activity of OTC (U/L) = x k 
D 
where k is a constant found by dividing the number of moles of citrulline (nmol) 
in standard by the amount of serum (L) multiplied by the incubation time 
� (min). 
Fig 8.8 Calculation of serum OTC activity 
By using the above'formula, the OTC activities in sera from 10 normal individuals 
were determined. All of the results lay in the range of 0-10 U/L which was the 
normal range of OTC activity. The mean OTC activity of these ten individuals was 
8 U/L, which was close to 3.0 U/L determined in 45 individuals in a previous study 
(Ohshita Me t al., 1976). 
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Absorbance of the Enzyme Assay Product of Serum at Wavelength 400nm to 800nm 
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Fig 8.9 Enzyme assay product of serum gave an absorbance maximum at 515 
nm. 
The wavelength scan of the enzyme assay product of serum from 400 nm to 800 nm. 
Line 1, Serum; Line 2，endogenous citrulline of the sample; Line 3，Spontaneously 
produced citrulline. 
The product formed in the enzyme assay of serum gave an absorbance maximum at 
515 nm. 
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8.3.4.2 Establishment of the linear relationship of enzymatic reaction in 
Streptococcus faecalis OTC enzyme assay 
Relationship Between Absorbance and Units of OTC 
in OTC Enzyme Assay 
0.8 
0.7 一 令 」 
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Fig 8.10 Graph showing the relationship between absorbance and units of 
Streptococcus faecalis OTC in OTC enzyme assay 
The absorbance of the enzyme assay showed a linear relationship from 0-0.05 U of 
Streptococcus faecalis OTC. The reaction plateaued upon 0.15 U OTC, indicating 
that at this point, all the substrates in the enzymatic reaction were consumed. 
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Absorbance of Enzyme Assay Product of Streptococcus faecalis OTC 
at Wavelength 400nm to 800nm 
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Fig 8.11 Enzyme assay product of OTC gave an absorbance maximum at 530 
nm 
The wavelength scan of the enzyme assay product of Streptococcus faecalis OTC 
from 400 nm to 800 nm. Lines 1-5, absorbance after addition of 0.025, 0.02，0.015, 
0.01，and 0.005 U of OTC; Line S, Spontaneously produced citmlline. 
The product formed in enzyme assay of OTC gave an absorbance maximum at 530 
nm. There is no need to measure endogeneous citmlline in this case, as the sample 
applied is pure OTC. 
I 
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8.3.4.3 Establishment of the linear relationship of colorimetric reaction in 
OTC enzyme assay 
Relationship Between Absorbance and No of Moles of Citrulline 
in OTC Enzyme Assay 
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Fig 8.12 Graph showing the relationship between absorbance and number of 
moles of citrulline in OTC enzyme assay 
The absorbance of the enzyme assay showed a linear relationship from 0-200 nmol 





Absorbance of Enzyme Assay Product of Citrulline at Wavelength 400nm to 800nm 
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Fig 8.13 Enzyme assay product of citrulline gave an absorbance maximum at 
530 nm 
The wavelength scan of the enzyme assay product of citrulline from 400 nm to 800 
nm. 
The product formed in enzyme assay of citrulline gave an absorbance maximum at 
530 nm. There is no need to measure endogeneous citrulline in this case, as the 
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8.3.4.4 OTC synthesized by cell-free expression system was not active 
Absorbance of Cell-free Expressed Products in Activity Assay 
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0.7 K e y : ‘ 
T Negative control 
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Fig 8.14 pOTC synthesized by cell-free expression system was not active 
The activity assay of 2 and 4) Wild-type OTC expressed in cell-free system (2) 
without and (4) with the addition of GroE; 1 and 3) the negative control in cell-free 
system (1) without and (3) with the addition of GroE; and 5) GroE. LacZ acted as a 
positive control of the cell-free expression and its activity was assayed by 6-Gal 
assay kit. -
Wild-type OTC, either with or without GroE, did not give a significant value in the 
activity assay when compared with the negative control, implying that cell-free 
expressed OTC was not active. The negative control, also gave a considerable 
absorbance value in the activity assay, indicating that the cell-free expression 
reagents, probably the E.coli extract, contained endogenous OTC or citrulline. The 
addition of GroE to the cell-free system appeared to give a higher absorbance value 
in the assay. But this increase was not due to refolding of OTC by GroE, but to 
interference of GroE to the assay itself. This was proved by the addition of GroE 
alone to the activity assay, which also gave a substantial absorbance value. LacZ 
gene acts as a positive control of the cell-free expression and its activity was assayed 
by the B-Gal assay kit. 
All the absorbance in the activity assay lay in the linear range, indicating that the 
activity assay was not yet saturated and the results were reliable. The results were 
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shown in meaniSD in triplicate experiments. WT OTC, either with or without the 
addition of GroE, did not show a significant absorbance compared with the negative 




Miitfltinns in QTC, Including Arg26Gln, Have no Effect on the 
Suncellular Localization in Hep3B and HepG2 
In studying the effect of mutations on the subcellular localization of the enzyme, 
mammalian cells were selected for expressing the protein. The mammalian cells 
serve as a good tool for expressing human protein as they provide all of the 
post-translational modifications and recognize the same synthesis, processing and 
intracellular trafficking signals as human. However, they have the disadvantages of ^ ^ 
being difficult to transfect and having low efficiency in expressing a protein. ^ H 
For studying subcellular localization of a protein, transfection efficiency does • I 
not need to be high. A single cell transfected with a strongly expressed gene can be 
visualized under fluorescence microscopy. In addition, even the transfection 
efficiency is as low as 10%, fluorescence microscopy still gives a clear image of the 
protein localization. Therefore, the low transfection efficiency in mammalian cells 
is not a major problem in this study. 
Furthermore, among various transfection methods, transfection done by cationic 
lipid reagent has a higher efficiency in transfecting a wide variety of eukaryotic cells 
(Ciccarone et al., 1999). Therefore, the low efficiency of using mammalian cells as 
the expression system can be partly compensated by using cationic lipid reagent as 
transfectant. 
The subcellular localization of one of the mutants found in our OTCD patients, 
Lysl44Term cannot be studied in this experiment. It is because the mutation of 
lysine into a termination codon would probably result in premature termination of the 
protein; as GFP is’ fused to the 3' end of OTC, it would not be transcribed or 
translated to give a fluorescence signal. The transfection of OTC carrying this 
mutation served as a negative control in the study. 
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9.1.1 Arg26Gln 
As arg26 is located in the signal peptide of the OTC gene, it may have an effect 
on mitochondrial uptake and processing of the pOTC into the mature form. Thus, 
its mutation possibly causes OTCD. 
In a previous study, it was shown that simultaneous mutation of arginine at 
positions 15, 23, and 26 into glycine caused failure of the pOTC to be taken up by 
intact mitochondria in vitro (Horwich et al., 1985). In another study, the same • • 
mutant has also shown mistargeting of the protein from mitochondria to cytosol in ^ H 
COS? cells (Yano et al., 1997). As mentioned in Chapter 1.3.2，the mitochondrial • 1 
import ofpOTC is started with the recognition of the leader peptide ofpOTC by the 
TOM receptor on mitochondrial surface, followed by the transport of protein through 
an import channel into the mitochondrial matrix. The findings suggested that 
arginine residues at position 15, 23 and 26 are likely to play a role in the recognition 
by the Tom receptor and in the uptake of OTC into mitochondria. 
In addition, the argl5gly, arg23gly and arg26gly combined mutant also failed to 
be cleaved upon incubation with a mitochondrial matrix fraction containing the 
protease that normally cleaves the leader peptide (Horwich et al., 1985). As 
mentioned in Chapter 1.3.2，once in the matrix, the leader peptide of pOTC is 
cleaved by mitochondrial processing peptidase (MPP), an enzyme that removes the 
first twenty four N-terminal amino acids by cleaving the bond between asn24 and 
phe25 (Kalousek et al” 1988). This results in iOTC which is further cleaved by 
MIP to form the mature protein. The findings of the previous study suggested that 
these three arginine residues, especially arg23 and arg26, which are proximal to the 
cleavage site of MPP may play a functional role in the cleavage of the first twenty 
four N-terminal amino acids. 
Of these three arginine residues, mutations in both arg23 (Grompe et al., 1991) 
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and arg26 (Grompe et al., 1989; current project) have been identified in OTCD 
patients. 
In this study, cells transfected with pOTC carrying Arg26Gln showed 
mitochondrial localization same as the wild-type OTC. This result suggests that the 
mutant can still be imported into the mitochondria. Previous studies also indicated 
that arg23 mutant can be imported into the mitochondria (Isaya et al., 1988). These 
results indicated that argl5 may be a critical residue for mitochondrial import. | | M 
Another possibility is that a single mutation of arginine residue may not affect the 
mitochondrial import of OTC, but a combination of mutations may do so by exerting • J 
a greater effect on the charges of the protein. Further study of argl5 mutant on 
mitochondria import will be useful to find out whether the mistargeting is solely 
from residue 15, or from the combination effect of the three mutations. 
The OTC activity detected in patients carrying the Arg26Gln mutation was 
found to be 0% of normal subjects in previous study (Grompe et al.’ 1989) and in 
this study (Chapter 5.6). Combining the findings that Arg26Gln mutant is still able 
to be imported into the mitochondria, the presence of the Arg26Gln mutation may 
affect the processing of pOTC，and the leader peptide may not be cleaved properly. 
The presence of the signal peptide affects the OTC monomers in assembly into 
trimers, resulting in OTCD. This is also found in arg23 mutant (Isaya et al., 1988). 
Another possibility is that the mutation may be disease-causing by affecting the 
stability of the protein, which leads to degradation. This hypothesis is supported by 
the arg23 mutant, which was shown to be unstable within the mitochondria and 
undergo degradation with a half-life less than 4 hours (Isaya et al., 1988). But this 
may not be the case as the fluorescence can still be observed 42 hours after 
transfection. 
These two hypotheses can be further proved by SDS-PAGE analysis of cell 
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lysates collected at different time point after transfection. 
9.1.2 LeulOlPhe, LeulllPro, Thrl78Met, and Asnl98Ile 
The four other mutations, PhelOlLeu, LeulllPro, Thrl78Met, and Asnl98Ile, 
investigated in this study do not affect the mitochondrial import of pOTC into the 
mitochondria of Hep3B and HepG2 cells. They are likely to affect the functions of 
— — I 
> 
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AraigfiHis Mutant may he Unstahlc 
Transfection of an OTC-GFP fusion carrying the Argl29His mutation could not 
be visualized under fluorescence microscopy. 
As previously mentioned in Chapter 5.3.3, in the spf-ash mouse, this mutation 
results in two proteins, one with a substitution of arginine to histidine in codon 129 
with normal size; the other with an insertion of 16 amino acids. Both of these 
proteins are imported into the mitochondria and proteolytically processed. • • 
However, the elongated one fails to assemble into an active trimer and results in a 
dysfunctional protein (Rosenberg LE et al., 1983) while the other assemblies • 1 
properly and has enzyme activity (Hodges et al., 1989). In our study, as the gene 
transfected was cDNA, it would not undergo splicing. Therefore, based on these 
results in the mouse model, the Argl29His mutation was expected to be observable 
under the fluorescence microscopy and to have a characteristic pattern of 
mitochondrial import. 
However, all of the previous studies were based on isolated mitochondria rather 
than whole cells. Probably Argl29His is not a stable protein and undergoes rapid 
degradation after entry into cytosol, probably by proteasomes, as observed in the 
995del5 mutation of the BRCA2 gene (Mikaelsdottir et al., 2004). 




9.3 Rnii-tree Expression may not fte a FeaslMe Method tor  
Expression of Active OTC Trimer 
In studying the effect of mutations on OTC activity, a cell-free expression 
system was selected for expressing the protein. This was an unusual choice as 
previous mutagenesis studies of OTC often utilized mammalian cells as the 
expression system as indicated in Table 6.1. 
Even though a cell-free expression system may not be able to provide ^ ^ 
eukaryotic post-translational modifications in some proteins, OTC is a ^ H 
well-characterized protein and known-to have no disulphide bonds. Therefore, the ^ M 
lack of post-translational modification should not interfere with OTC expression. 
Another main disadvantage of a cell-free expression system is the possibility of 
producing insoluble proteins trapped in inclusion bodies but since the cell-free 
expression system is an ‘open’ system, protein expression can be modified with the 
addition of chaperones. One of the major chaperones in assisting protein folding is 
GroE. GroE contains GroEL and GroES cytoplasmatic chaperones of E.coli. It 
has been found that GroE is involved in the folding of 10-30% of cytoplasmic 
proteins in E.coli (Ewalt et al., 1997). The presence of GroE has also been shown 
to assist the folding of many eukaryotic proteins as listed in Table 6.2. As 
mentioned in Chapter 1.3.4, OTC monomers are assembled into an active trimer, 
assisted by mhsp60 and cpnlO in the presence of ATP. Therefore, GroEL and 
GroES, which are bacterial homo logs of mhsp60 and cpnlO might assist the folding 
of OTC. This prediction is supported by a previous mutagenesis study, which 
showed that the presence of GroE resulted in the formation of up to 90% active OTC 
expressed by bacteria (Morizono et al., 1997). The cell-free expression system 
applied in this project utilizes extract from an S30 E.coli strain (Zubay, 1973) with an 
ATP regenerating system for energy (Lesley et al., 1991; Kim et al., 1996) and thus, 
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has similar properties to a bacterial expression system. Therefore, we anticipated 
that the addition of GroE supplement to the cell-free expression system would assist 
the folding of expressed pOTC monomers into active trimers and results in a soluble 
protein. 
There are several examples of protein expressed successfully in cell-free system 
despite failure in E.coli expression, such as human interleukin-2 and melanona 
inhibitory activity protein. This further supports the choice of a cell-free expression • • 
system for expressing active eukaryotic proteins. ^ H 
For these reasons, we considered that a cell-free expression system would serve • 1 
as a practical expression system in the mutagenesis study of OTC activity. The 
advantages in e伍ciency and ease of handling of the system make it even more 
convenient than other expression system, such as bacteria, yeast and baculovirus. 
Before evaluating the effects of mutations to OTC activity, we had to ensure that 
wild-type pOTC expressed was active. Thus, we first measured the activity of 
expressed wild-type pOTC. GroE was added to determine its value to OTC 
expression. 一 
In a preliminary study, it was found that the negative control with only cell-free 
expression reagents but no template DNA input resulted in a considerable absorbance 
in the OTC enzyme assay. This result may be due to endogenous OTC or citmlline 
present in the E. coli extract of the system. For wild-type pOTC, the enzyme assay 
did not give a significant absorbance value compared with the negative control, 
suggesting that it was not in an active state. Addition of GroE supplement during 
expression appeared to result in a higher absorbance in the enzyme assay. Thus, it 
was once inferred that the presence of GroE did assist in the folding of OTC. 
However, further studies indicated that using GroE supplement alone as the 
input material of the activity assay also gave rise to a considerable absorbance, 
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leading to false positive results. Taken together, OTC, either with or without GroE, 
did not give a significant absorbance difference in the enzyme assay when compared 
with the negative control. This indicates that the cell-free expression system did not 
succeed in producing active OTC trimers. 
There are several published reports of utilizing cell-free expression system, such 
as the rabbit reticulocyte lysate system (Horwich et al., 1984)，to express OTC for 
investigation of mitochondrial uptake and processing. However, these studies did • • 
not involve activity assay. And it was shown that the presence of a leader peptide is 
already sufficient to direct the import of protein into mitochondria. When the leader • J 
peptide of OTC was fused with the cytosolic enzyme dihydrofolate reductase 
(DHFR), the chimeric protein was imported into mitochondria in both CHO cell and 
isolated rat liver mitochondria (Horwich et al, 1985). Thus, demonstration of 
mitochondrial import of OTC does not depend on OTC activity and do not require 
that the protein can fold properly or have catalytic activity. 
In this study, pOTC is shown to be expressed by SDS-PAGE using total protein 
stain (Fig 8.3.2) and His-tagged protein stain (Fig 8.3.3). In the Lysl44Term 
mutation, the mutant has codon 144 changed to a termination codon, resulted in a 
truncated protein. The absence of a band for OTC carrying this mutation, compared 
with wild-type pOTC and other mutants, in both SDS-PAGE and His-tag in-gel stain 
further confirmed the OTC was expressed in the cell-free system. Although OTC 
was expressed in the preprotein form rather than the mature form, it should not be a 
problem in affecting its activity as it was previously shown that the presence of the 
leader peptide did not prevent pOTC from folding into an enzymatically active trimer 
in vitro (Murakami et al” 1990). 
However, the protein was fused with a His-tag and the Xpress™ epitode at the 5' 
terminus. The presence of this peptide may affect the folding of the pOTC 
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monomers into active trimer. Further experiments by treatment with enterokinase 
that cleaves at the enterokinase site will release the native OTC monomer. The 
ability for active trimer formation can be studied by further enzyme assay study. 
Another possibility is that the cell-free expression reagents may inhibit the 
assembly of homomultimeric protein. Thus, pOTC expressed may be remained in 
the monomer form, and failed to assembly into the active trimer. This can be 
further tested by a recovery study: adding the OTC from Streptococcus faecalis to the | | H 
cell-free expression reagents and to study the effect of the reagents on the enzyme 
activity. 
Also, it has to be noted that in the study of OTC activity, care must be taken that 
the presence of GroE with OTC may lead to false-positive results. A corresponding 
negative control, with only GroE added as the input material of the activity assay, 
can be set up to take this into account. As GroE will be released after assisting the 
folding of proteins (Zheng et al., 1993)，purification of OTC before activity assay 
may be a good solution to this problem. 
The feasibility of a cell-free expression system in expressing active OTC still 
awaits further studies. The effects of the seven mutations and the two questionable 
polymorphisms identified in OTCD patients will be identified by activity and 
kinetics study, probably after successful of expressing active WT OTC, either by 
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1 gagccccagg actgagatat ttttactata ccttctctat catcttgcac ccccaaaata 
61 gcttccaggg cacttctatt tgtttttgtg gaaagactgg caattagagg tagaaaagtg 
121 aaataaatgg aaatagtact actcagggct gtcacatcta catctgtgtt tttgcagtgc 
181 caatttgcat tttctgagtg agttacttct actcaccttc acagcagcca gtaccgcagt 
241 gccttgcata tattatatcc tcaatgagta cttgtcaatt gattttgtac atgcgtgtga 
301 cagtataaat atattatgaa aaatgaggag gccaggcaat aaaagagtca ggatttcttc 
361 caaaaaaaat acacagcggt ggagcttggc ataaagttca aatgctccta caccctgccc 
421 tgcagtatct ctaaccaggg gactttgata aggaagctga agggtgatat tacctttgct 
481 ccctcactgc aactgaacac atttcttagt ttttaggtgg cccccgctgg ctaacttgct 
541 gtggagtttt caagggcata gaatcgtcct ttacacaatt aaaagaagat gctgtttaat 
601 ctgaggatcc tgttaaacaa tgcagctttt agaaatggtc acaacttcat ggttcgaaat 
661 tttcggtgtg gacaaccact acaaaataaa gtgcagctga agggccgtga ccttctcact 
721 ctaaaaaact ttaccggaga agaaattaaa tatatgctat ggctatcagc agatctgaaa 
781 tttaggataa aacagaaagg agagtatttg cctttattgc aagggaagtc cttaggcatg 
841 atttttgaga aaagaagtac tcgaacaaga ttgtctacag aaacaggctt tgcacttctg 
901 ggaggacatc cttgttttct taccacacaa gatattcatt tgggtgtgaa tgaaagtctc 
961 acggacacgg cccgtgtatt gtctagcatg gcagatgcag tattggctcg agtgtataaa 
1021 caatcagatt tggacaccct tgctaaagaa gcatccatcc caattatcaa tgggctgtca 
1081 gatttgtacc atcctatcca gatcctggct gattacctca cgctccagga acactatagc 
1141 tctctgaaag gtcttaccct cagctggatc ggggatggga acaatatcct gcactccatc 
1201 atgatgagcg cagcgaaatt cggaatgcac cttcaggcag ctactccaaa gggttatgag 
1261 ccggatgcta gtgtaaccaa gttggcagag cagtatgcca aagagaatgg taccaagctg 
1321 ttgctgacaa atgatccatt ggaagcagcg catggaggca atgtattaat tacagacact 
1381 tggataagca tgggacaaga agaggagaag aaaaagcggc tccaggcttt ccaaggttac 
1441 caggttacaa tgaagactgc taaagttgct gcctctgact ggacattttt acactgcttg 
•  1501 cccagaaagc cagaagaagt ggatgatgaa gtcttttatt ctcctcgatc actagtgttc 
1561 ccagaggcag aaaacagaaa gtggacaatc atggctgtca tggtgtccct gctgacagat 
1621 tactcacctc agctccagaa gcctaaattt tgatgttgtg ttacttgtca agaaagaagc 
, 1681 aatgttcttc agtaacagaa tgagttggtt tatggggaaa agagaagaga atctaaaaaa 
1741 taaacaaatc cctaacacgt ggtatgggtg aaccgtatga tatgctttgc cattgtgaaa 
1801 ctttccttaa gcctttaatt taagtgctga tgcactgtaa tacgtgctta actttgctta 
1861 aactctctaa ttcccaattt ctgagttaca tttagatatc atattaatta tcatatacat 
1921 ttacttc 
Remarks: Reference sequence from GenBank accession number NM_00531, with OTC CDS from 589-1653nt. 
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flmiqo Acid Scquence of OTC 
1 mlfnlrilln naafrnghnf mvrnfrcgqp Iqnkvqlkgr dlltlknftg eeikymlwls 
61 adlkfrikqk geylpllqgk slgmifekrs trtrlstetg fallgghpcf Ittqdihlgv 
121 nesltdtarv Issmadavla rvykqsdldt lakeasipii nglsdlyhpi qiladyltlq 
181 ehysslkglt Iswigdgnni Ihsimmsaak fgmhlqaatp kgyepdasvt klaeqyaken 
241 gtkllltndp leaahggnvl itdtwismgq eeekkkrlqa fqgyqvtmkt akvaasdwtf 
301 Ihclprkpee vddevfyspr slvfpeaenr kwtimavmvs lltdyspqlq kpkf 
Remarks: Reference sequence from GenBank accession number NP_000522 
�� 
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J i ^ Sp l iRinf fS i t f tg innTn 
1 A A A T T T T C G g t a a g tacagGTGTGGACA 
2 AAAGGAGAGgtatg t a t ^ T A T T T G C C T 
3 CAGAAACAGataag tgt扭GCTTAGCAC 
4 C A C G G C C C G g t t t g c acagTGTATTGTC 
5 ACGCTCCAGgt tgg t t t ^ G A A C A C T A T 
6 ACTCCAAAGgtagg t t t a g G G T T A T G A G 
7 GCCAAAGAG^ta tg get扭AATGGTACC 
8 ACAATGAAGgtaca t t t a g A C T G C T A A A 




Miiitipiii fliiffnments of OTC P r o t e i n s f r o m 4 5 S p e c i e s 
llteeilasma •NeNmoitiae catabolic i • 
劍la删为. - 1 PMudomenas synnjae -j  Pseudtmonas'syiinjaejvjliase«licela i i Escherichia eoli aql i  gilmeneUaJyphmiHwii i  Esehenehia.eoli aifF i  Neisseria emenea catabolic i  Neisseria'mueosa'eatabolie i  Neisseria'meniiigifidis eatibolie i  Neisseria jolysiceharea  NeisseriajDHonlioeae catabolic  NeisseriaTaetamiea ealabtlie  Nej99eria:ilaveseeN5_eatabolic  Rhizobium etii  tfaemophiliis influenzae  Pseudemoiias aeniainosa catabolic  Pseudtmonasjiitida catab«lie  AenmMias fonnkaii  Ctostridiumjerfiinaens  Lactobacillusjbiifanim  
i i iK^ M s ：丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨—;;?31醒_ 1 SchizcsMcEai«M^esj>ombe ！‘ Sieelurimyces.cerevisiae ！ CMvnebaetenHinjIiiUnueum ！ •^bacterium bonis anabolic ！ 
BtTltl i i l A A F U r i i v i i 
丨丨丨；丨丨丨::::::::::::::::::::::::::::::::::::！ 
驗笠：亨巧?n||， a u t « t r » p h i c u m 二！二 二！二 ！！二 I ！ I 二 I ！ I ！ 二 I “ ！ ！ ！ I ！ I ！ 11 ： 
f l i S 练 广 ：—？丨：—^^ 申 — i i — I s 
"*-， Arg26Glu • 
1 
o^plaanajmimniiiae catabolic i g 
•一 I i i i i i i i i i i i i i i 
Nejl^ aMueosale^ Mie • ：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：! 
— -
Appendices WKk 
Leu101Phe LeulllPro Glu122Gly 
•^plasmajneunwHiae eatabalic i MlllfiblMllllflHA ••， 
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醑 二 國 i H i i i i i i i l m _ _ i _ 
S t i B s »! iii 也 tf 由 • 涵 丨 函 涵 iiiiiiiii 湘；涵�rs m iiiiiiiiiiiMiii 
„ 釅 liUi 
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111 i i i i i i i i i 酬 i i i i i � � | 
p i ^ . I : : :哪 I p p S i i i i i丨丨丨： I ^^ I � i 
E S S 巧!•丨丨丨丨�:-:丨丨丨丨丨丨丨丨丨丨丨丨丨丨I m^  1  •iliiiiil I ^ ^ ill ••Hb丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨I 一 ” 2 2 0 “ 
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1.5 Summar, 01 Patients' Inlormation 
Patient Mutation Sex Age Onset Source 
1 Arg26Gln M 12y N Caritas Medical Centre, HK 
2 Leu111 Pro M 11y N Children's Hospital of British Columbia, 
Canada 
3 Glu122Gly M 3y N Mainland China 
4 Arg129His M 7m L Caritas Medical Centre, HK 
5 Lys144Term F 12y L Children's Hospital of British Columbia, 
Canada 
6 Thr178Met F 2y L Children's Hospital of British Columbia, 
Canada 
7 Asn19811e M 6y N Children's Hospital of British Columbia, 
Canada 
8 IVS5+1G~T M NA N Tsan Yuk Hospital, HK 
Remarks: 'Age' is the age of the patient when the mutation was detected. 
~ 
Keys: y for years; m for months. 
N for neonatal onset; L for late onset. 
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J l ^ Primers iisRd In PCB and Sequencing of Patients' fienomic DNA 
and the Sequence Ampllfleil 
A.6.1 Exon 1 (Reference Sequence: Accession AL607040) 
241 tacacagcgg tggagcttgg cataaagttc aaatgctcct acaccctgcc ctgcagtatc 
301 tctaaccagg ggactttgat aaggaagctg aagggtgata ttacctttgc g n g ^ Q R S n 
361 gggggggggg catttcttag tttttaggtg gcccccgctg gctaacttgc tgtggagttt 
421 tcaagggcat agaatcgtcc tttacacaat taaaagaaga tgctgtttaa tctgaggatc 
481 ctgttaaaca atgcagcttt tagaaatggt cacaacttca tggttcgaaa ttttcggtaa 
541 gtgatggtca gagacttggg tttgatttag gaatcatggt gatgcataaa actatattct 
601 gcagtaaggc ctctttctgc agaatgtagt gccacgctct gctttactct tatttgagac 
661 agctgcctct aattccagca aagctttcat ttctcagtcc ttctgtaat|Jgggggggggg 
721 Is'i^ iilia'jM^ a ggggaagcca cccatggcag gtataacaga ctaaacgttc ttgacatctt 
781 tcgtttgtgt acattctaaa cgagcaagtg gctgaaggaa attaggggaa gtaatttaca 
OTC exon 1 primers (Amplified region: 379 bp with exon 1 underlined) 
OTCexonlF 5 ‘ -TCCCTCACTGCAACTGAACA-3 ’ 
OTCexonlR 5’-ACAGCACACGGTGAAATCTG-3‘ 
A.6.2 Exon 2 (Reference Sequence: Accession AL607040) 
14881 cagtgaactg agattgtgcc acactccagc ^ U 4 . i “ � j U M 4 J l f. M “ � … 
14 941 aaaaaaaaaa agaaaagaaa agaatgcctt atcaacagta aaacaatgaa tcaccatagt 
15001 acatgggtct tttctgaaat acatatttct cccttttaaa tctcttttta caggtgtqga 
15061 caaccactac aaaataaagt gcagctgaag ggccgtqacc ttctcactct aaaaaacttt 
15121 accggagaag aaattaaata tatgctatgg ctatcagcag atctgaaatt taggataaaa 
” 15181 cagaaaqqaq aggtatgtaa cattttcttt ttacgttcca ttactaccag tccccttttt 
15241 ttaaaggcag 十 a a a a a a t a c a ttaaaattct taaacagtag 
15301 ctaagtaatg aaacctcaca gtcaaggtaa ttgattatca tggagcatac aggcatacaa 
OTC exon 2 primers (Amplified region: 356 bp with exon 2 underlined) 
OTCexon2F 5 ’ - GCCACAGAGTGAGAACCTGTC - 3 ‘ 
OTCexon2R 5‘-TCCCTCTTTCTTTGGGAAGG-3‘ 
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A.6.3 Exon 3 (Reference Sequence: Accession AL607040) 
17281 tttttttttt ttttggtatt ttgagtagag atggggtttt gccatgttgg ccaggctggt 
17341 ctcgaactcc tgacctcagg tgatccacct gccttggcct cccaaagtgc tgggagg^gj 
17401 g H S S ^ ^ ^ ^ E c c t g g cctaaattca ctttttaaac aatattttaa acacttattt 
17461 gggggtagtt attacttatt ttctaataaa gaatatgttt taaaacataa tttatatata 
17521 agatatattt taattctatt cttgtccttg atttatagta tttqccttta ttgcaaqqqa 
17581 agtccttaqq catqattttt qagaaaaqaa qtactcqaac aaqattqtct acaqaaacaq 
17641 gtaagtccac tgccaaattc acacttgtgt tgaagagagg gattgaaggt gaagag9Qgg| 
17701 gatttgtctg cctctagcaa ccacaaagaa aaaatcattt 
17761 ttactgggag cagcaatgca agcctgtgaa tgagatttcc agttctcata aaagctgcaa 
OTC exon 3 primers (Amplified region: 320 bp with exon 3 underlined) 
OTCexonSF 5 ‘ -TTAAGGCATGAACCACCACA-3 ‘ 
OTCexonSR 5‘-ACTGGGTTACCCCTCCAAAG-3’ 
A.6.4 Exon 4 (Reference Sequence: Accession AL607040) 
28861 aggtcttgaa taagagggtg gagaaatggg cacacatgtg aaggagagtt aattacttga 
28921 gcacaaaatt ttatctactt ccctcaattc ctcattttgggjjgggggggggggggggat 
28981 cagagaagtt ggagagcttt aaagattttg acttttcagt tgagatgatg ccaattcttt 
29041 gtaattttgt tttccactft agttgttttt tcaaaatgat ttttttcttt tttttttatt 
29101 gtagqctttg cacttctqqq aqqacatcct tgttttctta ccacacaaqa tattcatttq 
29161 ggtqtqaatq aaaqtctcac qqacacqqcc cqgtttqtaa atattttctt ctctccaaag 
29221 ctgatttcag aatctgatgg ataaatttca aaaataaaac ataattctct ttaaataatg 
29281 gttttccctc taattgttct g t t g g ^ g g g g Q Q g Q g g t g a t a t t ctgaatacct 
29341 ctccctcatc ctgtggccac tttccatcgg ttgaaataat ttttcttggc aattttttga 
OTC exon 4 primers (Amplified region: 365 bp with exon 4 underlined) 
OTCexon4F 5 ‘ -GCTTTGCATGGGAATTCTGT-3 ’ 
OTCexon4R 5 ‘ -GGGAAAGAGGGAAAATGGAG- 3 ’ 
‘ 
Appendices 
A.6.5 Exon 5 (Reference Sequence: Accession AF241726) 
20761 attaattata actcatcatt atgtctgctg ggcccacaat tatctccata aaaaatgtaa 
20821 aatcgctggt cactggataa aatgaataca 
20881 tgtttaatat taccttttaa acctgtaatg ttggtaggtt ttcatgtagt aaaaattcta 
20941 tttattagta tttcttgtta ttatttctga tcttatatta aataaggcat tattaagcat 
21001 aattatctta gattatcttt ttcttggttt gccacagtgt attqtctaqc atggcaqatq 
21061 cagtattggc tcgagtgtat aaacaatcag atttggacac cctggctaaa gaagcatcca 
21121 tcccaattat caatqggctg tcagatttqt accatcctat ccaqatcctq qctqattacc 
21181 tcacgctcca ggttggttta tttatttgtc ttacaaaaga gcaaaatcaa ataattcctg 
21241 acttgcttta agtgaaacag tttacttaaa tcatggtatt ggtgttttat tttcaaatac 
21301 cagcttgaca aagaattaca gacattgtta 
21361 aaaacagact ctaagatcgc tctgcactca accctattcc caaacccttt tagcccatat 
OTC exon 5 primers (Amplified region: 482 bp with exon 5 underlined) 
OTCexonSF 5 ‘ -GGGAGGTAGAACATCTGGCTTA-3 ‘ 
OTCexon5R 5‘-TTCCCCAGAAAATGCACAC-3‘ 
A.6.6 Exon 6 (Reference Sequence: Accession AF241726) 
23161 tatggtgtct tggtttaaga tattaagaca ttttaccacg tttttgggat tgtacattca 
23221 tattatBgh,t,»t«��t»A4-jU»f«JMLJMSfaSgggaa aaattgggaa ttcattcctt ctaacaaggc 
23281 actaatactg agattaagac tatttatttt aaccttagta attgctacac ataagcgaat 
23341 ttacgcctgg atttcatctc cttcatcccg tgccttttag qaacactata qctctctqaa 
23401 aggtcttacc ctcagctqqa tcgqqqatqq gaacaatatc ctqcactcca tcatgatqaq 
23461 cgcagcgaaa ttcqqaatgc accttcaqqc agctactcca aaqgtaqqqa aactttttgc 
23521 cttgaaacta acccctctct taaatcatcc tcagatgcaa ttacccagtg acaaaaaaag 
23581 ctctcttcca tttaagtata acSHiffljyglBBWBgBigggliaBjtaaattar gttaccagcc 
23641 ctactattaa atagctatct ggcctcttga gagtccaatt tcccatctct acaataagag 
> 
OTC exon 6 primers (Amplified region: 396 bp with exon 6 underlined) 
OTCexon6F 5 ’ -TGAGTTGCTCTGTGTAATGCAA-3 ‘ 
OTCexon6R 5‘-AATTCTGTGGCCTCACCTGT-3‘ 
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A.6.7 Exon 7 (Reference Sequence: Accession AF241726) 
28321 taaattccaa aaggcactat tgagttttgg aattctagat gtaaaaatca tattctactg 
28381 aacatggtgg gaccacatct agaaaataat 
28441 atatatttaa gaaaacatgt ataataaaat tacctaaata agatttaaat tcttcctcct 
28501 ttagggttat qaqccggatq ctagtqtaac caaqttqgca qaqcagtatq ccaaaqaqgt 
28561 atgctcttta catgtaaagc tattattgcc ttttactgtc ccatgaagtt atttaaccag 
28621 cgtgtttatg tatgctagaa tggtaccaag ctgttgctga caaatgatcc attggaagca 
28681 gcgcatggag gcaatgtatt aattacagac acttggataa 
28741 aagaaaaagc ggctccaggc tttccaaggt taccaggtta caatgaaggt acaaattgat 
OTC exon 7 primers (Amplified region: 334 bp with exon 7 underlined) 
OTCexonTF 5 ‘ -AGGGAAGGAGACGCGATATT-3 ‘ 
OTCexonTR 5‘-CTCCTCTTCTTGTCCCATGC-3’ 
A.6.8 Exon 8 (Reference Sequence: Accession AF241726) 
28441 atatatttaa gaaaacatgt ataataaaat tacctaaata agatttaaat tcttcctcct 
28501 HBggffgPRgfflBfggggggBW ctagtgtaac caagttggca gagcagtatg ccaaagaggt 
28561 atgctcttta catgtaaagc tattattgcc ttttactgtc ccatgaagtt atttaaccag 
28621 cgtgtttatg tatgctagaa tggtaccaag ctgttgctga caaatgatcc attggaagca 
28681 gcgcatggag gcaatgtatt aattacagac acttggataa qcatgggaca agaagaggaq 
28741 aagaaaaagc ggctccaggc tttccaaggt taccaggtta caatgaaggt acaaattgat 
28801 gcctctctga aggttcatta attccattca tgaaggccag aaccatctaa tcacttattc 
28861 actttagggg gagcagactg tcctttcatt ccctataaaa ggactcactg actgtatccc 
28921 ctagggactt ctctccttcc aaagattagc tcrtatcctHMBSiifgBffBBPHCTPBWStgtq 
28981 gatgaaggaa tttgaaaccc actgagaaga gaggagcagg cttttccctc tcacaagaat 
OTC exon 8 primers (Amplified region: 459 bp with exon 8 underlined) 
OTCexon8F •• 5 ‘ -TTAGGGTTATGAGCCGGATG- 3 ‘ 
OTCexonSR 5 ‘ -GCACAAAAATGCCTTTCCAA- 3 ‘ 
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A.6.9 Exon 9 (Reference Sequence: Accession AF241726) 
31261 tctactaaaa atacaaaaat tcactgggca tggtggcaca tgcctgtagt cccagctact 
31321 caggaagctg aggcaggaga attgcttgag ctctggaggc ggaggttgca gtcagQ^SSS 
31381 ctccag cctgggtgac agagcgagac tctgtctcaa aaaaaaaaaa 
31441 aaatttgaaa gtaccatgta catttctcct aggtgtcttg agataaaacc atcactctgc 
31501 tcctttgtct ctccctttgc attgatgtct gactactggc catgtgtgtt tttagatact 
31561 gaagaaaaca aatatgactg ccacatataa tagtcaaaaa gtggtcttat ccccatctct 
31621 ttagactgct aaagttgctg cctctgactg gacattttta cactgcttgc ccagaaaqcc 
31681 agaagaagtg gatgatgaag tcttttattc tcctcgatca ctagtgttcc cagaggcaqa 
31741 aaacagaaag tggacaatca tggtaagcaa gaaacaagga atggaggata agttctttgt 
31801 gtggttccaa aagcaagtga gattatccaa 
31861 ctacattact tgctcatgta acatctattt ttttccagaa actttataat acatcattag 
OTC exon 9 primers (Amplified region: 463 bp with exon 9 underlined) 
OTCexon9F 5 ’ -CCGAGATTTTGCCACTGC-3 ‘ 
OTCexon9R 5‘-TATTTCCCCAAAGGCATGAA-3‘ 
A.6.10 Exon 10 (Reference Sequence: Accession AF241726) 
40621 taaataaata aatattagtt cagaactgtt ctcttaccat tttcttgaga aaacacattt 
40681 taacBBWi1iBMt33BBHgg|ggBIBg|iBar:r:l-_aa ttcaccttct ctaggtccct aagcagactg 
40741 tcgctaatgt ttatccattt ctttctttct ttgttgtgtc atcaggctqt catqqtqtcc 
40801 ctgctgacag attactcacc tcagctccaq aagcctaaat tttqatqttq tgttacttgt 
40861 caagaaagaa gcaatgttct tcagtaacag aatgagttgg tttatgggga aaagagaaga 
40921 gaatctaaaa aataaacaaa tccctaacac gtggtatggg tgaaccgtat gatatgcttt 
” 40981 gccattgtga aactttcctt aagcctttaa tttaagtgct gatgcactgt aatacgtgct 
41041 taactttgct taaactctct faMU-yiULHWUMBSBBBgiBliBBBaaata tcatattaat 
41101 tatcatatac atttacttca acataaaata ctgtgttcat aatgtataat gtctaagcca 




附 m M s Used In GeneStorm® Expresslon-Beadv Clone and 
the Sequence Amplitled 
AT GCT GT T T A A T C y j J S E S E S S ^ E S I S S S ^ " ^ ^ TTTAGA 
AATGGTCACAACTT CAT GGTTCGAAATTTT CGGTGTGGACAACCA 
CT ACAAAATAAAGTGCAGCTGAAGGGCCGTGACCTTCTCACTCTA 
AAAAACTTTACCGGAGAAGAAATTAAATATATGCTATGGCTATCA 
GCAGATCT GAAAT T TAGGATAAAACAGAAAGGAGAGTAT TT GCCT 
TTATT GC AA r^^ y*- ^ ^  .y^ y ^ ay. ！ ? T T T GAGAAAAGAAGT 
ACT CGAACAAGAT T GT C T Ji 山 
GGACATCCTTGTTT TCT TACCACACAAGATATT CATTTGGGTGT G 
AATGAAAGTCT CACGGACACGGCCCGTGTATTGTCTAGCATGGCA 
GAT GCAGTAT T GGC T C GAGT GT AT AAAC AAT CAGAT TTGGACACC 
CT GGC TAAAGAAGCAT C CAT C C CAAT T AT C AAT GGGCT GT CAGAT 





GGTACCAAGCTGT T GCT GACAAAT GAT CCAT TGGAAGCAGCGCAT 
GGAGGCAAT GT AT T AAT T ACAGAC ACT T GGATAAGCAT GGGACAA Keys 
GAAGAGGAGAAGAAAAAGCGGCTCCAGGCT T TCCAAGGT TACCAG • IF+IR 
GT T ACAAT GAAGACTGCTAAATOW»< M . U T • 2p+2R 
TTACACT GCT T GCCCAGAAAGCCAGAAGAAGTGGAT GAT GAAGT C S 
TT T TATT CTCCTCGAT CACTAGTGT TCCCAGAGGCAGAAAACAGA • ^卩+见 
AAGTGGACAAT CAT GGCTGTCATGGTGT CCCTGCTGACAGAT TAG • 4F+4R 
— T T T G A 
OTC clone 1 primers 
OTCcloneIF 5 ' -TGAGGATCCTGTTAAACAATGC-3 ‘ 
O T C c l o n e l R 5 ‘ -CCCAGAAGTGCTAAGCCTGT- 3 ‘ 
OTC clone 2 primers 
OTCclone2F 5 ‘ - GGGAAGTCCTTAGGCATGATT - 3 ‘ 
OTCclone2R 5 ‘ -ATCATGATGGAGTGCAGGAT - 3 ’ 
OTC clone 3 primers 
OTCcloneSF 5 ‘ -TTGTACCATCCTATCCAGATCC-3 , 
OTCcloneSR 5 丨-GTCCAGTCAGAGGCAGCAAC - 3 • 
OTC clone 4 primers 
OTCclone4F 5 • -AACCAAGTTGGCAGAGCAGT - 3 • 
OTCclone4R 5 ‘ - TTAGGCTTCTGGAGCTGAGG - 3 ‘ 
2 2 7 一 
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^ ^ Pr imfi rs HsfiH in pENTB Directional TOPO® Cloning Kit 
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PrimAFs Used in Mutagenesis anrt the Codon Changed 
1 ATG CTG TTT AAT CTG AGG ATC CTG TTA AAC AAT GCA GCT TTT AGA 15 
26 
16 AAT GGT CAC AAC TTC ATG GTT CGA AAT TTT CGG TGT GGA CAA CCA 30 
31 CTA CAA AAT AAA GTG CAG CTG AAG GGC CGT GAC CTT CTC ACT CTA 45 
46 AAA AAC TTT ACC GGA GAA GAA ATT AAA TAT ATG CTA TGG CTA TCA 60 
61 GCA GAT CTG AAA TTT AGG ATA AAA CAG AAA GGA GAG TAT TTG CCT 75 
76 TTA TTG CAA GGG AAG TCC TTA GGC ATG ATT TTT GAG AAA AGA AGT 90 
101 91 ACT CGA ACA AGA TTG TCT ACA GAA ACA GGC T]^ GCA CTT CTG GGA 105 
111 106 GGA CAT CCT TGT TTT CTT ACC ACA CAA GAT ATT. CAT TTG GGT GTG 120 
122 129 
121 AAT G ^ AGT CTC ACG GAC ACG GCC CGT GTA TTG TCT AGC ATG GCA 135 
144 136 GAT GCA GTA TTG GCT CGA GTG TAT AAA CAA TCA GAT TTG GAC ACC 150 
151 CTG GCT AAA GAA GCA TCC ATC CCA ATT ATC AAT GGG CTG TCA GAT 165 
178 166 TTG-TAG CAT CCT ATC CAG ATC CTG GCT GAT TAG CTC ACG CTC CAG 180 
181 GAA CAC TAT AGC TCT CTG AAA GGT CTT ACC CTC AGC TGG ATC GGG 195 
198 
196 GAT GGG A ^ AAT ATC CTG CAC TCC ATC ATG ATG AGC GCA GCG AAA 210 
211 TTC GGA ATG CAC CTT CAG GCA GCT ACT CCA AAG GGT TAT GAG CCG 225 
226 GAT GCT AGT GTA ACC AAG TTG GCA GAG CAG TAT GCC AAA GAG AAT 240 
241 GGT ACC AAG CTG TTG CTG ACA AAT GAT CCA TTG GAA GCA GCG CAT 255 
256 GGA GGC AAT GTA TTA ATT ACA GAC ACT TGG ATA AGC ATG GGA CAA 270 
271 GAA GAG GAG AAG AAA AAG CGG CTC CAG GCT TTC CAA GGT TAG CAG 285 
28 6 GTT ACA ATG AAG ACT GCT AAA GTT GCT GCC TCT GAC TGG ACA TTT 300 
301 TTA CAC TGC TTG CCC AGA AAG CCA GAA GAA GTG GAT GAT GAA GTC 315 
316 TTT TAT TCT CCT CGA TCA CTA GTG TTC CCA GAG GCA GAA AAC AGA 330 
331 AAG TGG ACA ATC ATG GCT GTC ATG GTG TCC CTG CTG ACA GAT TAG 345 
346 TCA CCT CAG CTC CAG AAG CCT AAA TTT TGA 
I 
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Arg26Gln 5‘-CTTCATGGTTCGAAATTTTCAGTGTGGACAACCACTACA-3‘ 
Anti-Arg26Gln S ‘ - TGTAGTGGTTGTCCACACTGAAAATTTCGAACCATGAAG - 3 ‘ 
Phe101 Leu 5‘-GTCTACAGAAACAGGCTTAGCACTTCTGGGAGG-3 ‘ 
Anti-Phe101 Leu s ‘ - CCTCCCAGAAGTGCTAAGCCTGTTTCTGTAGAC - 3 • 
Leu111 Pro 5 ‘ -GAGGGCATCCTTGTTTTCCTACCACACAAGATATTCATT-3‘ 
Anti-Leu 111 Pro S ’ -AATGAATATCTTGTGTGGTAGGAAAACAAGGATGCCCTC - 3 ’ 
Glu122Gly 5‘-TCATTTGGGTGTGAATGGAAGTCTCACGGACACG-3 ‘ 
Anti-Glu122Gly S, - CGTGTCCGTGAGACTTCCATTCACACCCAAATGA-3 ’ 
Arg129 His 5‘-ACGGACACGGCCCATGTATTGTCTAGCATGG-3‘ 
Anti-Arg129His S ‘ - CCATGCTAGACAATACATGGGCCGTGTCCGT - 3 • 
Lys144Term 5‘-GTATTGGCTCGAGTGTATTAACAATCAGATTTGGACACC-3‘ 
Anti-Lys144Term S ‘ -GGTGTCCAAATCTGATTGTTAATACACTCGAGCCAATAC - 3 ‘ 
Thr178Met 5 ‘ - CCTGGCTGATTACCTCATGCTCCAGGAACACTATA-3 ’ 
Anti-Thr178Met S, - TATAGTGTTCCTGGAGCATGAGGTAATCAGCCAGG - 3 , 
Asn198lle 5, -GATCGGGGATGGGATCAATATCCTGCACTCC - 3 ‘ 
Anti-Asn198lle S ‘ -GGAGTGCAGGATATTGATCCCATCCCCGATC-3 , 
I 
“ 
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JLllL Ifft^ tnr Infnrmfltlon of PCDNA-DEST47 
A.10.1 Multiple Cloning Site 
861 ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGT TAAGCTTGGT ACTCAAACAA 
TAATTATGCT GAGTGATATC CCTCTGGGTT CGACCGATCA ATTCGAACCA TGAGTTyGTT 
924 2775 .•. Pro Ala Phe Leu Tyr Lys Val 
921 GTTTGTACAA AMAGCAGGC NAC. CCA GCT TT€ TTG TAG AAA GTG 
CAAACATGTT TTTTCGTCCG N^G GGT CGA AAG AAC ATG TTT CAC 
attB1 attB2 
2800 3519 
Val Arg Ser Arg liET **j 
2788 GTT CGA TCT AGA ATG TAA TGAATTAAAC CCGCTGATCA 
C ^ GCT AGA TCT TAG ATT ACTTAATTTG GGCGACTAGT 
GFP 'cycle 3 mutant' 
A.8.2 Map 
m pcDNA-DEST47 % 
1 7952 bp 層 
Elements: CMV promoter: bases 232-819 
T7 promoter: bases 863-882 
attR^ recombination site: bases 917-1041 
Chloramphenicol resistance gene: bases 1318-1977 cccB gene: bases 2319-2624 �- attRZ recombination site: bases 2665-2789 
Cycle 3 GFP (C-terminal): bases 2800-3519 
BGH polyadenylation region: bases 3544-3771 
f1 origin: bases 3817-4245 
SV40 early promoter and origin: bases 4272-4581 
Neomycin resistance ORF: bases 4655-5449 
SV40 early polyadenylation region: bases 5625-5755 
, pUC origin: bases 6138-6811 
Ampicillin resistance ORF (bla): bases 6956-7816 (c) 
bla promoter: bases 7817-7915 (c) 
(c) = complementary strand 
231 
Appendices B B 
J ^ It 枕 tnr 丨 nfnmiatl0H0fpCllNA/BW47/CflT 
A.11.1 Map 
1 pcDNA/GW-47/ # 
m 6816 bp 眉 
Elements: CMV promoter: bases 232-819 
T7 promoter: bases 863-882 
atB^ recombination site: bases 917-941 
CATORF: 971-1627 -atB2 recombination site: bases 1629-1653 
Cycle 3 GFP (C-terminal): bases 1664-2383 
BGH polyadenylation region: bases 2408-2635 
f1 origin: bases 2681-3109 
SV40 early promoter and origin: bases 3136-3444 
Neomycin resistance ORF: bases 3519-4313 
SV40 early polyadenylation region: bases 4489-4619 
pUC origin: bases 5002-5675 
Ampicillin resistance ORF _ ) : bases 5820-6680 (c) 
�. bla promoter: bases 6681-6779 (c) 




Ufinf nr Inffnrmation Of PCDNA3.1/GS 
A.12.1 Map 
w 
ORF Insert « 
902 AA<3CTC<3CCCI^ACCATq. ^  : OOC GAG CTT CGA OCT CAC ... 
TTCGAGCCSG<3A fVGTGGTAC. • . FTC CCG CTC GAA GCT CCA GTG ,.. 
\ KBT.•./Lye Gly Glu Leu Arg Gly His ... 
\ /« ^ I 
i p c D N A 3 . 1 / G S e l 
I 4020bp 
Elements: CMV promoter; bases 209-863 
T7 promoter priming site: bases 863-882 
yORF cloning site: between base 914 and 915 
V5 epitope: bases 944-985 
Polyhistidine tag: bases 995-1012 
- pcDNA3.1/BGH Reverse priming site: bases 1035-1052 
BGH polyadenylation signal: bases 1034-1248 
f1 origin: bases 1311-1724 
SV40 promoter and origin: bases 1789-2114 
EM-7 promoter: bases 2130-2196 
Zeocin™ resistance gene: bases 2197-2571 
> SV40 polyadenylation: bases 2580-2782 
pMB1 origin (pUC-derived): bases 3214-3887 (opposite strand) 
— 
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Uftntnr Inffnrmarion Of pEXPI-DEST 
A.13.1 Multiple Cloning Site 
T7 promoter/priming site 
I ,T7 Pfgmglgr . | 
1 GATCTCGATC CCGCGAAATT AATACGACTC ACTATAGGGA GACCACAACG GTTTCCCTCT AGAAATAATT TTGTTTAACT 
HisG epitope 
Nde I I Polyhistidine (6xHis) region "“ I Nhe I 
RBS Met Arg Gly Ser' His His His His His His Gly' Met Ala Ser Met Thr Gly 
81 TTAAGAAGGA GATATACAT ATG CGG GGT TCT CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC ATG ACT GGT 
Xpress很 epitope  
I E K recognition sKe 1 210 
Gly Gin Gin Met Gly Arg 'Asp Leu Tyr" Asp Asp Asp Asp Lys'' Asp His Gin Thr Ser Leu Tyr Lys 
151 GGA CAG CAA ATG GGT CGG GAT CTG TAG GAC GAT GAC GAT AAG GAT CAT CAA ACA AGT TTG TAG AAA 
A GTT.TGT TCA AAC ATG TTT 
EK cleavage site att5l 
Lys Ala Gly *** 1892 
AAA GCA GGC TNN -ppijc" NACCCAGCTT TCTTGTACAA AGTGGTTCGA TCGAAGCTTG ATCCGdCTGC TAACAAAGCC 
TTT CGT CCG ANN --- NTGGGTCGAA AGAACATGTT TCACCAAGCT AGCTTCGAAC ‘ 5HB2 ‘ 
, T7 rgygrw priming site , 
T7 transcription termination region I I 
1941 CGAAAGGAAG CTGAGTTGGC TGCTGCCACC GCTGAGCAAT AACTAGCATA ACCCCTTGGG GCCTCTAAAC GGGTCTTGAG 
2021 GGGTTTTTTG CTGAAAGGAG GAACTATATC CGGATCTGGC 
A.13.2 Map 
. 1 I  
置 pEXP1-DEST 
m 4622 bp 
Elements: 丁7 promoter: bases 20-36 
T7 promoter priming site: bases 20-39 
Ribosome binding site: bases 85-92 
Initiation ATG: bases 100-102 
, Polyhistidine (6xHis) region: bases 112-129 
Xpress™ epitope: bases 169-192 
Enterokinase (EK) recognition site: bases 178-192 
attR1 site: bases 202-326 
Chloramphenicol resistance gene (CmR): bases 435-1094 
ccdB gene: bases 1436-1741 
attR2 site: bases 1782-1906 
T7 reverse priming site: bases 1966-1985 
T7 transcription termination region: bases 1927-2056 
f1 origin: bases 2127-2582 
bla promoter: bases 2669-2767 
Ampicillin resistance gene: bases 2768-3628 
pUC origin: 3773-4446 
— 
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J ^ i , lifintnr Inffnrmation Of pEXPI-GW/lacZ 
A.14.1 Map 
H pEXP1-GW//acZ 
m 6078 bp / 
Elements: T7 promoter: bases 20-36 
T7 promoter priming site: bases 20-39 
Ribosome binding site: bases 85-32 
Initiation ATG: bases 100-102 
Polyhistidine (6xHis) region: bases 112-129 
Xpress ™ epitope: bases 169-192 
Enterokinase (EK) recognition site: bases 178-192 
aftB1 site: bases 202-226 
/acZ gene: bases 247-3321 
aftB2 site: bases 3338-3362 
T7 reverse priming site: bases 3422-3441 
T7 transcription termination region: bases 3383-3512 
f1 origin: bases 3583-4038 
bla promoter: bases 4125-4223 
Ampicillin resistance gene: bases 4224-5084 
pUC origin: 5229-5902 
) 
— 
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^ ^ tfp.Rf nr Inffnrmatlon Of pENTB/D-TOPO 
A . 1 5 . 1 M a p 
M l , FS 
m pENTR/D-TOPO� 
M 2580 bp i 
Elements: rnB 12 transcription termination sequence: bases 268-295 
rrnB T1 transcription termination sequence: bases 427-470 
MIS forward (-20) priming site: bases 537-552 
attL1: bases 569-668 (complementary strand) 
TOPO® recognition site 1: bases 680-684 
Overhang: bases 685-688 
TOPO® recognition site 2: bases 689-693 
attL2: bases 705-804 
M13 reverse priming site: bases 845-861 
�� Kanamycin resistance gene: bases 974-1783 




Uftntnr inffnrmatlon Of pIBEK Control Wector GFP 
A . 1 6 . 1 M a p 
伞 a j _ 
AimU (>:)I6) HifKlli (400) T7-Pfomoter (618-634) 
^ ^ ^ ^ ^ g 10 (673-681) 
AmpR (684-689) 
I p^EX control vectorGFP l ^ O F P - V V T (697-1410) 
T 4235 bp | r 
\ 通 Urte+Hsiag(1411-1446) 
(W57) 
• U _ (1558-1596) 
• 刷丨(嶋 
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nRtailsnfiyiarkfir 
A.18.1 Ikb DNA Ladder 
I Kb DNA Ladder bp bp 






A.18.2 Kaleidoscope Prestained Standards 
kDa 
Myosin 208 
13 -galactosidase ' 127 
Bovine serum albumin 85 
Carbonic anhydrase 45 
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